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Heart failure (HF) affects an estimated 900 000 people within the United Kingdom 
(UK), resulting in approximately 60 000 hospital admissions each year (1). Mortality at 
one year is estimated at as high as 40%, with the risk of death rising with age (1). A 
common consequence of HF is mitral regurgitation (MR). 
 
MR is one of the most common valvular lesions worldwide. The prevalence within 
Europe is estimated at 4 million making MR the second most common valve lesion 
requiring surgery (2, 3). By nature of the disease, severity also worsens with advancing 
age, and as such by 2030, prevalence is expected to more than double (4). 
 
MR in HF can occur as a consequence of organic leaflet disruption (primary MR) or 
secondary to annular dilation (secondary MR), with both mechanisms ultimately 
resulting in geometric changes to the left atrium (LA) and left ventricle (LV), and 
concomitant symptoms. HF is commonly seen in patients with chronic long standing 
MR and also those who present in the acute setting. Patients with symptomatic primary 
MR typically undergo surgery which offers a survival benefit. Recommended treatment 
options for patients with secondary MR and symptoms focus on the optimisation of 
medical therapy, cardiac resynchronisation therapy and conventional open heart 
surgery. However more recently, transcatheter mitral valve repair (TMVR) has been 
recognised as a novel technique for MR patients with a high surgical risk and multiple 
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comorbidities, LV systolic dysfunction, and persistent symptoms despite optimal 
medical therapy (OMT). Currently, there remains a dearth of information regarding the 
number of HF patients with MR, and the proportion of these patients who despite OMT 
remain symptomatic with MR and an LV ejection fraction (EF) <50%. Additionally 
whether or not these individuals meet suitability criteria for TMVR, and the 
effectiveness of TMVR in reducing the degree of MR, improving symptoms and quality 
of life is largely unknown.  
 
This thesis therefore aimed to identify the prevalence of MR within the HF population 
as well as assess the degree of change as a result of OMT. It also investigated the 
population considered eligible for TMVR based on risk and echocardiography criteria. 
The thesis then focussed on using current literature and a systematic review to identify 
predictors of outcomes for patients who have undergone TMVR. Employing these 
findings, the project then prospectively assessed the usefulness of predictors in 
relation to quality of life and symptoms.  
 
The thesis concludes that one fifth of all patients presenting with HF have moderate 
or more MR and that patients with moderate or more MR have a greater risk of 
mortality. Patients who received OMT do see an element of relief from symptoms and 
a proportion also experience a reduction in the severity of MR. However, one half of 
patients with LV systolic dysfunction and MR still remain symptomatic despite OMT. 
When further evaluating the risk status for these patients, the thesis determines that a 
significant number of these patients are eligible for TMVR based on echocardiographic 
and risk criteria.  
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From a functional assessment perspective, the results of a systematic review 
demonstrated that six minute walk test (6MWT) may be predictive of outcome for 
patients who undergo TMVR. Exercise stress echocardiography may also play a role 
in determining patients with early stage exercise induced severe MR.  
 
The prospective study, although limited, demonstrated variation in quality of life and 
echocardiography outcomes across the recruited population of eight patients. Further 
recruitment is needed prior to the provision of more solid conclusions. 
 
More broadly, these findings suggest the burden of MR within the HF population is 
significant and although medical optimisation can assist in reducing the degree of MR 
and symptoms, a portion of high risk patients with LV systolic dysfunction remain 
symptomatic and should be considered for TMVR eligibility assessment. The thesis 
findings suggest that when identifying patients who have the potential for improvement 
with MV intervention, the value of 6MWT distance, exercise stress echo, LV volume, 
the LV/MR ratio, and the degree of LA dilation should be assessed and examined. 
Further studies should also focus on clarifying recommendations for TMVR in a variety 
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Figure 2.1.  Pathophysiology of heart failure (HF): structural changes in the 
geometry of the left ventricle occur as a component of 
compensatory mechanisms in the setting of HF. This figure 
outlines a normal response followed by a concentric response as 
well as an eccentric and combined response (more commonly 
seen in mitral regurgitation, dilated cardiomyopathies and 
ischaemic heart disease). Taken from Tanai and Frantz (8).  
 
Figure 2.2.  Characteristics of United Kingdom (UK) heart failure (HF) patients 
at first HF admission: age and gender demographics. Taken from: 
NICOR Heart Failure Audit: 2019 Summary Report (1). 
 
Figure 2.3.  Anatomy of the mitral valve. A: En face image of the mitral valve 
which denotes the middle scallop of the posterior leaflet as P2, 
with P1 lateral and P3 medial. The opposing segments of the 
anterior leaflet are designated as A1, A2, and A3. AC and PC 
represent the anterolateral and posteromedial commissures. 
Taken from: Stone et al (21). B: Anatomy of the mitral valve and 
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mitral apparatus including the papillary muscles and chordae 
tendineae in long axis view. Taken from: Clinical 
Echocardiography (22). Abbreviations: LA: left atrium; LV: left 
ventricle.  
 
Figure 2.4.  Mitral valve (MV) anatomy and Carpentier classification of mitral 
regurgitation (MR). This image depicts the different aetiologies 
which result in MR. Type I shows normal MV leaflets where 
annular dilation or perforation of the leaflet is the cause of MR; 
Type II shows excessive leaflet motion with a flail or prolapsed 
MV leaflet resulting in MR. Type IIIa shows restricted MV leaflets 
affecting opening and closing of the valve as a consequence of 
thickening or calcification of MV leaflets, commissures or chordae 
tendineae. Type IIIb demonstrates a problem with closure of the 
valve leaflets secondary to chordal thickening, shortening or LV 
dilation. Taken from: Stone et al (21). 
 
Figure 2.5.  Two dimensional echocardiography images obtained from an 
apical four chamber acoustic window with the application of 
colour Doppler imaging. (A) shows a large central jet of mitral 
regurgitation which occupies greater than 50% of the left atrium; 
(B) shows a large eccentric jet of mitral regurgitation which is 
directed anteriorly towards the interatrial septum, reaching the 
posterior wall of the left atrium. Both of these images denote 
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severe mitral regurgitation. Note: the mitral regurgitation jets are 
represented by the green/yellow/light blue disorganised, mosaic 
colour on the image. Abbreviations: LV: left ventricle; LA: left 
atrium.  
 
Figure 2.6.  The Abbott MitraClip device (A). (B) shows deployment of the 
MitraClip device at the P2, A2 mitral leaflet scallops. Using the 
edge to edge repair technique a small bridge between the anterior 
and posterior mitral valve (MV) leaflets is created resulting in a 




Figure 3.1.  Flowchart demonstrating the process by which patient data were 
collected for the retrospective heart failure study. Abbreviations: 
HF: heart failure; CRT: cardiac resynchronisation therapy; ICD: 
implantable cardioverter-defibrillator; NYHA: New York Heart 
Association; LV: left ventricle; RV: right ventricle; LA: left atrium. 
 
Figure 3.2.  Flowchart outlining the pathway for patients selected in the 
retrospective heart failure study. This also outlines those who 
were excluded and the reasons for exclusion. Abbreviations: MR: 
mitral regurgitation; EF: ejection fraction; TTE: transthoracic 
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echocardiogram; OMT: optimal medical therapy; MVR: mitral 
valve replacement.  
 
Figure 3.3.  Kaplan-Meier survival curve based on 12 month survival for heart 
failure (HF) admission patients with moderate or more mitral 
regurgitation (MR) versus those without moderate or more MR. 
 
Figure 3.4.  Kaplan-Meier survival curve based on 18 month survival for heart 
failure (HF) admission patients with moderate or more mitral 
regurgitation (MR) versus those without moderate or more MR.    
 
Figure 3.5.  Patients with heart failure and moderate or more mitral 
regurgitation: A comparison of sex across the categories of 





Figure 4.1.  Flowchart outlining the pathway for patients selected in the 
retrospective heart failure study. This also outlines those who 
were excluded and the reasons for exclusion. Abbreviations: MR: 
mitral regurgitation; EF: ejection fraction; TTE: transthoracic 
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Figure 4.2.  Flowchart demonstrating the process by which retrospective 
patient data were collected for the retrospective heart failure 
study (stages 1-5). Additional stages 6,7 & 8 have been included 
to outline further components introduced as part of the Chapter 4 
methodology. Abbreviations: HF: heart failure; CRT: cardiac 
resynchronisation therapy; ICD: implantable cardioverter-
defibrillator; NYHA: New York Heart Association, LV: left 
ventricle; RV: right ventricle; LA: left atrium; LVESD: left 
ventricular end systolic dimension; PASP: pulmonary artery 
systolic pressure; HCM: hypertrophic cardiomyopathy; RCM: 
restrictive cardiomyopathies; COAPT: Cardiovascular Outcomes 
Assessment of the MitraClip Percutaneous Therapy for Heart 
Failure Patients With Functional Mitral Regurgitation. Note: the 
red line denotes where the methodology was extended in Chapter 
4. 
 
Figure 4.3.  Echocardiography algorithm used to determine the degree of 
mitral regurgitation in the Cardiovascular Outcomes Assessment 
of the MitraClip Percutaneous Therapy for Heart Failure Patients 
With Functional Mitral Regurgitation (COAPT) trial. Taken from: 
Asch et al (2019) (85). 
 
Figure 4.4.  Flowchart outlining the selection criteria pathway for patients 
involved in the retrospective studies (Chapters 3 and 4). 
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Abbreviations: MR: mitral regurgitation; EF: ejection fraction; 
OMT: optimal medical therapy; LVESD: left ventricular end-
systolic dimension; PASP: pulmonary artery systolic pressure; 
HCM: hypertrophic cardiomyopathy; RCM: restricted 





Figure 5.1.  Flowchart outlining selection process for the systematic review of 
patients undergoing functional testing and transcatheter mitral 
valve repair. 
 
Figure 5.2. Forest plot using a weighted for random-effects model 
demonstrating that the six minute walk test (6MWT) is predictive 
of a combined end point of all cause mortality and prolonged 
hospital admission). The blue diamond on the left side of the 
vertical axis suggests that increased 6MWT distance predicts 
reduced risk. Abbreviations: HR: hazard ratio; OR: odds ratio; CI: 












Figure 6.1.  Flow diagram of the patient journey during the prospective 
transcatheter mitral valve research study. Activities beyond 
routine clinical care are highlighted in bold.   
 
Figure 6.2.  Quality of life scores before and after transcatheter mitral valve 
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Table 2.1.  Definition of heart failure according to the European 2016 heart 
failure guideline with criteria for the subclassifications of heart 
failure (10). Abbreviations: HF: heart failure; HFrEF: heart failure 
with reduced ejection fraction; HFmrEF: heart failure with mid-
range ejection fraction; HFpEF: heart failure with preserved 
ejection fraction; LVEF: left ventricular ejection fraction; LVH: left 
ventricular hypertrophy; LAE: left atrial enlargement. N/A: not 
applicable. bBNP >35pg/ml and/or NT-pro BNP >125pg/mL. 
 
Table 2.2.  A summary of echocardiographic criteria and cut points used to 
define severe mitral regurgitation across a selection of guidelines 
including the American Heart Association (AHA), American 
College of Cardiology (ACC), American Society of 
Echocardiography (ASE) and European Society of Cardiology 
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Table 2.3.  A comparison between the findings of two large scale 
transcatheter mitral valve repair studies: MITRA-FR (Multicentre 
Study of Percutaneous Mitral Valve Repair MitraClip Device in 
Patients With Severe Secondary Mitral Regurgitation) and 
COAPT (Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients With Functional 
Mitral Regurgitation); Abbreviations: GDMT: guideline directed 
medical therapy; CRT: cardiac resynchronisation therapy; HF: 
heart failure; EF: ejection fraction; LVESD: left ventricular end 
systolic dimension. RVol: regurgitant volume; EROA: effective 




Table 3.1.  A comprehensive list of parameters collected for comparison as 
part of a retrospective study of heart failure patients across 
Southwark and Lambeth. Abbreviations: MR: mitral regurgitation; 
PISA: proximal isovelocity surface area; EROA: effective 
regurgitant orifice area; RVol: regurgitant volume; MV: mitral 
valve; LV: left ventricle; 3D: three-dimensional; EF: ejection 
faction; LVESD: left ventricular end systolic dimension; RV: right 
ventricle; PASP: pulmonary artery systolic pressure; LA: left 
atrium; HF: heart failure; CRT: cardiac resynchronisation therapy; 
ICD: implantable cardioverter defibrillator; MI: myocardial 
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infarction; NYHA: New York Heart Association; PND: paroxysmal 
nocturnal dyspnoea; EPR: electronic patient record; NICOR: 
National Institute for Cardiovascular Outcomes Research; NT-pro 
BNP: N-terminal pro B-type natriuretic peptide; ACEI: 
angiotensin-converting-enzyme inhibitors; ARB: angiotensin 
receptor blocker; MRA: mineralocorticoid receptor antagonists; 
OMT: optimal medical therapy. 
 
Table 3.2.  Retrospective study assessing the burden of mitral regurgitation 
within the heart failure population across Southwark and 
Lambeth: inclusion and exclusion criteria. Abbreviations: GSTT: 
Guy’s and St Thomas’ Trust; KCH: King’s College Hospital; HF: 
heart failure; UK: United Kingdom; TTE: transthoracic 
echocardiogram; EF: ejection fraction; MR: mitral regurgitation. 
 
Table 3.3.  Patients with heart failure and moderate or more mitral 
regurgitation (MR): comparing those with an ejection fraction (EF) 
of <50% versus those with an EF of >50%. *Ethnicity was based 
on limited data. Where a p-value was not reported, there were 
inadequate data for analysis. Abbreviations: PM: pacemaker; 
ICD: implantable cardioverter-defibrillator; IHD: ischaemic heart 
disease; COPD: chronic obstructive pulmonary disease; NYHA: 
New York Heart Association; NT-pro BNP: N-terminal pro B-type 
natriuretic peptide; MR: mitral regurgitation; LOS: length of stay. 
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Statistics: Chi-square test for independence for categorical 
variables and independent T-test for continuous variables.  
 
Table 3.4.  Patients with heart failure and moderate or more mitral 
regurgitation: Device therapy across categories of ejection 
fraction (EF). Abbreviations: CRT-D: cardiac resynchronisation 
therapy defibrillator; CRT-P: cardiac resynchronisation therapy 
pacemaker; ICD: implantable cardioverter-defibrillator; PM: 
pacemaker.  
 
Table 3.5.  Multinominal logistic regression for variables age, New York 
Heart Association (NYHA) class and ejection fraction (EF) in the 
prediction of mortality in those with heart failure and moderate or 
more mitral regurgitation (MR). Abbreviations: HFrEF: heart 
failure with reduced ejection fraction; HFpEF: heart failure with 
preserved ejection fraction; HR: hazard ratio; CI: confidence 
interval. 
 
Table 3.6.  Baseline characteristics of patients with heart failure (HF), 
moderate or more mitral regurgitation (MR) and an ejection 
fraction of <50% who were on optimal medication therapy (OMT) 
(Group 1) compared with patients with HF on OMT with less than 
moderate MR +/- EF >50% +/- symptom relief (Group 2). 
Abbreviations: PM: pacemaker; ICD: implantable cardioverter-
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defibrillator; IHD: ischaemic heart disease; COPD: chronic 
obstructive pulmonary disease; NYHA: New York Heart 
Association; NT-Pro BNP: N-terminal pro B-type natriuretic 
peptide; *Ethnicity was based on a population size of 101. ^There 
were expected cell counts less than 5. #NT-pro BNP was based 
on a population of 104. Mitral regurgitation grades: 0=none or 
trivial; 1=mild; 1.5=mild to moderate; 2=moderate; 3=moderate to 
severe; 4=severe. Statistics: Chi square test for independence for 
categorical variables and independent T-test for continuous 
variables. 
 
Table 3.7.  Comparison before and after optimal medical therapy (OMT): 
change in clinical (New York Heart Association [NYHA] class) and 
echocardiographic (mitral regurgitation) characteristics after 
optimal medical therapy (OMT). +Based on cell counts less than 
5.  
 
Table 3.8.  Changes in mitral regurgitation (MR) and New York Heart 
Association (NHYA) class with optimal medical therapy (OMT) 












Table 4.1.  Inclusion and exclusion criteria for patients involved in this study 
focussing on suitability for transcatheter mitral valve repair based 
on echocardiographic and surgical risk criteria.  Abbreviations: 
GSTT: Guy’s and St Thomas’ NHS Foundation Trust; KCH: 
King’s College Hospital; HF: heart failure; MR: mitral 
regurgitation. EF: ejection fraction; OMT: optimal medical 
therapy; TTE: transthoracic echocardiogram. 
 
Table 4.2.  Parameters required for the calculation of surgical risk score 
using the online Euroscore II calculator. + Renal impairment was 
determined using the Cockroft-Gault creatinine clearance 
calculator which required plasma creatinine, age, weight, and 
sex. *CCS class 4 angina was defined by angina at rest. 
^Pulmonary hypertension (as per moderate 31-35mmHg; severe 
> 55mmHg). #For this study, all routine patients were allocated an 
urgency of ‘elective’, a weight of intervention of ‘single non-CABG’ 
and a surgery on thoracic aorta of ‘no’. Abbreviations: NYHA: 
New York Heart Association; MI: myocardial infarction (82). 
 
Table 4.3.  Echocardiographic inclusion and exclusion criteria used in the 
Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients With Functional 
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Mitral Regurgitation (COAPT) trial (21). Abbreviations: MR: mitral 
regurgitation; LVEF: left ventricular ejection fraction; LVESD: left 
ventricular end-systolic dimension; PASP: pulmonary artery 
systolic pressure; HCM: hypertrophic cardiomyopathy; RCM: 
restrictive cardiomyopathy.  
 
Table 4.4.  Calculations used for the quantitative echocardiographic 
assessment of mitral regurgitation. Abbreviations: SV: stroke 
volume; MV: mitral valve; D: diameter; r: radius; VTI: velocity time 
integral; PISA: proximal isovelocity surface area; LVOT: left 
ventricular outflow tract. 
 
Table 4.5.  Clinical variables stratified according to surgical risk in patients 
considered potentially suitable for transcatheter mitral valve 
repair Abbreviations: IHD: ischaemic heart disease; COPD: 
chronic obstructive pulmonary disease. Statistics: Chi square for 
categorical and one way ANOVA for continuous variables. 
 
Table 4.6.  Extrapolation of study data to English population level. 












Table 5.1.  Search terms used across five databases to determine articles 
relevant to our research question focussing on the use of 
functional testing for risk stratification and determination of 
prognosis in patients undergoing transcatheter mitral valve repair. 
 
Table 5.2.  Search terms and strategy across five databases (Medline, 
Scopus, Google Scholar, Clinicaltrials.org and Cochrane library) 
and the number of results returned prior to filtering and exclusion 
of duplication. 
 
Table 5.3.  Inclusion and exclusion criteria for selected articles related to 
functional testing in patients undergoing transcatheter mitral 
valve repair. 
 
Table 5.4.  Overview of publication-related, patient-related and study-related 
outcomes for articles focussed on the role of the six minute walk 
test (6MWT) in predicting outcomes following transcatheter mitral 
valve repair (TMVR). Abbreviations: TRAMI: TRAnscatheter 
Mitral valve Intervention; P: primary; S: secondary; MR: mitral 
regurgitation; HF: heart failure; Pts: patients; f/u: follow up; CPET: 
cardiopulmonary exercise test; LVEDD: left ventricular end-
diastolic dimension; LVESD: left ventricular end-systolic 
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dimension; LAD: left atrial dimension; LVEF: left ventricular 
ejection fraction; LVEDVi: left ventricular end diastolic volume 
indexed; LVESVi: left ventricular end systolic volume indexed; 
LAVi: left atrial volume indexed; DM: diabetes mellitus; CAD: 
coronary artery disease; AF: atrial fibrillation: ESII: euroscore II; 
NHYA: New York Heart Association; MI: myocardial infarction; 
NT-pro BNP: N-terminal pro B-type natriuretic peptide; COPD: 
chronic obstructive pulmonary disease; PASP: pulmonary artery 
systolic pressure; QoL: quality of life; +MINORS: Items were 
scored 0 (not reported), 1 (reported but inadequate) or 2 (reported 
and adequate) - global ideal score 16 for non-comparative 




Table 6.1.  Parameters recorded for the prospective transcatheter mitral 
valve research study including sub-category, relevant data 
sources and time points. MR: mitral regurgitation; EROA: 
effective regurgitant office area; RVol: regurgitant volume; VC: 
vena contracta; MV: mitral valve; 2D: two dimensional; PISA: 
proximal isovelocity surface area; LVOT: left ventricular outflow 
tract; MVA: mitral valve area; TTE: transthoracic echocardiogram; 
TOE: transoesophageal echocardiogram; LV: left ventricle; EF: 
ejection fraction; LVEDD: left ventricular end diastolic dimension; 
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LVESD: left ventricular end systolic dimension; GLS: global 
longitudinal strain; TDI: tissue Doppler imaging; VTI: velocity time 
integral; AV: aortic valve; SV: stroke volume; CO: cardiac output; 
PW: pulsed wave; LA: left atrium; RA: right atrium; RWMAs: 
regional wall motion abnormalities; RV: right ventricle; PASP: 
pulmonary artery systolic pressure; NYHA: New York heart 
association, EPR: electronic patient record; HR: heart rate; LVH: 
left ventricular hypertrophy; MI: myocardial infarction; BP: blood 
pressure; O2: oxygen; BMI: body mass index; BSA: body surface 
area; NT-pro BNP: N-terminal pro B-type natriuretic peptide; 
CRP: C-reactive protein: eGFR: estimated glomerular filtration 
rate. 
 
Table 6.2.  Inclusion and exclusion criteria for patients recruited to the 
prospective transcatheter mitral valve repair study. Abbreviation: 
MR: mitral regurgitation. 
 
Table 6.3.  Imaging and clinical endpoints for the transcatheter mitral valve 
study. Abbreviations: LV: left ventricle; LVEDD: left ventricular 
end diastolic dimension; LVEDV: left ventricular end diastolic 
volume; 2D: two dimensional; 3D: three dimensional; GLS: global 
longitudinal strain; EF: ejection fraction; EF1: first phase ejection 
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Table 6.4.  Demographic and clinical characteristics of patients recruited to 
the transcatheter mitral valve study. *Analysis based on eight 
patients only. Abbreviations: BMI: body mass index; IHD: 
ischaemic heart disease; COPD: chronic obstructive pulmonary 
disease; ICD: implantable cardioverter defibrillator; NYHA: New 
York Heart Association. 
 
Table 6.5.  Absolute and total quality of life scores for each patient across 
sub-categories of the SF-36 questionnaire. Abbreviations: Pt: 
patient; Pre: prior to intervention; F/U: at follow up.  
 
Table 6.6.  SF-36 quality of life questionnaire scores (individual domains 
and overall total) before (left) and after (right) transcatheter 
mitral valve repair. Statistics: paired t-test. Abbreviations: TMVR: 
transcatheter mitral valve repair. SD: standard deviation. 
 
Table 6.7.  Baseline echocardiographic parameters prior to transcatheter 
mitral valve repair. Abbreviations: MR: mitral regurgitation; RUPV: 
right upper pulmonary vein; MV: mitral valve; LVEDD: left 
ventricular end-diastolic dimension; LVESD: left ventricular end-
systolic dimension; LVEDV: left ventricular end-diastolic volume; 
LVESV: left ventricular end-systolic volume; BSA: body surface 
area; EF: ejection fraction; RV: right ventricle; TAPSE: tricuspid 
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annulus plane systolic excursion; PASP: pulmonary artery 
systolic pressure. 
 
Table 6.8.  Six minute walk test outcomes prior to transcatheter mitral valve 
repair. Abbreviations: m: metres. 
 
Table 6.9.   Laboratory results prior to transcatheter mitral valve repair. ̂ n=5, 
*n=4. Abbreviation: eGFR: estimated glomerular filtration rate; 
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2D  Two dimensional 
3D  Three dimensional 
6MWT Six minute walk test 
ACEI  Angiotensin-converting-enzyme inhibitors 
ACS  Acute coronary syndrome 
AF  Atrial fibrillation 
AHF  Acute heart failure 
ARB  Angiotensin receptor blocker 
BSA  Body surface area 
BMI  Body mass index 
BP  Blood pressure 
CAD  Coronary artery disease 
CFI  Colour flow imaging 
CMR  Cardiac magnetic resonance 
CI  Chief investigator 
COAPT Cardiovascular Outcomes Assessment of the MitraClip Percutaneous 
Therapy for Heart Failure Patients With Functional Mitral Regurgitation 
COPD  Chronic obstructive pulmonary disease 
CPET  Cardiopulmonary exercise test 
CRP  C-reactive protein 
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CRT  Cardiac resynchronisation therapy 
CT  Computed tomography 
CVIS  Cardiovascular information systems 
DM  Diabetes mellitus 
D  Diameter 
ECG  Electrocardiogram 
ECHO  Echocardiography 
EF  Ejection fraction 
EF1  First phase ejection fraction 
eGFR  estimated glomerular filtration rate  
EPR  Electronic patient record 
EROA  Effective regurgitant orifice area 
ESE  Exercise stress echocardiogram 
FAC  Fractional area change 
F/U  Follow up 
GDMT Guideline directed medical therapy 
GLS  Global longitudinal strain 
GSTT  Guy’s and St Thomas’ NHS Foundation Trust 
HCM  Hypertrophic cardiomyopathy 
HF  Heart failure 
HFmrEF Heart failure with mid-range ejection fraction 
HFpEF Heart failure with preserved ejection fraction 
HFrEF Heart failure with reduced ejection fraction 
HSST  Higher specialist scientist training 
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ICF  Informed consent form 
ICD  Implantable cardioverter-defibrillator 
IHD  Ischaemic heart disease 
IT  Information technology 
JVP  Jugular venous pressure 
KCH  King’s College NHS Foundation Trust 
LA  Left atrium 
LAE  Left atrial enlargement 
LAD  Left atrial dimension 
LAV  Left atrial volume 
LAVi  Left atrial volume indexed 
LBBB  Left bundle branch block 
LOS  Length of stay 
LV  Left ventricle 
LVOT  Left ventricular outflow tract 
LVEDD Left ventricular end diastolic dimension 
LVEDV Left ventricular end diastolic volume 
LVEDVi Left ventricular end diastolic volume indexed 
LVEF  Left ventricular ejection fraction 
LVESD Left ventricular end systolic dimension 
LVESV Left ventricular end systolic volume 
LVESVi Left ventricular end systolic volume indexed 
LVH  Left ventricular hypertrophy 
LVSD  Left ventricular systolic dysfunction 
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MMU  Manchester Metropolitan University 
MI  Myocardial infarction 
MITRA-FR Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device 
in Patients With Severe Secondary Mitral Regurgitation 
MR  Mitral regurgitation 
MRA  Mineralocorticoid receptor antagonists 
MS  Mitral stenosis 
MV  Mitral valve 
MVA  Mitral valve area 
MVR  Mitral valve replacement 
N/A  Not applicable 
NT-pro BNP N-terminal pro B-type natriuretic peptide  
NYHA  New York Heart association 
O2  Oxygen 
OMT  Optimal medical therapy 
PASP  Pulmonary artery systolic pressure 
PI  Principal investigator 
PISA  Proximal isovelocity surface area 
PM  Pacemaker 
PMVI  Percutaneous mitral valve intervention 
PND  Paroxysmal nocturnal dyspnoea 
QoL  Quality of life 
RCM  Restrictive cardiomyopathy 
RCT  Randomised controlled trial 
 
___________________________________________________________________ 
Mitral Regurgitation in Heart Failure: Burden, Treatment Options and Outcomes 
 
32 
REC  Research ethics committee 
RV  Right ventricle 
RVol  Regurgitant volume 
RV TDI S’ Right ventricular tissue Doppler imaging S’ wave 
SV  Stroke volume 
TAPSE Tricuspid annular plane systolic excursion 
TAVI  Transcatheter aortic valve implantation 
TDI  Tissue Doppler imaging 
TR  Tricuspid regurgitation 
TMVR  Transcatheter mitral valve repair 
TOE  Transoesophageal echocardiography 
TTE  Transthoracic echocardiography 
VC  Vena contracta 
UK  United Kingdom  
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1.1 Subject Overview 
 
Heart failure (HF) is a complex clinical syndrome characterised by inability of the heart 
to pump adequate blood volume around the body (1). It affects an estimated 26 million 
worldwide and is considered a serious disease, often associated with multiple and 
frequent hospital admissions and a poor prognosis. Mortality rates are high with 40% 
of newly diagnosed patients dying within one year (1).  
 
A recurrent feature of HF is concomitant mitral regurgitation (MR), which is one of the 
most common valvular heart abnormalities with a European prevalence exceeding 4 
million and an annual mortality of 5% in the absence of interventional treatment (2-4). 
In light of this, and in addition to an ageing population, it is not surprising that HF with 
MR is now viewed as a growing global health concern. 
 
MR can occur as a result of both degenerative changes to the valve leaflets (primary) 
or as a consequence of changes in the geometry of the left ventricle (LV) (secondary). 
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Regardless of the underlying aetiology, left untreated, severe MR ultimately leads to 
reduced cardiac output, often accompanied by symptoms of breathlessness, 
arrhythmia, oedema and reduced exercise tolerance.  However, international 
guidance for the medical and surgical management of patients with primary versus 
secondary MR differs considerably. 
 
Treatment options for HF patients with secondary MR include optimisation of medical 
therapy (OMT), cardiac resynchronisation therapy (CRT) and conventional mitral valve 
(MV) surgery (although for those patients who experience no improvement in the 
severity of MR or symptoms with medicines and CRT, conventional MV surgery is not 
always feasible due to prohibitive surgical risk). Fortunately, transcatheter mitral valve 
repair (TMVR) presents a novel and viable therapeutic option for symptomatic patients 
with multiple comorbidities and left ventricular (LV) systolic dysfunction who are 
considered a high surgical risk.  
 
To date, there remains uncertainty regarding the prevalence of MR within the HF 
population. Additionally, the degree to which there is an improvement in MR severity 
and symptoms in response to treatment is largely unknown. Furthermore, there 
remains debate regarding the benefit of TMVR in relation to symptoms, quality of life 
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1.2 Thesis Overview 
 
This thesis is in the style of a traditional thesis by monograph with eight chapters, 
divided into sections and subsections.  
 
Chapter 2 introduces the topics of HF and MR. It provides a background to the subject 
and discusses the diagnostic benefit of cardiac imaging, functional testing and 
biomarkers, and outlines the current treatment options. It also presents a 
comprehensive literature review focusing on the role of TMVR in relation to outcomes 
and mortality. This literature review provides the background information necessary 
for the development of the methodological component of the thesis which is designed 
to answer the research question. Chapter 2 ends with an outline of the thesis aims 
and objectives, and provides an impact statement. 
 
Chapter 3 focuses on assessing the prevalence of patients admitted with HF who 
have moderate or more MR. It investigates variations in LV systolic function, 
concomitant comorbidities, and mortality across the population. The impact of OMT 
on MR, ejection fraction (EF) and symptoms is also examined. 
 
Chapter 4 determines the number of high-risk patients with moderate or more MR, an 
EF 20-50% and symptoms, despite OMT. This allows for predictions in relation to the 
exact number of patients potentially eligible for TMVR on a local and population level 
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Chapter 5 provides a systematic review and meta-analysis focussed on the 
usefulness of TMVR for symptomatic patients with HF and MR, and the role of 
functional testing in relation to predicting outcomes. It presents informed conclusions, 
suggesting the application of six minute walk tests and exercise stress echo in future 
research studies. 
 
Chapter 6 uses a prospective pilot study approach to examine changes in symptoms, 
quality of life, and echocardiographic parameters following TMVR. This chapter also 
aims to investigate the usefulness of functional testing and biomarkers in predicting 
changes in LV performance. Unfortunately this project work was limited by the 
consequences of the Covid-19 pandemic which affected recruitment and follow up. 
The chapter discusses the limitations and concludes with important considerations in 
relation to symptomatic improvement, and parameters useful in the selection of TMVR 
candidates. 
 
Chapters 7 and 8 provide a concluding overall discussion with a focus on important 
questions that arose throughout the research. The chapters discuss breaking theories 
and concepts in relation to the application of TMVR. Additionally, the chapters promote 
rethinking our current ways of work, with suggestions for possible future clinical 
applications and research. 
 
Prof Bernard Prendergast at Guy’s and St Thomas’ NHS Foundation Trust (GSTT), 
London, United Kingdom (UK) and Dr Garry McDowell at Manchester Metropolitan 
University (MMU), Manchester, UK, have overseen all components of the research 
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project. Prof Mark Monaghan (King’s College Hospital, London, UK) and Dr Jane 
Hancock (GSTT, London, UK) have been additional external onsite associate 
supervisors. Dr Fiona Wilkinson (MMU, Manchester, UK) provided assistance with the 














ACUTE HEART FAILURE AND MITRAL 




2.1 Acute Heart Failure 
 
Acute heart failure (AHF) is a complex yet common syndrome. Patients most 
frequently present with symptoms of breathlessness, fatigue and reduced exercise 
tolerance (1). Affiliated signs of heart failure (HF) may include oedema, tachycardia, 
elevated jugular venous pressure (JVP) and ascites. In addition, patients experience 
a change in heart anatomy and volume, and the ability of the heart to eject sufficient 
forward stroke volume (SV) becomes impaired.   
 
A HF diagnosis is formally defined by the presence of signs and symptoms caused by 
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2.1.3 Aetiology and pathophysiology of HF 
 
HF occurs due to a decrease in the number of functional myocardial cells as a 
consequence of heart injury (6). The cause of the injury can be isolated or 
multifactorial. Worldwide, the most frequent causes of HF include ischaemic heart 
disease (IHD), diabetes and hypertension, with the latter condition doubling the risk of 
HF development compared to the normotensive patient (7). Within the United Kingdom 
(UK), atrial fibrillation (AF), and valve disease are also considered common triggers. 
Less often, HF may occur as a consequence of cardiomyopathies, pericardial disease, 
infections, or toxins.  
 
There are a number of compensatory mechanisms that occur as part of the HF 
sequalae. This includes activation at a structural, cellular and molecular level. In the 
first instance, the heart attempts to increase cardiac output via the Frank-Starling 
mechanism, with ventricular volumes and wall thickness increasing in response to 
ventricular remodelling (6, 8). This occurs on a macro level, with structural changes in 
the myocardial architecture resulting in adaptations to the geometry of the elliptical left 
ventricular (LV) chamber (9). Classifications in relation to remodelling have been 
defined as concentric, eccentric and combined, with eccentric and combined more 
associated with dilated cardiomyopathies, mitral regurgitation (MR) and IHD (Figure 
2.1). Tissue perfusion is maintained through the activation of neurohormonal systems. 
Increased vascular tone and autonomic activity assist in delaying decompensation (8). 
This multifactorial network of adaptations provides an initial benefit in the early stages 
of HF, successfully maintaining physiological functioning. Yet despite these attempts, 
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these changes lead to additional signs and symptoms in the long-term and a vicious 
cycle of worsening and progressive HF.  
 
 
Figure 2.1. Pathophysiology of heart failure (HF): structural changes in the geometry of the left ventricle 
occur as a component of compensatory mechanisms in the setting of HF. This figure outlines a normal 
response followed by a concentric response as well as an eccentric and combined response (more 
commonly seen in mitral regurgitation, dilated cardiomyopathies and ischaemic heart disease). Taken 







Mitral Regurgitation in Heart Failure: Burden, Treatment Options and Outcomes 
 
47 
2.1.2 Clinical manifestations of HF 
 
Patients with HF can be broken down into two broad groups: those with preserved 
ejection fraction (HFpEF) and those with reduced ejection fraction (HFrEF). HFrEF is 
defined by impaired left ventricular systolic function and a reduced ejection fraction 
(EF). By contrast, diastolic HF (HFpEF) results as a consequence of impaired 
ventricular relaxation and filling, increased stiffness of the ventricle, and raised filling 
pressures, yet systolic function and EF remain preserved. Cut points defining those 
with impaired versus preserved EF vary between guidelines. According to the 2016 
European guideline, HFrEF encompasses patients with an EF <40% (10). Those with 
an EF >50% are considered amongst the HFpEF category. However, this leaves a 
grey area for those with an EF >40-49% which has subsequently been defined as 
heart failure with mid-range ejection fraction (HFmrEF) (10). Despite its prevalence, 
HF can be complicated, with no one single marker capable of diagnosing HF in 
isolation. It is important therefore to note that the diagnosis and categorisation of HF 
are not based on EF alone. The presence of signs and symptoms, raised natriuretic 
peptides, and manifestations of structural heart disease, such as left ventricular 
hypertrophy (LVH) and left atrial (LA) enlargement, all play a fundamental role in 
determining diagnosis (Table 2.1). Ensuring accurate classification and differentiation 
of the types of HF is essential due to distinctive aetiologies and co-morbidities but 
most importantly due to their impact in forecasting responses to therapies and 
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Table 2.1. Definition of heart failure according to the European 2016 heart failure guideline with criteria 
for the subclassifications of heart failure (10). Abbreviations: HF: heart failure; HFrEF: heart failure with 
reduced ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure 
with preserved ejection fraction; LVEF: left ventricular ejection fraction; LVH: left ventricular 
hypertrophy; LAE: left atrial enlargement. N/A: not applicable. bBNP >35pg/ml and/or NT-pro BNP 
>125pg/mL. 
Type of HF HFrEF HFmrEF HFpEF 
Criteria 1 Symptoms + Signs Symptoms + Signs Symptoms + Signs 
2 LVEF <40% LVEF 40-49% LVEF >50% 
3 N/A 1. Elevated levels of 
natriuretic peptidesb 
2. At least one additional 
imaging criterion: 
a) relevant structural 
heart disease (LVH 
and/or LAE) 
b) diastolic dysfunction 
1. Elevated levels of 
natriuretic peptidesb 
2. At least one additional 
imaging criterion: 
a) relevant structural heart 
disease (LVH and/or LAE) 
b) diastolic dysfunction 
 
 
2.1.3 Prevalence, incidence and mortality 
 
Having reached epidemic proportions, HF has now become recognised as a public 
health concern. Current data suggest that HF affects an estimated 900 000 people 
within the UK and 26 million people worldwide (11). In the year preceding March 2018 
there were approximately 56 000 hospital admissions in England with a primary 
diagnosis of HF (1, 11). This compares to around 51 000 in 2014. Other UK based 
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studies estimate new HF diagnoses progressively climbing by 20 000 over the last 12 
years (12). However, incidence rates from small studies in 2014 sit at 330 persons per 
100 000 suggesting no large incremental increase (12).  In light of a proposed 
reasonably steady rate of incidence, the increased prevalence is likely to be a 
consequence of an aging population and improved HF survival due to advanced 
therapies. It may also be related to behavioural changes and prevention programmes 
focussed on seeking earlier medical attention in acute coronary syndromes (ACS) and 
reduced rates of smoking. Despite this, projections are worrisome with prevalence 
expected to rise by 46% by 2030 (11).   
 
The median age for patients admitted with HF in the UK is approximately 80 years, 
with women slightly higher and men slightly lower (Figure 2.2). It is well recognised 
that HF is more prevalent in the aging population. On average, there are more men 
across all age categories other than >85 years (where women are in the majority). In 
addition, patients with multiple comorbidities including (but not limited to) obesity, 
diabetes, hypertension, and also those who are considered socio-economically 
deprived are more likely to develop HF (12). This is the case on a global scale with 
likely culprits being limited access to healthcare, education in prevention, and dietary 
habits. There remains, however, a lack of public health data in relation to disease 
incidence at population level, with some reports documenting an increase in the 
incidence of HFpEF (13). As such, conclusions regarding total burden and future 
resource planning can only be based on limited evidence (which may not be 
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Demographics of United Kingdom heart failure patients: age and gender 
 
Figure 2.2. Characteristics of United Kingdom (UK) heart failure (HF) patients at first HF admission: 
age and gender demographics. Taken from: NICOR Heart Failure Audit: 2019 Summary Report (1). 
 
 
Nationally, in-patient mortality for patients with a HF hospital admission is estimated 
at around 10%.  The 1-year mortality for patients after a HF admission remains high 
at  32% (2017/2018) (1). The quoted 1-year mortality for Europe has been estimated 
at between 6-24% depending on acute versus chronic HF (14). In the United States of 
America  (US), this was sub-categorised according to the degree of HF and ranged 
between 35-37% (15). The UK mean length of stay (LOS) for patients with HF ranges 
depending on the level of care provided, with patients seen within cardiology often 
staying longer in hospital compared with those cared for within general medicine (9 vs 
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6 days) (1). This is likely a result of more severe cases within cardiology who may also 
require initiation and implementation of medical and device therapies. For those 
patients who survive, their quality of life (QoL) can be poor. Although varying across 
the HF population, the literature suggests that a diagnosis of HF has a greater impact 
on QoL compared with many other chronic diseases (including arthritis and chronic 
lung disease), and a greater influence on mental health than depression (16). 
 
 
2.2  Mitral Regurgitation in Acute Heart Failure 
 
Mitral regurgitation (MR) is a widespread problem affecting approximately 10% of the 
UK population, increasing with age to approximately 20% in those >65 years (17, 18). 
It can present in two forms, either ‘primary’ or ‘secondary’ (18). Left untreated, both 
forms may lead to HF as a consequence of ventricular remodelling and changes in 
chordal and valve anatomy. Unfortunately for patients with HF, concomitant MR 
contributes to a poor prognosis, frequent hospitalisations, and higher rates of mortality 
(19).  
 
2.2.1 Anatomy of the mitral valve  
 
The mitral valve (MV) comprises two leaflets, the posterior and anterior. Both leaflets 
are of similar area with noticeable differences in structure. The posterior leaflet is 
narrower and extends approximately two thirds around the length of the left 
atrioventricular junction. By contrast, the anterior leaflet is much broader and shorter, 
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encompassing the remaining one third of the junction. Each leaflet is divided by clefts 
into three scallops (commonly labelled P1, P2, P3 and A1, A2 and A3) that meet at an 
anterior or posterior commissure (Figure 2.3). Leaflets and scallops are supported by 
an annulus, chordae tendineae and papillary muscles. The annulus is located at the 
junction between the LV and LA and provides attachment for the MV. The fan shaped 
tendinous chords attach to the leaflets either on the free edge, the ventricular surface 
or the basal region of the posterior leaflet. At the other end, the chords attach directly 
to the papillary muscles (typically two papillary muscles in the anterolateral and 
posteromedial positions) within the mid to apical left ventricular wall. There are 
anatomical variations in the position and number of papillary muscles (20). 
 
 








Figure 2.3. Anatomy of the mitral valve. A: En face image of the mitral valve which denotes the middle 
scallop of the posterior leaflet as P2, with P1 lateral and P3 medial. The opposing segments of the 
anterior leaflet are designated as A1, A2, and A3. AC and PC represent the anterolateral and 
posteromedial commissures. Taken from: Stone et al (21). B: Anatomy of the mitral valve and mitral 
apparatus including the papillary muscles and chordae tendineae in long axis view. Taken from: Clinical 
Echocardiography (22). Abbreviations: LA: left atrium; LV: left ventricle. 
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2.2.2 Mechanisms of mitral regurgitation 
 
Mechanisms of MR can be categorised as primary and secondary (also commonly 
referred to as degenerative and functional respectively). Primary MR occurs where 
there is a structural or degenerative abnormality with the MV leaflets, chordae 
tendineae, papillary muscles or MV annulus. Secondary or functional MR occurs in 
the absence of an organic valve abnormality but in the presence of LV dysfunction. 
More recent studies also acknowledge the role of LA dilation, annular dilation and AF 
in the setting of secondary MR (23). Further explanation regarding secondary 
(functional) MR is outlined below. Categories for MR aetiology are based on the 




Figure 2.4. Mitral valve (MV) anatomy and Carpentier classification of mitral regurgitation (MR). This 
image depicts the different aetiologies which result in MR. Type I shows normal MV leaflets where 
annular dilation or perforation of the leaflet is the cause of MR; Type II shows excessive leaflet motion 
with a flail or prolapsed MV leaflet resulting in MR. Type IIIa shows restricted MV leaflets affecting 
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opening and closing of the valve as a consequence of thickening or calcification of MV leaflets, 
commissures or chordae tendineae. Type IIIb demonstrates a problem with closure of the valve leaflets 
secondary to chordal thickening, shortening or LV dilation. Taken from: Stone et al (21). 
 
 
In the setting of acute HF, primary MR is usually associated with Type II changes 
characterised by increased leaflet motion as a result of prolapse or chordal rupture. 
Although Type II primary MR is common, it is less often associated with HF unless 
volume overload is chronic, prolonged and severe, and myocardial damage has 
occurred.   
 
For secondary (functional) MR, the most common aetiology is Type IIIb, defined by 
restricted leaflet motion and closure in systole which is frequently the result of 
ischaemia (18). Put simply, ischaemia leads to myocardial infarction which causes 
local remodelling and geometric changes in the LV, resulting in papillary muscle 
displacement. Dysfunction also offer leads to LV enlargement which causes MV 
annulus dilation and a simultaneous loss in the saddle shape of the MV annulus (24). 
From here we see increased tethering forces on the MV leaflet, tenting of the leaflets 
with reduced leaflet closure forces, and thus MR  (24). Although in most instances this 
will be in the setting of HFrEF, there will be occasions where even in the presence of 
a regional wall motion abnormality and MR, overall EF remains preserved. LV 
dyssynchrony may be an additional mechanism by which MR occurs secondary to 
ischaemia, leaflet dysfunction and retraction. MR is typically posteriorly directed as 
localised remodelling tends to impact the posteromedial papillary muscle and posterior 
MV leaflet. Non-ischaemic secondary (functional) MR is characterised by global 
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dilation and increased LV sphericity, and largely results from long standing 
hypertension or idiopathic cardiomyopathy (18). The MV tenting height increases 
symmetrically, reducing coaptation with MR generally central in origin.  Occasionally, 
secondary MR can be the result of isolated mitral annular dilation in the absence of 
tethering or prolapse (Type I). This is mainly the result of chronic AF but can also be 
seen in patients with HFpEF (25). Secondary (functional) MR leads to increased 
preload, LV wall stress and LV workload, and a vicious spiral towards HF. 
 
Prognosis for patients with acute HF and primary MR is very good with any LV volume 
overload quickly corrected through surgical repair allowing for a normal lifespan (26). 
Unfortunately, secondary MR portends poor clinical outcomes with MR as a result of 
myocardial infarction carrying an increased risk of death. Despite the differences in 
prognosis and clinical outcomes, HFpEF with associated MR and HFrEF are quite 
evenly balanced in relation to rates of hospital admission and overall impact on 
hospital resources (27).  
 
2.2.3 Diagnosing mitral regurgitation 
 
  2.2.3.1 Echocardiography 
 
Echocardiography is an extensively utilised, non-invasive investigative tool that can 
be used in the identification of MR. It is inexpensive, widely available and has no 
known side effects. Transthoracic (TTE) and transoesophageal echocardiography 
(TOE) are commonly used in combination in order to definitively diagnose the 
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mechanism of MR, its severity and any other underlying concomitant cardiac lesions. 
Both of these diagnostic tools use an integrative approach, merging qualitative, 
quantitative and semi-quantitative measures in the assessment of MR. Current 
recommendations regarding the defining features of severe MR from the American 
Heart Association (AHA), American College of Cardiology (ACC) (2017 and 2020), 
American Society of Echocardiography (ASE) (2017) and European Society of 
Cardiology (ESC) (2017) are outlined in Table 2.2 (28-31). A small degree of variation 
can be noted but general guidance is reasonably consistent between the 2017 
guidelines. 
Table 2.2. A summary of echocardiographic criteria and cut points used to define severe mitral regurgitation across a selection of guidelines including the 
American Heart Association (AHA), American College of Cardiology (ACC), American Society of Echocardiography (ASE) and European Society of Cardiology 
(ESC) (28-31).  
Parameter AHA / ACC guideline 
(2017) 
ASE guideline  
(2017) 




Quantitative     










>40 for both Primary and 
Secondary 
PISA radius (cm) Not defined >1.0 Not defined  










>60 for both Primary and 
Secondary 
Regurgitation Fraction (%) >50 >50 Not defined >50 
Semi-quantitative     
MV inflow (m/s) Not defined >1.2 E-wave dominant >1.5m/s Not defined 
Pulmonary Vein Flow Not defined Systolic flow reversal Systolic flow reversal Not defined 
Vena Contracta (mm) >7 >7 >7 >7 
 
Of note, during the submission and revision of this thesis, AHA/ACC updated the 
guidelines regarding the management of patients with valvular heart disease (Table 
2.2) (31). Interestingly, the 2020 AHA/ACC guideline made the decision to align criteria 
for both primary and second MR. The reasoning for this was based on the premise 
that the criteria for severe primary MR had been used in determining severe for 
secondary MR in foundation surgical intervention randomised controlled trials (RCTs) 
(31). Reviewing the RCTs in detail it appears that although in some cases an effective 
regurgitant orifice area (EROA) cut point of >0.4cm2 (criteria for severe primary MR) 
had been applied, there was also flexibility within the criteria with MR being defined as 
severe with an EROA <0.4cm2 but with other echocardiographic features of severe 
MR, indicating that this change in guidance had been supported by outcomes using 
integrative criteria (32-34). Alongside the change, the guideline does denote 
controversies surrounding the definition of severe secondary MR. It describes: 1) 
established data reporting a smaller EROA in secondary MR being associated with 
adverse outcomes when compared to primary MR; 2)  secondary MR as carrying an 
increased risk of progression and deterioration due to adverse LV or MV annulus 
remodelling; and 3) secondary MR as suffering from potential underestimation due to 
crescentic shape of the regurgitant orifice when measured by the flow convergence 
method (31). Moreover, though not included in guideline reasoning, it is also well 
established that in the presence of LV dysfunction and concomitant low stroke volume, 
a smaller regurgitant volume represents a small regurgitant fraction; and that MR is 
dynamic and as such severity can vary depending on the phase of the cardiac cycle 
and the loading condition. Importantly, all guidelines emphasise that assessment of 
MR should be integrative and based on a combination of parameters to minimise the 
 
___________________________________________________________________ 
Mitral Regurgitation in Heart Failure: Burden, Treatment Options and Outcomes 
 
59 
impact of the intrinsic limitations of each individual method and ensure more precision 
in determining severity. 
 
In addition to the parameters outlined above, guidelines further support the use of two 
dimensional (2D) and three dimensional (3D) imaging to provide detailed information 
in relation to anatomy and pathology (prolapsed or flail leaflets, ruptured papillary 
muscles or large coaptation defects). Leaflets should be thoroughly inspected to 
determine if valve anatomy is amenable to repair. The application of colour flow 
imaging also facilities examination of the jet size and direction. A large central jet 
(greater than 40-50% of the LA) or an eccentric jet adhering to the wall or inter-atrial 
septum and reaching the posterior wall of the LA may denote severe MR (Figure 2.5 
A, B) (29). Additionally, a large flow convergence zone would be cause for concern. 
Furthermore, the shape and density of the continuous wave Doppler signal may assist 
in determining severity, with those that are dense, triangular and holo-systolic aligning 
with severe MR.  
 
 
A                                                      B 
                           LV                                                    LV 







                           
                            LA                                                    LA 
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Figure 2.5. Two dimensional echocardiography images obtained from an apical four chamber acoustic 
window with the application of colour Doppler imaging. (A) shows a large central jet of mitral 
regurgitation which occupies greater than 50% of the left atrium; (B) shows a large eccentric jet of mitral 
regurgitation which is directed anteriorly towards the interatrial septum, reaching the posterior wall of 
the left atrium. Both of these images denote severe mitral regurgitation. Note: the mitral regurgitation 
jets are represented by the green/yellow/light blue disorganised, mosaic colour on the image. 
Abbreviations: LV: left ventricle; LA: left atrium.  
 
 
Assessing the size and function of the LV is crucial for these patients and can be best 
performed with 2D biplane and 3D volume measurements.  Across both primary and 
secondary aetiologies of MR, LV performance may vary from poor to hyperdynamic. 
Therefore, obtaining an accurate estimate of stroke volume can prove useful in 
determining if there is adequate forward circulation. Most current guidelines also 
advise on inspecting the size and/or volume of the LA as this measurement can be 
vital in determining eligibility for surgery. Likewise, the estimated pulmonary artery 
systolic pressure (PASP) contributes to the decision making process in terms of 
surgical intervention and this measurement is key (in conjunction with assessment of 
right ventricular (RV) size and function, and the presence of concomitant tricuspid 
regurgitation).  
 
While echocardiography remains the first line investigation for the assessment of MR, 
other cardiac imaging modalities may be useful. Magnetic resonance imaging (MRI) 
can provide accurate information in relation to LV and RV volumes, function and MR 
severity and aetiology when these are not clear on echocardiography. MRI has the 
advantage of not being limited by body habitus or a narrowed selection of imaging 
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planes, and can provide additional valuable information in relation to myocardial 
viability and scarring. 
 
2.2.3.2  Functional testing 
 
On the occasions when there is a discrepancy between symptoms and 
echocardiographic findings, or when disease severity is borderline, functional testing 
can provide useful additional information. The AHA/ACC, ASE and ESC guidelines all 
endorse the use of exercise testing, whether through the use of treadmill, exercise 
stress echocardiography or cardiopulmonary testing (28-30). Exercise testing may 
unmask symptoms in individuals who are sedentary as well as providing an overall 
estimate of functional capacity. Testing can also be useful as a serial comparative 
measure. Additional information pertaining to the LV response to exercise, as well as 
the PASP and degree of MR at peak exercise can assist in determining risk 
stratification and predicting outcomes. Yet the feasibility, practicality and usefulness 
of functional testing specifically within the HF and MR population requires further 
examination. Chapter 5 provides a systematic review and meta-analysis explicitly 
critiquing the role of functional testing. 
 
2.2.3.3  Biomarkers 
 
The use of biomarkers in the setting of MR still requires further investigation. Although 
limited studies have shown that B-type natriuretic peptide (BNP) can independently 
predict outcome in asymptomatic primary MR, a greater number of large scale studies 
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need to be performed before BNP can be used as a definitive trigger for surgery, 
particularly for the HF population who may have coexisting AF (35). Current 
recommendations from the ESC suggest the use of brain natriuretic peptide and N-
terminal pro B-type natriuretic peptide  (NT-pro BNP) as predictors of outcome, 
particularly at symptom onset (29). Additionally NT-pro BNP can be used as a ‘rule 
out’ test, categorising patients with a normal value as low risk where follow up with 
close monitoring and echocardiographic surveillance is the recommended course of 
action.   
 
2.2.4 Treating mitral regurgitation in heart failure 
 
  2.2.4.1 Primary MR in heart failure 
 
By definition, patients with HF and severe MR will be symptomatic. Therefore this 
section will focus primarily on treatment for symptomatic patients. Surgery is indicated 
in acute severe symptomatic MR. In the setting of chronic severe MR, surgery is 
indicated in symptomatic patients with an EF >30%. For those with an LV EF <30% or 
left ventricular end systolic dimension >55mm refractory to medical therapy, surgical 
MV repair should be considered where the likelihood of successful repair is high and 
comorbidity low (29, 30). MV replacement should be considered with caution within 
this same population where the likelihood of surgical MV repair is considered low. 
Finally, transcatheter edge to edge repair should be considered for patients with 
symptomatic severe primary MR who are high surgical risk and considered inoperable 
(29). Important decisions for the Heart Team to consider prior to transcatheter mitral 
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valve repair (TMVR) include fulfilling echocardiographic eligibility criteria (with 
anatomy deemed favourable for transcatheter repair) and a reasonable life 
expectancy (29, 30). 
 
  2.2.4.2  Secondary MR in heart failure 
 
The presence of severe secondary MR has been shown to negatively impact 
prognosis. However, it is unclear if prognosis is independently affected by MR or 
whether this is a consequence of LV dysfunction. To date, there remains debate as to 
whether reducing secondary MR results in survival benefit. For patients with HF, the 
degree of MR can be dynamic. Therefore, the first step in management of secondary 
MR should be to ensure that all patients are on OMT in line with recommendations for 
the management of HF (10, 36).  This may include initiation of a beta-adrenergic 
receptor antagonist (more commonly known as a beta-blocker) and an angiotensin-
converting enzyme (AVE) inhibitor or angiotensin II receptor blockers (ARB). Where 
symptoms persist a mineralocorticoid receptor antagonist (MRA) may be considered 
(37). In the setting of signs and/or symptoms of congestion, a diuretic may be 
recommended. Ongoing input from a HF specialist is fundament. 
 
Where patients remain symptomatic on OMT, cardiac resynchronisation therapy 
(CRT) should be considered for patients who meeting eligibility criteria. CRT is 
indicated for patients who have an LVEF of 35% or less, sinus rhythm, left bundle-
branch block (LBBB) with a QRS duration of >130ms, and New York Heart Association 
(NYHA) class II, III, or ambulatory IV symptoms on OMT (36, 38, 39). Studies have 
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shown that patients who undergo CRT experience a reduction in the degree of MR 
alongside improvement in symptoms, functional capacity and QoL (40). Improvement 
may occur acutely or progressively over time and is thought to be related to the degree 
and location of dysynchrony (41).  
  
Conventional MV surgery should be considered for patients with an EF >30% and 
persistent symptoms despite OMT and CRT who are undergoing CABG and for those 
with an EF <30% where revascularisation is an option based on positive myocardial 
viability assessment.  Indications for isolated MV surgery are restrictive in patients not 
undergoing concomitant revascularisation, owing to high rates of mortality and 
residual MR as well as limited evidence to suggest a survival benefit (42, 43). 
Conventional surgery without revascularisation may be indicated within this cohort 
when surgical risk is low.  However, for patients with multiple comorbidities and a 
prohibitive surgical risk, edge to edge TMVR may be considered with the primary aim 
of reducing the degree of MR with additional clinical outcomes focussed on symptom 
relief, enhanced lifestyle and longevity. 
 
Valve intervention is uncommon and not advised in those with an EF <15% (29). 
Cardiac transplantation or destination LV mechanical assist device therapy should be 
considered for patients who have severe refractory symptoms or irreversible severe 
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The first TMVR was performed in Venezuela in 2003 (44-46). Five years later this 
experience was shared by the UK (47). Since this time, there has been rapid 
progression and significant evolution in the sphere of TMVR devices, with broadening 
indications for their use and increased degrees of success.  
 
As a consequence of lifelong learning from surgical colleagues and subsequent 
collaboration with interventional specialists, the last decade has seen the development 
of a significant number of TMVR devices; each with slight variations in design and 
alterations in anatomical approach and delivery techniques. The European approved 
TMVR toolbox comprises devices such as the MitraClip (Abbott Vascular, Inc., Santa 
Clara, California), the DS1000 device (NeoChord, Inc., St. Luis Park, Minnesota), the 
Carillon (Cardiac Dimensions, Inc., Kirkland, Washington), the CardioBand (Valtech 
Cardio, Or Yehuda, Israel), and the Mitralign device (Mitralign, Inc., Tewksbury, 
Massachusetts) (48). Many more are currently undergoing clinical evaluation in order 
to obtain approval. Transcatheter edge to edge repair using the MitraClip system 
(Abbott Vascular, Inc., Santa Clara, California) remains the most well established and 
commonly used (Figure 2.6) (49). Having treated 35 000 patients globally with 

















      
	
 
Figure 2.6. The Abbott MitraClip device (A). (B) shows deployment of the MitraClip device at the P2, 
A2 mitral leaflet scallops. Using the edge to edge repair technique a small bridge between the anterior 




The excitement surrounding TMVR was based on the premise that it presented a novel 
and innovative alternative to conventional open heart surgery via a minimally invasive 
route. By 2003, we had already lived the experience and seen the benefit of 
transcatheter aortic valve implantation (TAVI). However, TMVR remained largely 
untested with unknown outcomes in a population of complex HF patients with a 
complicated continuum of MV anatomy. Early studies therefore focussed on the 
feasibility, safety and efficacy of TMVR, drawing comparisons with conventional 
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surgery. The Endovascular Valve Edge-to-Edge Repair Study (EVEREST II trial) set 
the stage for comparison by performing a randomised controlled trial (RCT) separating 
patients into one of two arms: 1) TMVR or 2) surgical repair or replacement (51, 52). 
This study showed that TMVR was feasible with low rates of mortality and a reduction 
in MR in the majority of patients (52). More specifically, it found that major adverse 
events rates were lower in those who underwent TMVR compared to MV surgery (15% 
vs 48%, p<0.001). Yet, reported findings also demonstrated that reduction in the 
severity of MR (to grade 1+ or less) was more common in the surgical group (100% 
vs 73%, p=0.18). The study concluded that TMVR was less effective in reducing the 
degree of MR compared to conventional surgery, but was safer and just as effective 
in improving quality of life (QoL) and symptoms. This was supported by a comparison 
of NYHA class at 12 months which showed only 2% of TMVR patients had NHYA class 
III/IV versus 13% of patients who underwent surgical intervention. By this time, other 
foundation studies focussing on TMVR were supporting the usefulness of 
percutaneous technology and also drawing comparisons with conventional surgery in 
relation to perceived high levels of safety and efficacy but questionable outcomes in 
relation to the degree of residual MR (53).  
 
Given these findings, researchers shifted their focus to the role of TMVR amongst frail 
patients with multiple comorbidities considered too high risk for surgical repair. Studies 
consequently concentrated on comparing high risk TMVR patients with a retrospective 
cohort of high risk patients receiving standard care. Early outcomes demonstrated that 
TMVR was feasible within this cohort with additional benefits in relation to LV geometry 
and positive remodelling, as well as symptoms (54). The most significant conclusion 
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was a reduced rate of HF hospitalisation following TMVR. The study concluded that 
the annual rate of HF hospitalisation amongst TMVR patients reduced to 0.32 
compared to 0.59 for ‘matched’ patients who received standard care (p=0.034) (54). 
 
At this point, no study had looked at distinguishing outcomes of patients with primary 
versus secondary MR, or randomised those who underwent TMVR versus optimal HF 
medical therapy, or conclusively determined the effects on longevity. The ACCESS-
Europe Phase I Trial did just that. With a primary focus on delivering TMVR to patients 
with inoperable degenerative MR, it showed significant reduction in MR and 
improvements in clinical condition 12 months following intervention (55). This was 
supported by the work of Buzzatti et al who showed that in octogenarians, the aging 
population with the highest incidence of MR, TMVR was associated with lower 
procedural complications and improved QoL but more residual MR compared with 
surgical repair. Interestingly though, recurrent MR was not significantly associated with 
follow up mortality (56). Five years on and rapidly moving forward, 2020 delivered  the 
5-year follow up results of the EVEREST II trial. This demonstrated no difference in 
rates of redo surgery for patients who had conventional surgery versus those who 
underwent TMVR where patients were event free at 12 months (TMVR 5% vs MVR 
3%, p=>0.99). This evidence provided reassurance in relation to TMVR and its impact 
on longevity (57). 
 
With the accumulation of relevant studies and debate surfacing regarding the patient 
groups for whom TMVR is most effective, Chiarito et al performed a meta-analysis 
interrogating the use of TMVR in primary versus secondary MR (2018). Based on nine 
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studies, this review showed no significant difference in the degree of residual MR 
between patients, but a higher rate of MV re-intervention required for patients with 
degenerative MR (58). Additionally, and as expected, a higher percentage of patients 
with secondary MR remained in NYHA class III/IV and required re-admission for heart 
failure (58). The final conclusions of this meta-analysis suggested that large 
randomised clinical studies were still needed to confirm the benefit of TMVR within the 
separate aetiological groups, with a particular focus on secondary MR (58).  
 
In 2018, two large scale ground-breaking studies (MITRA-FR and COAPT) were 
published in the New England Journal of Medicine (59, 60). Each study focussed on 
assessing clinical outcomes following TMVR in patients with secondary MR. On first 
impressions, both delivered very different results, opposing clinical messages, and 
contradictory recommendations for treatment. However with greater inspection it is 
possible to provide explanation of the diverging results and see outcomes as more 
complementary rather than conflicting, These studies are outlined in Table 2.3 and 
discussed in more detail below. 
 
 
Table 2.3. A comparison between the findings of two large scale transcatheter mitral valve repair 
studies: MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients 
With Severe Secondary Mitral Regurgitation) and COAPT (Cardiovascular Outcomes Assessment of 
the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation); 
Abbreviations: GDMT: guideline directed medical therapy; CRT: cardiac resynchronisation therapy; HF: 
heart failure; EF: ejection fraction; LVESD: left ventricular end systolic dimension. RVol: regurgitant 
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 MITRA-FR (2018) COAPT (2018) 
Country France United States and Canada 
Study Design Prospective, randomised Prospective, randomised 
Arms Intervention: MitraClip + GDMT Intervention: MitraClip + GDMT 
 Control: GDMT Control: GDMT 
Sample Size 304 614 
Centres 37 78 
Primary Outcome Death and HF hospitalisation at 12 
months 
HF hospitalisation at 24 months 
Inclusion criteria EF: 15-40% EF: 20-50% 
 LVESD: no specific criteria LVESD: <70mm 
 MR: RVol >30mL, EROA >20mm2 MR: RVol >45mL, EROA >30mm2 
 RV Function: no specific criteria RV Function: < moderate dysfunction  
 SPAP: no specific criteria SPAP: <70mmHg  
 HF history: Minimum of 1 HF 
admission within 12/24 months 
preceding recruitment 
HF history: At least one hospitalisation for 
HF in the 12 months prior to enrolment 
and/or a corrected BNP ≥300 pg/ml or a 
corrected NT-pro BNP ≥1500 pg/ml 
GDMT Received HF meds at baseline. 
Allowed variable adjustments in 
each group during follow up. No 
specific protocol. 
Protocol approach to maximal tolerated 
medications. Minor changes in follow up 
only 
CRT in situ (yes) Not specified 224 (36%) 
Combined primary 
outcome of death and 
HF hospitalisation at 
12 months 










Intervention (48.7%) vs. control 
(47.4%) at 12 months 
Intervention (35.8%) vs. control (67.9%) 
(p=<0.001) at 24 months 
Death from any cause Intervention (24.3%) vs. control 
(22.4%) at 12 months 
Intervention (29.1%) vs. control (46.1%) 
at 24 months 
 
The MITRA-FR study (Multicentre Study of Percutaneous Mitral Valve Repair 
MitraClip Device in Patients With Severe Secondary Mitral Regurgitation), based in 
France, was centred on a cohort of approximately 300 HF (NYHA class II-IV) patients 
with severe secondary MR and an LVEF 15-40%. The primary outcome was based 
on the composite of death from any cause or unplanned HF hospital admission. This 
randomised controlled trial demonstrated that the rate of death or unplanned 
hospitalisation at 12 months was no different between patients who underwent TMVR 
in addition to OMT, and those who received OMT alone (59, 61).  
 
However only one month later, in the US, Stone et al released the results of the 
COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous 
Therapy for Heart Failure Patients With Functional Mitral Regurgitation) study (60). 
This study also focused on drawing comparisons between secondary MR HF patients 
who received OMT and subsequently underwent TMVR, and those who received OMT 
alone. Based on randomisation, 600 patients were divided into the two separate 
treatment groups and followed up for 24 months. Patients in this study had moderate 
to severe or severe MR, NYHA II-IV, and an LVEF 20-50%. This study focussed on 
the end point of all cause HF hospitalisation and demonstrated a lower HF 
hospitalisation rate (reduced by 32%) and lower all-cause mortality at 24 months 
(reduced by 17%) in the treatment arm (TMVR + OMT) compared to OMT alone (60). 
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These results disputed those obtained in the MITRA-FR trial, raising questions 
regarding the most appropriate treatment options for patients with secondary MR 
going forward.  
 
Critically evaluating the outcomes of these studies there were some inherent 
differences in study design and patient population. Firstly, recruitment into COAPT 
was larger and a larger number of centres were included in recruitment. Secondly, 
patient selection within the MITRA-FR trial targeted many more patients with moderate 
(as opposed to severe) MR with clear differences in the echocardiographic inclusion 
criteria. To clarify this point, the MITRA-FR trial recruited patients with an EROA 
>20mm2/ RV >30mL compared to the COAPT trial which included those with an EROA 
>30mm2/RV >45mL, suggesting those within the COAPT had more significant MR. 
Additionally there were also considerable differences in the LV volumes and EFs in 
those who were recruited. The COAPT trial used a LVESD cut point of <70mm as a 
marker for inclusion but MITRA-FR did not stipulate any maximum LVESD. Likewise, 
the EF range for inclusion varied between studies. MITRA-FR applied a range of 15-
40% with COAPT focussing on those with an EF of 20-50%. Of note, patients with 
moderate/severe RV dysfunction or a SPAP >70mmHg were excluded from the 
COAPT trial but not from the MITR-FR trial. Thirdly, there were limited data within 
MITRA-FR outlining the number of patients with pre-existing CRT. Fourth, OMT was 
more stringently monitored within the COAPT trial with only those fulfilling strict criteria 
accepted into the study. By contrast, MITRA-FR was more true-to-life and medical 
therapy rates were not tracked throughout the trial. An additional difference was rates 
of hospitalisation prior to recruitment. In the MITRA-FR trial all patients had been 
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admitted to hospital in the subsequent 12 months. Those recruited to the COAPT trial 
were included based on hospital admission, but were also included based on high 
levels of BNP or NT-pro BNP but in the absence of recent HF admission. The end 
points between the studies also varied, with MITRA-FR focussing on death and 
unplanned hospitalisation combined, and COAPT investigating rates of hospitalisation 
and freedom from device related complications. Follow up times also differed between 
the studies and MITRA-FR had missing echocardiographic and functional follow up 
data.   
 
In addition to this, the proportion of patients enrolled in the COAPT was lower than 
MITRA-FR (61% vs 32%). This was likely due to the echocardiography exclusion 
criteria for COAPT but also may have been influenced by processes for the 
assessment of optimal medical therapy. The COAPT trial required both a local heart 
team evaluation in addition to a central selection committee review (24). For the 
MITRA-FR study patients were screened by the local heart team only. Of note, 
treatment varied between groups with higher rates of renin-angiotesin-aldosterone 
system blockers in the MITRA-FR patients compared to the COAPT patients but 
unfortunately pre and post device therapy, and whether or not this was further 
optimised, was not possible in both groups (the MITRA_FR study did not look at 
medical therapy following TMVR intervention). 
 
Following careful evaluation of the different characteristics of the two studies, what 
becomes apparent is whether it is in fact reasonable to compare the two. The 
differences reveal two very disparate patient populations with the MITR-FR study 
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recruiting patients with less severe MR but more severe LV dilatation and dysfunction, 
and more advanced HF who were proportionally more severely symptomatic. With this 
in mind, it may be that the LV was the main culprit in the MITRA-FR study and MR the 
bystander, suggesting that treatment of the MR may have therefore proved less 
effective in reducing symptoms and/or death. In the COAPT trial we saw quite the 
opposite (more MR, less LV dilatation and dysfunction), making the effects of TMVR 
more effective in reducing hospitalisation (62). Therefore rather than conflicting, it may 
be that these studies should be regarded as complementary, both evaluating MR and 
HF at different points along a continuum (24).  
 
Nevertheless, the results of these two foundation studies leave the HF and intervention 
communities still searching for clarification; not really knowing when to refer HF 
patients with secondary MR for valve intervention whilst also appreciative and 
sympathetic that TMVR may be the only source of relief from life limiting symptoms in 
certain patients. One thing that both studies made clear was the importance of 
appropriate patient selection and increased focus on determining patients who might 
benefit (63). As a result of these studies, philosophies relating to ‘proportionate’ and 
‘disproportionate’ MR to LV volume have been proposed (discussed further in Chapter 
8) (64, 65). These frameworks suggest it may be worth homing in on patients who 
have undergone appropriate optimisation with medical therapy and CRT (if eligible) 
who still have a MV effective regurgitant orifice area >0.3cm2 without excessive LV 
dilatation. For these patients, reducing MR with percutaneous devices may effectively 
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A review of the current literature demonstrates the benefits of TMVR in relation to QoL 
and symptoms. For primary MR there is also a proven survival benefit. Although TMVR 
in secondary MR may be promising for selected patients, more research is required to 
ascertain if there is an impact on mortality within this patient cohort. There is a clear 
research gap with a dearth of information and very little scrutiny into a number of key 
areas including: 1) the actual burden of MR within the HF cohort; 2) the mortality risk 
for those without MR versus those with MR; 3) the degree to which we are failing to 
treat those who are suitable for TMVR; and 4) identifying parameters which may be 
useful in determining which patients will gain the most benefit from TMVR. Further 
research studies should therefore be focussed on investigating these areas, with a 
view to generating evidence to support greater clinical advantage in relation to patient 
selection and improved patient outcomes. 
 
 
2.4 Aims and Objectives 
 
The overall aim of this study was to determine the prevalence of HF patients with 
significant MR and investigate responses to treatment and methods for risk 
stratification.  
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Aim 1. Determine the proportion of patients admitted with HF who have 
moderate or more MR,  their mortality risk, and the impact of OMT 
on MR, EF and symptoms. 
 
Objective 1:  Perform a retrospective consecutive study of patients 
admitted with HF across Lambeth and Southwark over a five year period 
and use TTE data to determine the proportion of patients who have 
moderate or more MR. 
Objective 2: Using ONS data, compare mortality 12 and 18 months 
following the index HF admission across patients with and without 
moderate or more MR. 
Objective 3: Use TTE and clinical data to determine the effects of OMT 
in relation to cardiac function (MR and EF) and symptoms (NYHA), and 
the number of patients who remain with moderate or more MR, EF <50% 
and symptoms, despite OMT. 
 
Aim 2. Determine the number of high-risk patients with moderate or more 
MR, an EF 20-50% and symptoms despite OMT who are potentially 
eligible for TMVR based on echocardiographic criteria, and 
extrapolate this on a population level.  
 
Objective 1: Perform a retrospective consecutive study of Lambeth and 
Southwark patients admitted with HF and use echocardiography and 
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clinical data to determine those who have moderate or more MR, an EF 
20-50% and symptoms, despite OMT. 
Objective 2: Use clinical data and the Euroscore II algorithm to 
determine those patients who are high and intermediate risk. 
Objective 3: For patients with HF, MR, and symptoms who are deemed 
high and intermediate risk, determine those who are potentially suitable 
for TMVR through application of the COAPT selection criteria and Heart 




Aim 3.  Perform a systematic review of the available evidence in relation to 
TMVR and the role of functional testing in predicting outcomes. 
 
 Objective 1: Search five databases for publications related to TMVR 
and functional testing. 
 Objective 2: Focus on articles where functional testing is predictive of 
outcome and use meta-analysis to calculate effect size so as to 
determine the usefulness of functional testing in risk stratification for 
patients undergoing TMVR. 
 
Aim 4. Examine the effectiveness of TMVR for patients with MR and 
symptoms, and the usefulness of echocardiographic markers, 
functional testing and biomarkers in predicting changes in LV 
performance and improvements in symptoms and QoL. 
 
___________________________________________________________________ 




 Objective 1: Prospectively recruit patients undergoing TMVR and draw 
comparisons between pre and post TTE data to determine if TTE can 
predict changes in LV performance following TMVR. 
 Objective 2: Perform functional tests (6MWT and exercise stress 
echocardiograms) to examine their usefulness in discriminating MR 
patients who demonstrate improved LV parameters and QoL following 
TMVR. 
 Objective 3: Examine the effects of residual MR (post TMVR) on LV 
performance and QoL using TTE and QoL questionnaires.  
 Objective 4: Using TTE,  clinical, laboratory and functional data, explore 
and characterise the relationship between changes in LV parameters 
and clinical outcomes. 
 Objective 5: Assess the usefulness of TTE parameters combined with 
functional, clinical and biochemical parameters in providing better 
prediction of post-procedural outcomes following TMVR. 
 
 
2.5 Impact Statement 
 
It is envisaged that the presented project will provide a framework for the generation 
of further research in the area of HF, MR, and TMVR. By quantifying the burden of MR   
in HF patients within a precise geographical area, this work will allow other research 
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groups to plan further studies and in particular help aid more precise power 
calculations. 
 
Additionally, through the dissemination and communication of abstracts and 
publications at a national and international level, the wider cardiology community will 
become more aware of the burden of MR within the HF population and the relevant 
treatment options available. Raising the profile of the problem and the treatment 
therapies means that medical professionals are more cognisant and responsive when 
faced with these dilemmas in the clinical context. The work should also encourage 
clinicians to integrate these novel treatment options into HF pathways. 
 
This project work provides evidence that can be used by healthcare providers and 
NHS decisionmakers in regard to the provision of resources. More specifically, it is 
anticipated that this research will help support NHS specialised commissioning in 
planning national resources, most likely leading to further increases in the number of 
commissioned TMVR treatments centres, ultimately resulting in improvements in 
accessibility to TMVR. 
 
Additionally, recommendations from the research may also influence commercial 
partners in relation to subsequent design features and deployment approaches related 
to TMVR devices, or when creating selection criteria parameters for subsequent 
research studies. I am hopeful that this research helps leads to a better understanding 
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This research also highlights the importance of key echocardiographic considerations 
in the work up to TMVR. Through an appreciation of the necessary expertise required, 
it is anticipated that echocardiographers will strengthen their skills and knowledge in 
these areas. Training programmes should be focussed on an integrative approach to 
the assessment of MR as well as the role of the LV, left atrium and the right heart. 
 
HF is one of the largest problems within cardiovascular medicine. Most of the cost, 
morbidity and mortality is centred around acute admissions, which is the group of 
patients this thesis studied. HF affects just short of a million people in the UK and has 
outcomes worse than most cancers. However it is often a very treatable condition and 
the hope is that this thesis will help contribute to improving treatment options for the 
subgroup of HF patients who have significant MR, leading to improvements in both 













ACUTE HEART FAILURE: WHAT IS THE BURDEN 





Mitral regurgitation (MR) is common in patients with acute heart failure (AHF). 
However, the burden of MR within this population has not been definitively quantified 
across a complete geographical sector. Within the London boroughs of Lambeth and 
Southwark, there is limited data available regarding the prevalence and severity of 
MR, the impact of medical therapy in relation to symptoms and severity of MR, and 
the relationship between MR severity and mortality. In order to ensure we provide 
appropriate monitoring and treatment options for our patients on a local, London-wide 
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3.2 Aims and Objectives 
 
The primary aim of this retrospective study was to investigate those patients with heart 
failure (HF) and significant MR. I hypothesised that a substantial number of Lambeth 
and Southwark patients admitted with HF would have moderate or more MR, and that 
a considerable proportion of patients would experience limited improvements in MR 
severity, left ventricular ejection fraction (EF) and symptoms despite optimal medical 
therapy (OMT). 
 
My objectives were to determine: (1) the proportion of patients with a HF admission 
with moderate or more MR and their survival; (2) the number of HF patients with 
moderate or more MR and an <EF 50%; 3) the effectiveness of OMT in reducing the 
severity of MR and symptoms for these patients; (4) the number of HF patients with 
moderate or more MR, an EF <50% and symptoms despite OMT. 
 
 
3.3 Methods  
 
3.3.1 Study Design 
 
This retrospective observational study was performed across two tertiary care centres, 
involving collaboration between the Department of Cardiology at Guy’s and St 
Thomas’ NHS Foundation (GSTT), the Department of Cardiology at King’s College 
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NHS Foundation Trust (KCH), and the Department of Life Sciences and Centre for 
Bioscience at Manchester Metropolitan University (MMU). The study involved 
collecting NICOR national audit data, UK Office of National Statistics (ONS) mortality 
data, patient demographics, clinical and laboratory data, and co-morbidity details for 
patients presenting with an AHF admission between January 2013 and December 
2017. Where patients underwent a transthoracic echocardiogram (TTE) assessment 
six months prior to or one month following the index admission, these data were used 
to assess the degree of MR, using EF as a surrogate for left ventricular systolic 
function. Patients with an EF <50% and moderate or worse MR were then further 
examined with a focus on symptoms (NYHA class), and current and subsequent 
treatments and medical therapies. Where patients underwent subsequent TTE on 
maximally tolerated medical therapy, the changes in the degree of MR, EF, and 
symptoms (NYHA class) were re-examined. In these circumstances, only TTE 
performed a minimum of one month after commencement on OMT were included.  
 
 A comprehensive list of the parameters recorded and relevant data sources can be 
found in Table 3.1. 
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Table 3.1. A comprehensive list of parameters collected for comparison as part of a retrospective study of heart failure patients across Southwark and Lambeth. 
Abbreviations: MR: mitral regurgitation; PISA: proximal isovelocity surface area; EROA: effective regurgitant orifice area; RVol: regurgitant volume; MV: mitral 
valve; LV: left ventricle; 3D: three-dimensional; EF: ejection faction; LVESD: left ventricular end systolic dimension; RV: right ventricle; PASP: pulmonary artery 
systolic pressure; LA: left atrium; HF: heart failure; CRT: cardiac resynchronisation therapy; ICD: implantable cardioverter defibrillator; MI: myocardial infarction; 
NYHA: New York Heart Association; PND: paroxysmal nocturnal dyspnoea; EPR: electronic patient record; NICOR: National Institute for Cardiovascular 
Outcomes Research; NT-pro BNP: N-terminal pro B-type natriuretic peptide; ACEI: angiotensin-converting-enzyme inhibitors; ARB: angiotensin receptor 
blocker; MRA: mineralocorticoid receptor antagonists; OMT: optimal medical therapy. 
Category Assessment 
Type 
Parameter Time points Data Source 
Echocardiography Mitral assessment Visual impression of severity of MR, vena contracta, PISA, EROA, 
RVol, pulmonary vein systolic reversal, MV E wave velocity, 
continuous wave Doppler envelope shape 
(1) At the time of 
HF admission 
(2) On OMT 
Transthoracic 
echocardiography 
reports and digital echo 
images. 
 LV assessment LV 3D EF, LV Simpson’s biplane EF, visual LV EF, LVESD, visual 
impression of LV systolic function 
(1) At the time of 
HF admission 
(2) On OMT 
Transthoracic 
echocardiography  
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 Other Visual impression of RV size and function, PASP, LA size (1) At the time of 
HF admission 
(2) On OMT 
Transthoracic 
echocardiography  
reports and digital echo 
images. 
Clinical General Date of HF admission, medical team allocated to follow up care (i.e. 
tertiary, community), presence of CRT/ICD, date of death 
(1) At time of HF 
admission 
(2) At 12 and 18 
months 
EPR records, NICOR 
and ONS data 
 HF presentation 
parameters 
NYHA classification, oedema, orthopnoea, PND, abdominal 
swelling, raised venous pressure, basal crackles, third heart sound 
At time of HF 
admission 
EPR records and 
NICOR data 
 HF symptoms at 
medical 
optimisation 
NYHA classification, oedema, orthopnoea, PND, abdominal 
swelling, raised venous pressure, basal crackles, third heart sound 
At time of HF 
review 
EPR records and 
NICOR data 
Demographics  Age, gender, height, weight, ethnicity At time of HF 
admission 
EPR records and 
NICOR data 
Laboratory  Plasma creatinine, haemoglobin, urea, serum sodium, serum 
potassium, NT-pro BNP 
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Co-morbidity  Angina at rest, recent MI, extra-cardiac arteriopathy, poor mobility, 
previous cardiac surgery, chronic lung disease, active infective 
endocarditis, diabetes on insulin 
At time of HF 
admission 
EPR records 
Medical therapy  Date of medical optimisation, medical therapy regime including: 
ACEI / ARB, beta blocker, MRA, ICD or CRT, appropriate diuretic 
therapy 
(1) At time of 
admission 
(2) On OMT 








3.3.2 Study Population 
 
Using national audit and United Kingdom (UK) Office of National Statistics (ONS) data, 
2821 AHF admissions were recorded at the two nominated tertiary care centres 
between the time period January 2013 – December 2017, including a population of 
1884 patients local to Lambeth and Southwark, London, United Kingdom (UK). 
Patients were included and excluded based on the criteria below (Table 3.2). Inclusion 
and exclusion criteria were determined based on combined opinions from local experts 
specialising in HF and cardiac imaging, including HF consultants, valve consultants, 
clinical scientists, nurses and researchers. 
 
Table 3.2. Retrospective study assessing the burden of mitral regurgitation within the heart failure 
population across Southwark and Lambeth: inclusion and exclusion criteria. Abbreviations: GSTT: 
Guy’s and St Thomas’ Trust; KCH: King’s College Hospital; HF: heart failure; UK: United Kingdom; 
TTE: transthoracic echocardiogram; EF: ejection fraction; MR: mitral regurgitation. 
Inclusion Criteria Exclusion Criteria 
1. Presentation to either GSTT or KCH with 
HF between January 2013 and December 
2017 
2. Resident of Southwark or Lambeth, 
London, UK 
3. 18 years or older 
1. TTE performed either within 1 month of, 
or up to 6 months preceding, the index 
admission 











3.3.3        Patient Recruitment 
 
As this was a retrospective observational study, there was no formal prospective 
recruitment process. Patients were recruited based on an AHF admission following 
presentation to one of two tertiary care centres (GSTT or KCH) between 1st January 
2013 and 31st December 2017. Figure 3.1 provides an outline of retrospective patient 
data collection using four modalities: NICOR data, ONS data, echocardiography data, 
electronic patient records (individual parameters collected as outlined in Table 3.1).  
 
 
Figure 3.1. Flowchart demonstrating the process by which patient data were collected for the 
retrospective heart failure study. Abbreviations: HF: heart failure; CRT: cardiac resynchronisation 
NICOR data – unscheduled HF 
admissions  (time point 1)






• HF admission details
• Demographics and comorbidities
• Clinical signs and symptoms
• Electrocardiogram
• Presence of CRT/ICD
• NYHA class
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• Review of medical therapies
• Clinical signs and symptoms
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• Laboratory results
Echocardiography data    
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therapy; ICD: implantable cardioverter-defibrillator; NYHA: New York Heart Association; LV: left 
ventricle; RV: right ventricle; LA: left atrium. 
 
3.3.4 National audit and UK Office of National Statistics 
 mortality data 
 
The National Heart Failure Audit group collects data concerning unscheduled 
admissions to hospital in England and Wales where a death or discharge is associated 
with a diagnosis of HF as the primary aetiology (1). Only patients 18 years or over are 
included in the audit. Patients were included based on a primary entry of death or 
diagnosis of HF, corresponding with episodes of care for the following NICOR 
discharge codes (1): 
 
• I11.0 Hypertensive heart disease with (congestive) heart failure 
• I25.5 Ischaemic cardiomyopathy 
• I42.0 Dilated cardiomyopathy 
• I42.9 Cardiomyopathy, unspecified  
• I50.0 Congestive heart failure 
• I50.1 Left ventricular failure 
• I50.9 Heart failure, unspecified  
 
Additional data obtained from the NICOR record included New York Heart Association 
(NYHA) classification, oedema, orthopnoea, paroxysmal nocturnal dyspnoea (PND), 
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abdominal swelling, raised venous pressure, basal crackles, third heart sound, 
medical therapy, date of HF admission, responsible follow up team (i.e. cardiology, 
elderly care, community care), and presence of cardiac resynchronisation therapy 
(CRT) or implantable cardioverter-defibrillator (ICD).  
 
The UK Office of National Statistics (ONS) collects data on mortality. The registration 
of life events (i.e. deaths) is a service carried out by the Local Registration Service in 
partnership with the General Register Office. Mortality statistics are based on 
information recorded when deaths are certified and registered by the doctor certifying 
the death, the informant to the registrar, or the coroner to the registrar. This information 
is used to formulate ONS mortality data and available on request (68). Only data 
regarding mortality were collected using this mechanism. 
 
3.3.5 Echocardiographic data 
 
Echocardiographic data, where available, were collected at two time points. Firstly, six 
months prior to or one month following the index HF admission. Where patients had 
multiple admissions, the index admission was the first admission. If the patient did not 
undergo TTE six months pre- or one month post-admission, other admission dates 
within the study period for the same patient were reviewed for eligibility. 
 
The second time point was once maximally tolerated HF medical treatment had been 
reached. To ensure this was robust, only TTEs performed a minimum of one month 
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post OMT were included (details regarding how OMT was determined are outlined in 
section 3.3.8). 
 
Information was obtained based on review of the echocardiogram report. Where data 
were missing or incomplete, the digital images were reviewed by a cardiac physiologist 
trained and accredited in echocardiography. Where measurements were missing, 
these were performed by the cardiac physiologist in line with British Society of 
Echocardiography (BSE) recommendations (themselves based on recommendations 
from the American Society of Echocardiography [ASE] and the European Association 
of Echocardiography [EAE] 2013) (69-71). 
  
3.3.5.1      Equipment and information technology 
 
Comprehensive TTE studies were performed across two cardiology sites using 
commercially available cardiac ultrasound machines including: Philips IE33, EPIQ, 
Affiniti, Cx50, GE E9, E95, S70, Vivid Q, Vivid I, Vivid 7. Images were obtained using 
a 3MHz or 5MHz fixed array ultrasound probe. Echo images were stored using digital 
loops and transferred to an archiving database (Echopac Imagevault, or Xcelera) to 
enable further offline analysis.  
 
Studies were performed in line with recommendations of the British Society of 
Echocardiography (themselves based on recommendations from the American 
Society of Echocardiography [ASE] and European Association of Echocardiography 
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[EAE] (2013)). Both GSTT and KCH echocardiography departments are nationally 
certified and hold BSE departmental accreditation. Studies were performed by a 
cardiac physiologist accredited in TTE, or a trainee doctor or physiologist. Where a 
trainee performed the scan, all images and the clinical report were reviewed and 
finalised by a senior cardiac physiologist prior to formal publication on electronic 
medical records. Comprehensive TTE reports were uploaded to CVIS (formally known 
as Tomcat) or Xcelera.  
 
3.3.5.2      Measurements and technique 
 
The degree of MR was determined using an integrative multiparametric approach. 
Quantitative measures such as vena contracta, effective regurgitant orifice area 
(EROA), proximal isovelocity hemispheric surface area (PISA) and regurgitant volume 
(RVol) were combined with semi-quantitative and qualitative parameters. These 
included increased MV E wave, the presence of reversal within the right upper 
pulmonary vein (RUPV) and the density, shape and duration of the MR continuous 
wave Doppler envelope. A visual impression of the severity of MR contributed to this 
integrative approach.  
 
EF was determined based on quantitative measurement in the first instance. Where 
three-dimensional (3D) measurements were possible, these were considered the gold 
standard. In the absence of 3D, two dimensional (2D) Simpson’s biplane disk method 
was used. In the absence of both of these measures, a visual impression of EF was 
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estimated. Where a range was used for EF, this was averaged (i.e. 30-35% = 32.5%). 
Assessment of LV systolic function was based on forward stroke volume, cardiac 
output and a visual impression. The left ventricular end systolic dimension (LVESD) 
was also collected as it is of particular importance in the timing of surgical intervention.  
 
Right ventricular (RV) function was assessed using tricuspid annular plane systolic 
excursion (TAPSE) and RV tissue Doppler imaging (TDI) peak S wave (S’) for the 
assessment of longitudinal contractility and a visual approach or fractional area 
change (FAC) for the assessment of radial contractility. This information was 
combined to give an overall impression of RV systolic function. Pulmonary artery 
systolic pressure (PASP) was estimated using the peak of a complete continuous 
wave Doppler envelope of tricuspid regurgitation (when available).  
 
3.3.5.3     Echocardiographic exclusions 
 
When evaluating patients for the presence of moderate or more MR, those who had 
previously undergone surgical or transcatheter mitral valve repair, or MV replacement 
were excluded. Incomplete studies and those with poor image quality were excluded 











3.3.6 Diagnosis and symptoms of heart failure  
 
The initial diagnosis of HF was determined at admission by the HF team based on a 
combination of signs, symptoms and echocardiographic findings. Medical records 
were searched to determine NYHA class, and concomitant clinical signs and 
symptoms, such as evidence of oedema, orthopnoea, abdominal swelling, raised 
jugular venous pressure (JVP), a third heart sound or basal crackles at the lung bases.  
 
Signs and symptoms were reassessed at a second time point marked by medical 
treatment at a maximally tolerated dose as determined by a HF specialist (cardiology 
consultant or HF specialist nurse). 
 
3.3.7 Demographic, clinical, laboratory and   
  comorbidity data 
 
Demographic information including sex, age, ethnicity, locality, height and weight were 
collected as part of the NICOR data. Additionally, clinical data such as body mass 
index (BMI), systolic blood pressure, diastolic blood pressure, heart rate and 
electrocardiogram findings (rhythm, QRS width) were documented.    
 
Biochemistry results were collected from internal electronic medical record systems. 
Specifically NT-pro BNP, haemoglobin, urea, creatinine, serum sodium and potassium 
were recorded.  
 
____________________________________________________________________________________________ 




Information pertaining to past medical history and comorbidities including ischaemic 
heart disease (IHD), valve disease, hypertension, diabetes, asthma, and chronic 
obstructive pulmonary disease (COPD) was also collected from internal electronic 
medical records.  
 
3.3.8 Optimisation of medical therapy 
 
Following a review of clinical records and medical therapies, OMT was determined by 
a consultant cardiologist with a specialist interest in HF specialisation. OMT was 
defined as: 
  
1. Maximal tolerated dose of angiotensin-converting enzyme (ACE) inhibitors / 
angiotensin II receptor blockers (ARB). 
2. Maximal tolerated dose of beta blocker. 
3. Addition of a mineralocorticoid receptor antagonist (MRA) (spironolactone or 
eplerenone) where symptomatic despite maximal ACE inhibitor (or ARB) and 
beta blocker. 
4. Implantable cardioverter-defibrillator (ICD) / cardiac resynchronisation therapy 
pacemaker (CRT-P) or cardiac resynchronisation therapy defibrillator (CRT-D) 
where appropriate as part of national guidelines. 








The date of OMT was determined by one of two consultant cardiologists based on the 
case notes review. 
 
3.3.9 Data management 
 
All information that had been gathered as part of routine clinical practice was obtained 
from digital medical records within the relevant Trust. Permission to access medical 
records was granted by GSTT and KCH. Multiple onsite electronic hospital IT systems 
were accessed, including CVIS, EPR, e-noting, EPR Sunrise, and Xcelera. Access to 
electronic systems was via the cardiac outpatient department at both GSTT and KCH.  
 
All collected data were stored in a password protected Excel spreadsheet. An active 
version was updated and adapted using secure e-mail transfer (nhs.net) and a master 
version stored on GSTT networked hospital IT systems. No patient data were taken 




The end-points for this study were:  
1) Death 
2) Change in symptoms as defined by NYHA class 








3.3.11 Statistical analysis 
 
Statistical analysis was performed using SPSS IBM software (version 25) (72). 
Baseline characteristics were expressed as means and standard deviations for 
continuous variables, and frequencies and percentages for categorical variables. The 
normality of distribution was evaluated using skewness and kurtosis (-2 to +2). 
Bivariate analysis focussed on determining a significant difference between matched 
baseline and OMT data across the variables: 1) MR 2) LV EF; 3) NHYA class. This 
was achieved using Chi-square test for independence or McNemar’s test for non-
parametric comparisons. An independent T-test was used for continuous variables. 
Mortality at 12 and 18 months for those with and without moderate or more MR was 
determined using Chi-square test for independence. Kaplan Meier survival curves 
evaluated death across groups with and without moderate or more MR. Logistic 
regression was used to look at the individual and summative predictive value of EF, 
age, comorbidities and MR severity using mortality at 12 months following index 
admission. For paired data, a paired T-Test was used for continuous variables, and 
Chi-square and ANOVA for categorical variables. A p-value of 0.05 was used to 
conclude statistical significance. 
 
3.3.12 Research ethics statement  
 
This research project was submitted as a service evaluation, reviewed by the research 
governance teams at both Trusts and granted exemption from formal ethical approval 
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via REC by GSTT, UK (approval number 9161; see Appendix B for e-mail 
confirmation) and KCH, UK (approval granted by Dr Alexandros Papachristidis 
30/01/2019, see Appendix C for e-mail confirmation).  
 
As part of this retrospective review, all patient identifiable information was removed. 
All information collected was obtained as part of routine clinical practice. Patients’ 
informed consent was not required.  
 
3.3.13 Individual contributions to the research team 
 
The entirety of this project was the responsibility of the principal investigator. Prof 
Bernard Prendergast was the principal supervisor. Prof Prendergast is the lead of 
valve services at the primary research site, GSTT. Prof Mark Monaghan and Dr Jane 
Hancock assisted in the interrogation of echocardiographic data. Dr Garry McDowell 
and Dr Fiona Wilkinson were joint academic supervisors on behalf of Manchester 
Metropolitan University. The lead consultant specialists for the King’s, and Guy’s and 
St Thomas’ hospital heart failure, echocardiography, and non-invasive cardiology 
teams provided access to the NICOR, ONS, echocardiographic data and electronic 
patient records. Dr Vasileios Stylianidis, Dr Fatima Bangash and Mr Andrew Guilder 














There were a total of 2821 HF admissions to either GSTT or KCH over the five year 
period, 1st January 2013 – 31st December 2017. This included repeat admissions and 
therefore translated to 1884 HF patients who were local to Lambeth or Southwark, UK.  
 
Of this cohort, 1733 (92%) underwent TTE either within 1 month of the index admission 
or up to 6 months preceding the index admission. There were 16 patients where the 
quality of the TTE did not allow accurate assessment of MR. A small portion of patients 
(n=36, 9%) with MR underwent conventional MV surgery. Both of these groups were 
excluded from our analysis. 
 
This left a total of 1681 patients. Of this group, 1300 (77%) patients had a TTE which 
showed less than moderate MR, whilst 381 patients had moderate or more MR. This 
translated to one fifth (20%) of the total number of HF patients who were admitted 
within the specified five year period. The flowchart below (Figure 3.2) outlines the 
number of patients who were selected at each stage of the selection criteria pathway, 









Figure 3.2. Flowchart outlining the pathway for patients selected in the retrospective heart failure study. 
This also outlines those who were excluded and the reasons for exclusion. Abbreviations: MR: mitral 
regurgitation; EF: ejection fraction; TTE: transthoracic echocardiogram; OMT: optimal medical therapy; 
MVR: mitral valve replacement.  
 
3.4.2 HF patients: with and without MR 
 
There were 1681 patients who underwent TTE as part of their HF admission. The 
mean age was 72.8 ± 14.8 years and a small majority were male (51.8%).  Of the 
1681, 58 patients died during the index admission. There were proportionally higher 
death rates amongst those with moderate or more MR when compared to those with 
less than moderate MR (n=20 [5.2%] vs. n=38 [2.9%]). There were 395 (24.34%) 
patients who died within 12 months and 501 (30.9%) who died within 18 months. Of 
the population with MR, 220 (57.7%) had moderate MR, 80 (21.0%) had moderate to 
severe MR and 81 (21.3%) had severe MR.  
Lambeth or Southwark resident + 
acute admission with heart failure
(n=1884) 




No TTE <6 months preceding or <1 month post     
index admission  (n=151)
Unable to quantify MR on TTE (n=16)
Prosthetic or repaired mitral valve (n=36)
Symptomatic + > moderate 
MR and EF < 50% 
(n=299)
Excluded: 
Died before OMT, lost to follow up (n=41)
Transplant or surgical MVR (n=11)
No subsequent TTE (n=48)
No TTE 1 month or more after optimisation (n=54)
Despite OMT, symptomatic +          
> moderate MR + EF < 50% 
(n=77)
Excluded: 
Unable to quantify EF on TTE (n=11)
> moderate MR and EF >50% 
(n=71)
TTE with < moderate MR  
(n=1300)
< moderate MR (n=53) 








When comparing those patients with and without moderate or more MR, there was a 
significant difference in 12 month mortality between groups. The risk of mortality for 
those with moderate or more MR was 32.5% versus 25.3% for those with less than 
moderate MR (p=0.006; Fisher’s exact 2-sided). Results were paralleled at 18 months, 
with a difference of 37.8% versus 31.9% mortality risk (p=0.036; Fisher’s exact 2-
sided). Similarly, 12 month survival curves showed a significant difference between 
groups suggesting a mean survival of 293.5 days (281-306 days) for those with 
moderate or more MR versus 312.6 days (307-318) for those with less than moderate 
MR (p=0.003; Kaplan-Meir survival curve) (Figure 3.3). Results were again 
comparable at 18 months with mean survival estimated at 413 days (≥ moderate MR) 
versus 444 days (< moderate MR) (p=0.015; Kaplan Meier survival curve) (Figure 3.4). 
 
Using univariate logistic regression, both moderate or more MR and age were 
predictors of 12 month mortality (p=0.005 for MR, p<0.0001 for age). Gender was not 
found to be a significant predictor of outcome. Multiple logistic regression including 
age and presence of moderate or more MR showed that age was the strongest 
predictor of mortality, with the presence of moderate MR also an independent 
predictor. For each year of age, the odds of survival decreased by 3.7% (OR 0.963, 
95% CI 0.955-0.971, p<0.0001). Additionally, the odds of mortality were 1.5 times 
higher for patients with moderate or more MR compared to those with less than 









Figure 3.3. Kaplan-Meier survival curve based on 12 month survival for heart failure (HF) admission 
patients with moderate or more mitral regurgitation (MR) versus those without moderate or more MR.    
 
 
Figure 3.4. Kaplan-Meier survival curve based on 18 month survival for heart failure (HF) admission 
patients with moderate or more mitral regurgitation (MR) versus those without moderate or more MR.    
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3.4.3 Moderate or worse MR: comparing EF  
 
Patients with moderate or more MR were subsequently categorised into two groups: 
those with an EF of >50% and those with an EF of <50%. Of the 381 patients with 
moderate or more MR, there were 71 with an EF greater than 50%. There were a small 
number of patients where the quality of the TTE did not allow quantification of EF 
(n=11). This resulted in a remaining pool of 299 patients with at least moderate MR 
and an EF of 50% or less. The baseline characteristics for this group are outlined in 
Table 3.3 with an additional column to outline the characteristic of those with EF >50%. 
 
Table 3.3. Patients with heart failure and moderate or more mitral regurgitation (MR): comparing those 
with an ejection fraction (EF) of <50% versus those with an EF of >50%. *Ethnicity was based on limited 
data. Where a p-value was not reported, there were inadequate data for analysis. Abbreviations: PM: 
pacemaker; ICD: implantable cardioverter-defibrillator; IHD: ischaemic heart disease; COPD: chronic 
obstructive pulmonary disease; NYHA: New York Heart Association; NT-pro BNP: N-terminal pro B-
type natriuretic peptide; MR: mitral regurgitation; LOS: length of stay. Statistics: Chi-square test for 















Variables >Moderate MR +  
EF <50% 
>Moderate MR +   
EF >50% 
P-value 
Patients n (%) 299 (80.82%) 71 (19.18%) 
 
Age (years) Mean ± SD 70.44 ± 15.91 78.41 ± 14.66 0.064 
Sex (male) n (%) 165 (55.2%) 24 (33.8%) 0.01 
Ethnicity (White)* (n=139) n (%) 78 (43.8)* 23 (43.4%)* - 
Device (PM or ICD) n (%) 58 (19.4%) 11 (15.5%) - 
Mortality at 12 months n (%) 58 (19.4%) 15 (21.1%) 0.742 
LOS in hospital (days) Mean ± SD 13.66 ± 12.22 15.3 ± 19.86 0.15 
Hypertension n (%) 181 (60.5%) 52 (73.2%) 0.113 
IHD n (%) 116 (38.8%) 17 (23.9%) 0.048 
Diabetes n (%) 91 (30.4%) 25 (35.2%) - 
COPD n (%) 46 (15.4%) 8 (11.3%) - 
Asthma n (%) 25 (8.4%) 5 (7.0%) - 
Atrial fibrillation n (%) 116 (42.5%) 40 (61.5%) 0.004 
NT-pro BNP Mean ± SD 5230 (IQR 11861) 2829 (IQR 6373) 0.23 
Creatine Mean ± SD 108.50 (IQR 63) 104.00 (IQR 78) 0.828 
NHYA class I 7 (2.3%) 4 (5.6%) 
 
 
II 29 (9.7%) 12 (16.9%) 
 
 
III 132 (44.1%) 27 (38.0%) 
 
 
IV 129 (43.1%) 26 (36.6%) 
 
 
Unknown 2 (0.7%) 2 (2.8%) 
 
MR moderate n (%) 170 (56.9%) 41 (57.7%) 
 
MR moderate-severe n (%) 66 (22.1%) 13 (18.3%) 
 
MR severe n (%) 63 (21.1%) 17 (23.9%) 0.738 








This showed patients were reasonably matched in terms of their age (p=0.064) 
although there was a difference between groups in relation to sex. There were more 
patients in the impaired EF group who were male (55.2%) as opposed to the preserved 
EF group which predominantly included females (66.2%) (p=0.01) (Figure 3.5). There 
was also a significant difference in the frequency of patients with IHD, with 
considerably more patients with IHD in the group with an EF <50% (p=0.048). There 
was also a significant difference in the number of patients with AF. Interestingly, more 
patients had AF within the EF >50% group (p=0.004).  
 
 
Figure 3.5. Patients with heart failure and moderate or more mitral regurgitation: A comparison of sex 













In total there were 69 (34.9%) patients with an intra-cardiac device. Those with an EF 
<50% were more likely to have a cardiac resynchronisation therapy defibrillator (CRT-
D), cardiac resynchronisation therapy pacemaker (CRT-P) or implantable 
cardioverter-defibrillator (ICD) (Table 3.4).  
 
Table 3.4. Patients with heart failure and moderate or more mitral regurgitation: Device therapy across 
categories of ejection fraction (EF). Abbreviations: CRT-D: cardiac resynchronisation therapy 
defibrillator; CRT-P: cardiac resynchronisation therapy pacemaker; ICD: implantable cardioverter-





CRT-D CRT-P ICD PM Not 
known 
Total 
EF <50% 241 21 4 11 18 4 299 
EF >50% 60 0 0 0 10 1 71 
Total 301 21 4 11 28 5 370 
 
 
Within this cohort there were 73 patients who died within 12 months, 58 with an <50% 
and 15 with an EF >50%. When we compared mortality at 12 months for patients with 
moderate or more MR and an EF <50% with those with an EF >50%, there was no 
significant difference (p=0.742, Fisher’s exact test). There was no significant 
difference in the length of hospital stay between groups (p=0.15, t-test) and no 
significant difference in NT-pro BNP levels (p=0.23, t-test).  Neither the presence of 
IHD or AF were statistically significant predictors of death (p=0.416, p=0.497; Chi 
Squared test).  
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Multivariate logistic regression was performed to assess predictors of 12 month 
mortality and demonstrated that age (p=0.008; univariate logistic regression) and 
NYHA class (p=0.031; univariate logistic regression) were predictive of mortality in 
those with moderate or more MR across categories of EF. For multinominal logistical 
regression results see Table 3.5. This showed that age was an independent predictor 
of mortality in those with moderate or more MR (p=0.008). There was a trend 
suggesting NYHA class may have been an independent predictor but this was not 
statistically significant (p=0.062). The type of HF (HFpEF vs HFrEF) was not an 
independent predictor of outcome. 
 
Table 3.5. Multinominal logistic regression for variables age, New York Heart Association (NYHA) class 
and ejection fraction (EF) in the prediction of mortality in those with heart failure and moderate or more 
mitral regurgitation (MR). Abbreviations: HFrEF: heart failure with reduced ejection fraction; HFpEF: 
heart failure with preserved ejection fraction; HR: hazard ratio; CI: confidence interval. 
Variable HR CI P-value 
Age 0.974 0.956-0.993 0.008 
NYHA class 0.704 0.487-1.108 0.062 
EF (HFrEF or HFpEF) 1.001 0.983-1.019 0.955 
 
 
3.4.4 Patients on OMT: MR severity, EF and symptoms 
 
Of the 299 patients with moderate or more MR and an EF of <50%, 11 underwent 
conventional surgery or transplantation. A further 41 patients either died before 
medical optimisation was reached or were lost to follow up.  
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There were 247 patients who were on OMT. Of these, 36 had undergone CRT. There 
were 48 patients who did not undergo TTE following optimisation and a further 54 who 
did not have an echo performed a minimum of one month post optimisation. This left 
a pool of 145 patients.  
 
From the total group, 68 (46.9%) patients saw an improvement in the degree of MR 
(to less than moderate MR) and/or an improvement in EF >50% and/or became 
asymptomatic on OMT. Baseline characteristics for these patients and the remaining 
77 patients are outlined in Table 3.6.  
 
Table 3.6. Baseline characteristics of patients with heart failure (HF), moderate or more mitral 
regurgitation (MR) and an ejection fraction of <50% who were on optimal medication therapy (OMT) 
(Group 1) compared with patients with HF on OMT with less than moderate MR +/- EF >50% +/- 
symptom relief (Group 2). Abbreviations: PM: pacemaker; ICD: implantable cardioverter-defibrillator; 
IHD: ischaemic heart disease; COPD: chronic obstructive pulmonary disease; NYHA: New York Heart 
Association; NT-Pro BNP: N-terminal pro B-type natriuretic peptide; *Ethnicity was based on a 
population size of 101. ^There were expected cell counts less than 5. #NT-pro BNP was based on a 
population of 104. Mitral regurgitation grades: 0=none or trivial; 1=mild; 1.5=mild to moderate; 
2=moderate; 3=moderate to severe; 4=severe. Statistics: Chi square test for independence for 












moderate MR + 
EF <50% 
OMT with < 
moderate MR +/- 




Group 1 Group 2  
Patients n (%) 77 (53%) 68 (47%)  
Age (years) Mean ± 
SD 
69.95  ± 14.13 65.79 ± 17.21 0.082 
Sex (male) n (%) 48 (62.3%) 37 (54.4%) 0.212 
Ethnicity (White)* (n=101) n (%) 19 (24.7%) 24 (35.3%) 0.301 
Device (PM or ICD) n (%) 27 (35.1%) 9 (13.2%) 0.04^ 
Hypertension n (%) 49 (64.5%) 36 (52.9%) 0.108 
IHD n (%) 40  (53.3%) 22 (33.3%) 0.013 
Diabetes n (%) 27 (35.1%) 22 (32.4%) 0.411 
COPD n (%) 11 (14.7%) 14 (20.9%) 0.226 
Asthma n (%) 10 (13.3%) 4 (6.0%) 0.117 
Mortality at 12 months n (%)  16(20.8%) 7(10.3%) 0.06 




14.68 ± 10.98 12.79 ± 10.47 0.271 
NT-pro BNP# (n=104) Mean ± 
SD 
6637.6 ± 133447 4849.6 ± 8391 0.07 
Mitral regurgitation 
grade 
0 n (%) 0 (0%) 12 (17.6%)  
1 n (%) 0 (0%) 27 (39.7%)  
1.5 n (%) 0 (0%) 16 (23.5%)  
2 n (%) 40 (51.9%) 9 (13.2%)  
3 n (%) 20 (26%) 2 (2.9%)  
4 n (%) 17 (22.1%) 2 (2.9%) <0.0001 
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NHYA Class 1 n (%) 0 (0%) 21 (30.9%)  
 2 n (%) 35 (45.5%) 29 (42.6%)  
 3 n (%) 27 (35.1%) 13 (19.1%)  
 4 n (%) 15 (19.5%) 5 (7.4%) <0.0001 
 
 
For the group with remaining MR, EF <50% and symptoms (Group 1), the mean age 
was 77 years and the majority were male. Those patients with improved status (Group 
2) were slightly younger (mean age 68 years). Age was not statistically different 
between groups. As expected, a larger number of patients in Group 1 had an intra-
cardiac device (35.1% vs 13.2%).   
 
In terms of comorbidities, hypertension was the most common across both groups 
(Group 1: 64.5% vs. Group 2: 52.9%), followed by IHD (Group 1: 53.3% vs. Group 2: 
33.3%), and diabetes (Group 1: 35.1% vs. Group 2: 32.4%). On the whole, Group 1 
had more comorbidities aside from chronic obstructive pulmonary disease (COPD). 
Length of stay (LOS) did not differ between groups (p=0.271; t-test). However, there 
was a trend suggesting greater mortality within Group 1, namely those with persistent 
moderate or more MR, EF <50% and symptoms despite OMT (p=0.06, Fisher’s exact 
test). Despite OMT, over half (n=77, 53%) of HF patients with moderate or more MR, 










3.4.5  Patients on OMT: MR severity, EF and symptoms 
 
In order to assess change in MR and NYHA with OMT, it was necessary to separately 
assess patients with moderate or more MR, EF <50% on OMT who underwent 
echocardiographic evaluation at two time points in line with our selection criteria 
(before OMT, and at least 1 month post OMT). Paired sequential comparisons of 
echocardiographic findings, medical therapy and symptom status pre- and post-
optimisation were therefore performed.  
 
There were 82 patients. This analysis showed that medical optimisation reduced the 
number of patients with moderate, moderate to severe and severe MR from 82 to 43. 
Following OMT, there were 12 patients with severe MR, 10 with moderate to severe 
MR and 21 with moderate MR. Compared to pre-OMT, there was a significant 
difference in MR severity suggesting that medical therapy is helpful in reducing MR 
(p=0.001, Pearson Chi-Square).  Unfortunately, there was no significant change in 
NYHA class pre- and post-OMT (p=0.650, Chi-square test) (Table 3.7). This was 
based on analysis with cell counts less than five so the accuracy of this outcome is 
questionable. When repeated using ANOVA, examining the raw percentages 
suggested an improvement in NYHA class on OMT (63.4% showed improvement, 









Table 3.7. Comparison before and after optimal medical therapy (OMT): change in clinical (New York 
Heart Association [NYHA] class) and echocardiographic (mitral regurgitation) characteristics after 
optimal medical therapy (OMT). +Based on cell counts less than 5.  
   
Pre OMT Post OMT P-value 
Mitral regurgitation Moderate  n (%) 42 (51.2%) 12 (14.6%) 
 
 
Moderate-severe n (%) 21 (25.6%) 10 (12.2%) 
 
 
Severe n (%) 19 (23.2%) 21 (25.6%) 0.001 
      
NYHA classification Class I n (%) 0 (0%) 14 (16.9%) 
 
 
Class II n (%) 11 (13.3%) 35 (42.2%) 
 
 
Class III n (%) 36 (43.4%) 25 (30.1%) 
 
 




Table 3.8. Changes in mitral regurgitation (MR) and New York Heart Association (NHYA) class with 
optimal medical therapy (OMT) based on the categories improved, unchanged and worsened.   
Variable Change n (%) 
MR severity post OMT Improved 44 (53.0%) 
 
Unchanged 31 (37.4%) 
 
Worsened 8 (9.6%) 
NYHA class post OMT Improved 52 (63.4%) 
 
Unchanged 25  (30.5%) 
 












This retrospective study focussed on a large consecutive unfiltered cohort of adult 
patients admitted with a primary diagnosis of HF and demonstrated that one fifth of all 
HF patients have moderate or more MR. There are limited data available in relation to 
the prevalence of MR specific to the HF population. Our national audit data suggest 
that 41% of the HF population has valvular disease although this is not specific to MR 
(1). Other evidence suggests significant MR within the HF population with prevalence 
as high as 49%.  However, these data were based on filtering of recruited patients, 
with only those with an EF of 35% or less included (73). An EF of 35% or less is what 
we could consider severe according to British Society of Echocardiography guidance, 
thus introducing a certain degree of bias in the interpretation of MR prevalence within 
the HF population. Additional population based data from the UK suggest that 
significant MR is present in 2.3% of those over the age of 65 years (17). However, this 
fails to examine prevalence across the subset of HF.    
 
Aside from these resources, robust evidence is scarce. A smaller American study 
suggested up to 59% of patients presenting with HF have moderate or more MR. 
However, this study was based on those with an EF <40% only and was not founded 
on the total population of HF referrals (TTE results missing) (74). Having excluded 
patients with an EF >40% from the examination cohort, it is plausible that this predicted 
number was over-estimated due to a more clinically unstable population where referral 
for TTE may have been more likely. Moreover, this study was published in 2002, since 
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when the diagnosis and management of patients with HF has changed significantly, 
raising uncertainty as to how a diagnosis of HF was defined in this study (74).  
 
In the study cohort, mortality at 12 months was higher for individuals with moderate or 
more MR compared to those with less than moderate MR. This experience has been 
long supported by the literature (75-77). Studies have found a strong association 
between functional MR and long term risk of death (76, 78). The severity (across all 
grades of MR) has also been shown to inversely relate to survival. One study 
suggested a 12 month survival rate of 70% for those with moderate MR and 59% for 
those with severe MR (73). Our study assessed survival based on moderate and 
severe MR combined and suggested a 12 month survival rate of 67.5% which appears 
to align with the previous study. More than moderate MR and age were found to be 
independent predictors of death. This finding was corroborated by Cioffi et al who also 
identified age and degree of MR as independent predictors of mortality at 12 months, 
albeit with a focus on a population aged greater than 70 years (79).   
 
The purpose of the current study was to determine the burden of MR at local 
population level. Therefore patients with both primary and secondary MR aetiologies 
were included. The current European recommendations regarding primary MR 
suggest that surgery should be considered in patients with symptoms and an EF 
<60%. Around 10% of our cohort underwent surgical MV repair or replacement and it 
is therefore expected that patients with primary MR were excluded from our analysis 
in the early stages. This does however raise the question as to whether more patients 
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should have been considered for surgical intervention. Over 80% of our patients with 
moderate or more MR had an EF <50% and an admission with HF (implying that they 
were symptomatic). However, many patients in our cohort were older (70 ± 16 years) 
with multiple comorbidities. A large number of patients had IHD and hypertension. It 
is important also to note that the mean EF for patients under scrutiny in this study was 
29% (± 10%). This suggests a population of which the majority of patients had MR that 
was secondary in nature, alongside high, or even prohibitive, risk. Given that surgery 
is not currently indicated for isolated secondary MR (as it has not been shown to offer 
a survival benefit), this provides reasoning as to the low percentage of patients who 
underwent surgical intervention (30).  
 
OMT is recommended for secondary MR in both the European HF and valve 
guidelines to aid in improving overall LV systolic contractility and assist in reducing the 
degree of MR. Our study demonstrated that 50% of patients had an improvement in 
symptoms (NYHA class) as a result of OMT. Additionally, there was a significant 
reduction in the degree of MR with OMT.  It is feasible that this would have resulted in 
a reduced number of avoidable hospital admissions, improved quality of life for many 
and associated cost savings for the health service.   
 
Despite CRT and OMT there were still 77 patients with moderate or more MR and an 
EF <50% with significant symptoms. Left untreated, the future for these patients will 
likely involve frequent hospitalisation, worsening quality of life (QoL) and premature 
death. It is reasonable then to consider what other options may be available to this 
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population. The national guidelines last updated in 2017 (prior to publication of the 
COAPT and MITRA-FR studies) highlighted a lack of evidence supporting improved 
survival as a consequence of a reduction in chronic secondary MR (10). However, 
over the last five years TMVR has been shown to reduce the rate of hospitalisation 
and lower all cause mortality for patients with LV systolic dysfunction and more than 
moderate MR (60). Moreover, it has been shown to improve symptoms, functional 
capacity and QoL as well as potentially playing a role in positive LV reverse re-
modelling (80). Worldwide, the jury is still out as large scale RCTs debate the 
effectiveness of TMVR with one mutual, recognisable and resonating 
recommendation: the need for further long term studies with stringent research 






There were a number of limitations within this study. Firstly, data obtained from NICOR 
was based on hospital admissions rather than patients and it is possible that there was 
duplication of patients who may have presented to different tertiary centres. Efforts 
were made to overcome this limitation by applying filtering, sorting and matching tools.  
 
Secondly, I wanted to gain an appreciation of the burden of MR at local population 
level and therefore included those with both primary and secondary MR aetiologies. 
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Our interpretation has thus not separated the two. However, it is likely that most 
patients with primary MR and an EF <50% would have undergone MV surgery given 
the difference in treatment guidelines for patients with primary and secondary MR, and 
would have therefore been excluded from the analysis in the early stages.   
 
Thirdly, survival modelling has been based on the whole population. This means we 
have included patients with MR of mixed aetiologies (primary and secondary MR) 
alike.  It is possible that other underlying confounding variables biased the results of 
this modelling (i.e. ischaemic heart disease, dilated atria, idiopathic 
cardiomyopathies). 
 
Fourthly, we did not collect data on patient’s adherence to medical therapy and 
therefore we cannot be sure that patients’ who we classified as being on OMT were in 
fact adhering to their medical therapy recommendations. Current guidance suggests 
that optimisation of medical therapy is best achieved through the supervision of a 
cardiologist expert (31). 
 
Additionally, only 27% of patients had matching echocardiographic, symptom and 
medical therapy data to allow interrogation of the effects of medical therapy. Aside 
from those who underwent surgical MVR, transplant, or those who improved or did not 
improve, the remaining patients were either lost to follow up, died, or did not undergo 








Finally, the inherent nature of a retrospective review limited our interpretation. 
Although I investigated admissions over a 5 year period, I was only able to assess the 





MR is common within the Lambeth and Southwark HF population. At least one fifth of 
patients demonstrate moderate or worse MR, with the large majority also having an 
EF of 50% or less. For those with moderate or more MR, there is an increased risk of 
premature death. When treated with OMT, patients experience improvement both 
through reduction in MR and symptom resolution. However, half of patients continue 
to have moderate or more MR, an EF <50% and remain symptomatic. I propose that 
a portion of these patients are potential candidates for TMVR according to current 














MITRAL REGURGITATION IN ACUTE HEART 
FAILURE: POTENTIAL PREVALENCE OF 
PATIENTS SUITABLE FOR TRANSCATHETER 





Mitral regurgitation (MR) is one of the most common valvular lesions with a global 
prevalence exceeding 6 million and an annual mortality of 5% without interventional 
treatment (2-4, 81). In the previous chapter, I demonstrated that one fifth of all heart 
failure (HF) admissions had moderate or more MR. This retrospective study combined 
both primary and secondary aetiologies, but it is likely that the majority of patients had 
secondary MR given the high incidence of ischaemic heart disease (IHD), 
hypertension, and impaired ejection fraction (EF) within our aging cohort. Current 
treatment options for secondary MR include medical therapy, cardiac 
resynchronisation and conventional mitral valve (MV) surgery, with transcatheter 
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mitral valve repair (TMVR) reserved for high surgical risk patients with multiple 
comorbidities, significant MR, left ventricular impairment and persistent symptoms 
despite optimal medical therapy (OMT).  
 
 
4.2 Aims and Objectives 
 
Based on the outcomes of the previous chapter and an established cohort of 
symptomatic HF patients with moderate or MR and an EF <50%, I aimed to investigate 
the potential for treating HF patients who have MR using TMVR. I hypothesised that a 
significant number of Lambeth and Southwark HF patients with moderate or more MR 
remain symptomatic despite OMT, and may be candidates for TMVR. 
 
My objectives were to determine: (1) the number of patients presenting with HF who 
have an EF of 20-50% and moderate or more MR despite OMT; (2) the number of 
patients within this group who are considered high or intermediate risk using the 
Euroscore II risk algorithm; (3) the sub-group who may be candidates for TMVR based 
on Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for 
Heart Failure Patients With Functional Mitral Regurgitation (COAPT) 
echocardiographic criteria, surgical risk and Heart Team review; 4) estimated 









4.3 Methods  
 
As described in Chapter 3, this was a retrospective study based on the interrogation 
of a large database of patients presenting with HF to two tertiary centres over a five 
year period. Those patients with moderate or more MR were then compared to those 
without MR, and those with moderate or more MR were then sub-categorised into one 
of two groups: those with an EF >50% and those with an EF ≤50%. Subsequent to 
this, patient records were reviewed to evaluate which patients were receiving OMT 
(and which of these remained symptomatic). Sections 3.3.1-3.3.3 provide a 
comprehensive outline of the methodology and Figure 4.1 provides a flowchart 












Figure 4.1. Flowchart outlining the pathway for patients selected in the retrospective heart failure study. 
This also outlines those who were excluded and the reasons for exclusion. Abbreviations: MR: mitral 
regurgitation; EF: ejection fraction; TTE: transthoracic echocardiogram; OMT: optimal medical therapy; 
MVR: mitral valve replacement. 
 
 
Methods for identification of the population of symptomatic HF patients with moderate 
or more MR and an EF <50% despite OMT are outlined in Chapter 3. The methodology 
was extended in this chapter as outlined in Figure 4.2 (please refer to stages 6,7 and 
8).  
 
Lambeth or Southwark resident + 
acute admission with heart failure
(n=1884) 




No TTE <6 months preceding or <1 month post     
index admission  (n=151)
Unable to quantify MR on TTE (n=16)
Prosthetic or repaired mitral valve (n=36)
Symptomatic + > moderate 
MR and EF < 50% 
(n=299)
Excluded: 
Died before OMT, lost to follow up (n=41)
Transplant or surgical MVR (n=11)
No subsequent TTE (n=48)
No TTE 1 month or more after optimisation (n=54)
Despite OMT, symptomatic +          
> moderate MR + EF < 50% 
(n=77)
Excluded: 
Unable to quantify EF on TTE (n=11)
> moderate MR and EF >50% 
(n=71)
TTE with < moderate MR  
(n=1300)
< moderate MR (n=53) 








     
     
 
NICOR data – unscheduled HF 
admissions  (time point 1)






• HF admission details
• Demographics and comorbidities
• Clinical signs and symptoms
• Electrocardiogram
• Presence of CRT/ICD
• NYHA class
• Index medical therapies
• Review of medical therapies
• Clinical signs and symptoms
• Presence of CRT/ICD
• NYHA class
• Laboratory results
Echocardiography data    
(time point 1)














Surgical risk data • Patient related factors
• Cardiac related factors
• Operation related factors
Stage 6.
COAPT criteria (operator 1) 
• Exclusion based on: 
- LVESD >70mm
- Presence of PASP >70mmHg
- Presence of HCM, RCM, constrictive 
pericarditis, or infiltrative cardiomyopathies
- Presence of moderate or severe right 
ventricular dysfunction 
Stage 7.
COAPT criteria (operator 1-3) • Exclusion based on: 
- Insufficient mobile leaflet for grasping
- Evidence of calcification in grasping area
- Presence of significant cleft
- Lack of primary /secondary chordal     
support
- Leaflet mobility length <1cm









Figure 4.2. Flowchart demonstrating the process by which retrospective patient data were collected for 
the retrospective heart failure study (stages 1-5). Additional stages 6,7 & 8 have been included to outline 
further components introduced as part of the Chapter 4 methodology. Abbreviations: HF: heart failure; 
CRT: cardiac resynchronisation therapy; ICD: implantable cardioverter-defibrillator; NYHA: New York 
Heart Association, LV: left ventricle; RV: right ventricle; LA: left atrium; LVESD: left ventricular end 
systolic dimension; PASP: pulmonary artery systolic pressure; HCM: hypertrophic cardiomyopathy; 
RCM: restrictive cardiomyopathies; COAPT: Cardiovascular Outcomes Assessment of the MitraClip 
Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation. Note: the red 
line denotes where the methodology was extended in Chapter 4. 
 
 
4.3.1 Study design 
 
All patients underwent detailed echocardiographic examinations with MR assessed 
using an integrative multiparametric approach.  Left ventricular (LV) size and function, 
right ventricular (RV) size and function, and pulmonary artery systolic pressure (PASP) 
were also key areas for interrogation. These data were used to determine potential 
suitability for TMVR based on application of the Cardiovascular Outcomes 
Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With 
Functional Mitral Regurgitation (COAPT) trial echocardiographic inclusion and 
exclusion criteria (21). Additionally, patient records were used to determine surgical 
risk (Euroscore II). Demographics, laboratory data and co-morbidity details were 









4.3.2 Study population 
 
Previously examining patients with an EF <50%, this chapter focussed on patients 
with an EF between 20-50% to ensure alignment with inclusion and exclusion criteria 
applied in the COAPT trial. Therefore, patients with an EF of 19% or less were 
subsequently excluded from this Chapter. There were additional specific echo criteria 
which were used to define suitability (Table 4.3) and wider inclusion and exclusion 
criteria are outlined below (Table 4.1). 
 
 
Table 4.1. Inclusion and exclusion criteria for patients involved in this study focussing on suitability  for 
transcatheter mitral valve repair based on echocardiographic and surgical risk criteria.  Abbreviations: 
GSTT: Guy’s and St Thomas’ NHS Foundation Trust; KCH: King’s College Hospital; HF: heart failure; 
MR: mitral regurgitation. EF: ejection fraction; OMT: optimal medical therapy; TTE: transthoracic 
echocardiogram. 
Inclusion Criteria Exclusion Criteria 
1. Presentation to either GSTT or KCH with HF 
between Jan 2013 and December 2017 
2. Resident of Southwark or Lambeth 
3. 18 years or older 
4. Moderate or more MR, EF <50% and 
symptoms despite OMT 
1. TTE performed either within 1 month of, or up 
to 6 months preceding, the index admission 
2. Unable to estimate EF or quantify MR on TTE 












4.3.3 Demographics, laboratory and clinical information 
 
As outlined in Chapter 3, demographics, clinical data, information relating to medical 
history, comorbidities, and biochemistry results were obtained from the NICOR data 
set and electronic patient records. This information was obtained by myself and a 
cardiology doctor in training (FB) using electronic patient records such as EPR and 
EPR Sunrise. 
 
4.3.4 Surgical risk 
 
4.3.4.1  Determining surgical risk 
 
The European System for Cardiac Operative Risk Evaluation (Euroscore) II was used 
to determine the risk of in-hospital mortality after major cardiac surgery.  Parameters 
required for the calculation of surgical risk score are outlined in Table 4.2. Risk was 
determined by inputting the relevant data into the online Euroscore II algorithm tool 
(http://www.euroscore.org) (82). I performed this task assisted by a cardiology doctor 
in training (FB) using information that was obtained by searching through electronic 
patient records. In order to ensure simplicity, only one risk score was used in this 
study. This particular risk score most reliably relates to UK experience and the decision 
to use it was based on expert opinion from our internal surgical consultant body. To 
maintain simplicity within the calculation, all routine patients were allocated an urgency 
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of ‘elective’, a weight of intervention of ‘single non-CABG’ and a surgery on thoracic 
aorta of ‘no’.  
 
Table 4.2. Parameters required for the calculation of surgical risk score using the online Euroscore II 
calculator. + Renal impairment was determined using the Cockroft-Gault creatinine clearance calculator 
which required plasma creatinine, age, weight, and sex. *CCS class 4 angina was defined by angina at 
rest. ^Pulmonary hypertension (as per moderate 31-35mmHg; severe > 55mmHg). #For this study, all 
routine patients were allocated an urgency of ‘elective’, a weight of intervention of ‘single non-CABG’ 
and a surgery on thoracic aorta of ‘no’. Abbreviations: NYHA: New York Heart Association; MI: 
myocardial infarction (82). 
Patient Related Factors Cardiac Related Factors Operation Related Factors 





Previous cardiac surgery 
Chronic lung disease 
Active endocarditis 
Critical pre-operative state 
Diabetes on insulin 
NYHA 






Weight of the intervention# 












4.3.4.2  Categories of surgical risk 
 
Based on empirical evidence and recommendations from the literature, pre-operative 
risk and in-hospital mortality risk categories were defined in this study as (83, 84): 
• low risk <3% 
• intermediate risk 3 - < 6% 
• high risk >6%;   
 
4.3.5 Echocardiography data 
 
I reviewed archived digital images for all intermediate and high risk patients with 
symptomatic HF despite OMT who had moderate or more MR and an EF <50%. 
Details regarding the lead investigator review are outlined in Section 4.3.6. Potential 
suitability for TMVR was determined by application of the COAPT trial 
echocardiographic inclusion and exclusion criteria. 
 
4.3.5.1  COAPT inclusion and exclusion criteria 
 
Table 4.3 outlines the criteria used in the COAPT trial relating to echocardiographic 
measurements (21). This was used in conjunction with the COAPT algorithm for 
determining the severity of MR (Figure 4.3). Finally, technical suitability for TMVR was 
determined based on consensus amongst a group of experts (Section 4.3.6). Patients 
with both primary and mixed primary/secondary mitral valve disease were excluded. 
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Table 4.3. Echocardiographic inclusion and exclusion criteria used in the Cardiovascular Outcomes 
Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral 
Regurgitation (COAPT) trial (21). Abbreviations: MR: mitral regurgitation; LVEF: left ventricular ejection 
fraction; LVESD: left ventricular end-systolic dimension; PASP: pulmonary artery systolic pressure; 
HCM: hypertrophic cardiomyopathy; RCM: restrictive cardiomyopathy.  
Echocardiographic  Inclusion Echocardiographic Exclusion 
• Functional MR (>3+) 
• Global or regional abnormality 
• LVEF >20% and <50% 
• Primary MR jet is non-commissural 
• LVESD <70mm 
• PASP >70mmHg 
• Presence of HCM, RCM, constrictive 
pericarditis, or infiltrative cardiomyopathies 
• Presence of moderate or severe right 
ventricular dysfunction 
• Mitral valve orifice area <4.0cm2 
• Leaflet anatomy precluding clip implantation: 
• Insufficient mobile leaflet for grasping 
• Evidence of calcification in grasping area 
• Significant cleft 
• Lack of primary / secondary chordal               
     support 
• Leaflet mobility length <1cm 












Figure 4.3. Echocardiography algorithm used to determine the degree of mitral regurgitation in the 
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure 
Patients With Functional Mitral Regurgitation (COAPT) trial. Taken from: Asch et al (2019) (85). 
 
4.3.5.2  Measurement and assessment technique 
 
Digital images were interrogated with additional measurements made offline in order 
to determine the aetiology and severity of MR, and suitability for TMVR. 
Measurements were made in line with British Society of Echocardiography 
recommendations (themselves based upon recommendations from the American 
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Society of Echocardiography [ASE] and European Association of Echocardiography 
[EAE]) (69-71). 
 
Mitral valve (MV) leaflets were assessed for the presence of thickening, calcification 
and tethering. The degree of tenting throughout systole was also examined. Each of 
these were graded as follows: 1) nil 2) mild 3) significant. The length of the leaflets 
was reviewed for appropriateness and leaflets examined for rheumatic changes, 
commissural fusion and the presence of stenosis. Where the MV areas were <4.0cm2, 
this was documented.  
 
In each case, the aetiology of the MR was determined as either primary or secondary. 
The severity of regurgitation was assessed using an integrative approach. Regurgitant 
volume was calculated one of two ways:  
 
1) Stroke volume (SV) method using the difference between transmitral flow and 
flow across the left ventricular outflow tract. In this case, 2D linear 
measurements of both the LVOT in systole and mitral valve annulus in diastole 
were required (Table 4.4).  
2) Proximal isovelocity surface area (PISA) method: PISA was performed with a 
Nyquist limit of 30-40cm/sec. When PISA was obtained and considered 
accurate, the radius was measured from the point of colour aliasing to the vena 








Effective regurgitant orifice area (EROA) was calculated based on measures of 
regurgitant flow and peak velocity of the MR continuous wave envelope (Table 4.4). 
Regurgitant fraction (RF) was determined based on MV regurgitant volume (RVol) as 
a proportion of total mitral volume converted to a percentage.  
 
Table 4.4. Calculations used for the quantitative echocardiographic assessment of mitral regurgitation. 
Abbreviations: SV: stroke volume; MV: mitral valve; D: diameter; r: radius; VTI: velocity time integral; 




Regurgitant volume (mL) 
(by SV method) 
RVol SV MV – SV LVOT  
Where SV is (0.795 x D2 x VTI) 
Regurgitant volume (mL) 
(by PISA method) 
RVol 2!r2 x Va (where Va is the Nyquist limit) / 
regurgitation velocity of the MR jet x VTI of 
the MR jet 
Effective orifice area (cm2) EROA RVol / Peak velocity of the MR jet 
Regurgitant fraction (%) RF SV MV – SV LVOT / 100 
 
 
Flow reversal within the pulmonary vein was assessed based on pulsed wave Doppler 
with a small sample volume placed approximately 1cm into the mouth of the pulmonary 








Vena contracta width was measured when proximal flow convergence was best 
visualised. Where possible, this was taken from the PLAX window to allow alignment 
between the proximal flow convergence, vena contracta and MR jet. PISA radius was 
measured as outlined above in regurgitant volumes.  
 
A large holosystolic jet wrapping around the left atrium (LA) was assessed visually 
using colour flow imaging (CFI) and continuous wave (CW) Doppler. A dense and 
uniform trace throughout systole or a biphasic CW Doppler trace was required to 
define moderate to severe or severe MR.  A triangular jet also suggested severe MR. 
Colour flow imaging was also used to exclude the presence of a commissural jet. 
 
The peak E-wave of mitral inflow was obtained using pulsed wave Doppler aligned 
with the MV forward flow and positioned at the tip of the valve leaflets in diastole 
(obtained in the four chamber view). A peak velocity >1.50m/s was deemed consistent 
with severe MR. 
 
Additionally, digital images were used to exclude the presence of vegetations, masses 
or thrombus. Colour flow imaging was used to assess the degree of tricuspid 
regurgitation and 2D images were used to inspect the suitability of the interatrial 
septum for TMVR via trans-septal approach. Right ventricular systolic function was 
assessed based upon a combination of visual assessment and the interpretation of 
quantitative measures, such as fractional area change (FAC), tricuspid annular plane 
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systolic excursion (TAPSE) and tissue Doppler of the right ventricle in systole (RV S’).  
A 2D linear measurement of the left ventricular end systolic dimension was recorded. 
  
4.3.6 Echocardiography review 
 
In the first instance, I reviewed the echocardiographic images. I am trained and 
accredited in transthoracic and transoesophageal echocardiography and have more 
than 15 years experience working in echocardiography and valve disease.   
 
Following initial screening by myself, TTEs of patients considered suitable for TMVR 
based on echocardiographic criteria and procedural risk, were reviewed by an expert 
valve specialist within the valve team (JH or MM), both of whom are imaging 
consultants trained and accredited in transthoracic and transoesophageal 
echocardiography with more than 25 years experience working in valve disease and 
echocardiography. If agreement was met, the patient was considered ‘suitable based 
on echocardiographic and risk criteria’. Any discrepancies between investigator 1 and 
expert 1, were resolved by a second expert (BP) who is the chief investigator and lead 
for valve disease services at Guy’s and St Thomas’ Hospital.  
 
Inter-operator reproducibility was examined in all patients being assessed for eligibility 
following exclusion of patients with LVESD >70mm, the presence of PASP >70mmHg, 
HCM, RCM, constrictive pericarditis, or infiltrative cardiomyopathies, or moderate or 
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severe right ventricular dysfunction (Stage 7 of methodology flowchart, Figure 4.2), 
using blinded reads by two experts.   
 
4.3.7 Extrapolation of data 
 
For the extrapolation of data, figures published within the NICOR 2017/2018 report (1) 
were used to determine HF incidence at the level of the English population.  
4.3.8 End points 
 
The end points for this chapter were:  
1) Number of patients potentially suitable for TMVR based on risk criteria. 
2) Number of patients potentially suitable for TMVR based on echocardiographic 
and risk criteria. 
 
4.3.9 Statistical analysis 
 
Limited statistical analysis was required in this Chapter. Categorical outcomes were 
based on frequencies and percentages, and continuous variables on standard 
deviations and means. Bivariate analysis was performing using Chi Square for 











In Chapter 3, I was able to establish that 1884 patients presented with acute HF over 
a five year period (Jan 2013 – Dec 2017). Of this cohort, 237 (12.6%) had moderate 
or more MR and an EF of <50%. Following stabilisation on OMT, 77 patients remained 
symptomatic with moderate or more MR and an EF <50%.  Figure 4.4 provides an 
overview of the patient selection process. 
 
 
Figure 4.4. Flowchart outlining the selection criteria pathway for patients involved in the retrospective 
studies (Chapters 3 and 4). Abbreviations: MR: mitral regurgitation; EF: ejection fraction; OMT: optimal 
medical therapy; LVESD: left ventricular end-systolic dimension; PASP: pulmonary artery systolic 
pressure; HCM: hypertrophic cardiomyopathy; RCM: restricted cardiomyopathy; RV: right ventricle; 
TMVR: transcatheter mitral valve repair. 
Lambeth or Southwark resident + 
Acute admission with heart failure
(n=1884) 
TTE with moderate MR and EF < 50% 
(n=299)
Despite OMT, symptomatic + 
moderate MR + EF < 50% 
(n=77)
Despite OMT, symptomatic + 
moderate MR + EF < 20% 
(n=18)
Despite OMT, symptomatic + 













One of LVESD >70mm, PASP 
>70mmHg, presence of HCM, RCM, 
constrictive pericarditis, or 












There were 18 patients with an EF <20% and these individuals were excluded from 
our population. Thus, 59 patients had an EF 20-50%, moderate or more MR and 
symptoms despite OMT.  
 
For each of the 59 patients, risk was determined based on the Euroscore II algorithm. 
There were 26 (44%) patients with high risk (>6%), and 14 (24%) with intermediate 
risk (3-<6%). Those with low risk (<3%) were examined and excluded from further 
analysis (n=19 (32%)). Across the groups, the mean age was 69.88 years (SD ± 13.57) 
and the mean EF 31.6% (SD ± 8.8%). 
 
In the intermediate and high risk groups, the mean age and mean EF were 70 and 79 
years and 30% and 33%, respectively. Variations between groups are highlighted in 
Table 4.5. The mean calculated risk scores across different groups were as follows: 
low risk 1.89%, intermediate risk 3.88%, high risk 15.67%. Two variables which were 
statistically different across the three risk groups were age (p=<0.001) and history of 
IHD (p=0.001). Of those in the higher risk group (>6%), 81% had IHD, 72% had 
hypertension and half (52%) were diabetic. When combining the intermediate and high 
risk patients (>3%), 67.8% had IHD, 72% had hypertension and 40% were diabetic. 
Additionally there were 10 patients in the high risk group with a CRT-D, CRT-P or 










Table 4.5. Clinical variables stratified according to surgical risk in patients considered potentially 
suitable for transcatheter mitral valve repair Abbreviations: IHD: ischaemic heart disease; COPD: 
chronic obstructive pulmonary disease. Statistics: Chi square for categorical and one way ANOVA for 
continuous variables. 







Patients n (%) 26 14 19  
Risk (%) Mean ± SD 15.67 ± 7.96 3.88 ± 0.512 1.89 ± 0.723 <0.001 
Age Mean ± SD 79.46 ± 9.71 69.5 ± 8.14 57.05 ± 10.4 <0.001 
Sex (male) n (%) 16 (61.54%) 9 (64.28%) 10 (52.6%) 0.07 
IHD n (%) 21 (80.7%) 6 (46.15% 4 (78.9%) 0.001 
Hypertension n (%) 18 (72.0%) 11 (78.6%) 9 (47.3%) 0.206 
Diabetes n (%) 13 (52.0%) 3 (21.43%) 4 (21.05%) 0.105 
Asthma n (%) 4 (16.6%) 2 (14.3%) 2 (10.5%) 0.447 
COPD n (%) 4 (16.0) 4 (28.57%) 0 (0.0%) 0.07 
Ejection fraction  Mean ± SD 30.17 ± 8.97 33.067 ± 9.02 32.0 ± 8.55 0.105 
 
 
Of the 40 patients with high and intermediate risk, 13 met COAPT echocardiographic 
exclusion criteria. There were 15 patients with high risk and 12 patients with 
intermediate risk remaining. Digital echo images were reviewed by an expert panel 
and based upon risk and COAPT criteria, a total of 20 patients were deemed 








Inter-operator reproducibility showed 100% alignment between investigator 1 and 
expert 1 with no requirement for cases to be reviewed by a second expert (chief 
investigator). Therefore inter-operator variability was 0%.   
 
Extrapolating these data to the population of England suggested a provisional 
requirement of approximately 400 TMVR procedures per year for the acute HF cohort 
with secondary MR alone (Table 4.6). In 2019 in England there were a total of 124 
TMVR using MitraClip, the only currently available edge to edge mitral repair device.  
 
Table 4.6. Extrapolation of study data to English population level. Abbreviation: TMVR: transcatheter 
mitral valve repair. 
 
Study Population 
Total heart failure admissions over 5 years 2 821 
 
280 289 
(based on 71 188 per year) 
Patients deemed potentially eligible for TMVR 20 2 000 














Within this chapter, this study concludes that there were a large proportion of patients 
with increased pre-operative surgical risk (based on the Euroscore II algorithm) within 
a cohort of medically optimised HF patients with moderate or more MR and an EF 20-
50%. Over two thirds of patients were in the high (>6%) or intermediate risk groups (3-
<6%).  
 
Surgical risk scores have been used for many years to assist estimation of the pre-
operative risk and subsequent risk of in-hospital death following cardiothoracic 
surgery. Once relying on the original logistic Euroscore, 2011 saw an updated 
Euroscore II that was designed to be more accurate as a result of updated datasets 
reflecting improved surgical outcomes (86).  The Society of Thoracic Surgeons (STS) 
score is another well-known risk score which can be used for this purpose but is more 
widely applied in the United States. Currently, there remains debate regarding which 
risk score provides the best estimate with studies disagreeing whether Euroscore II is 
superior or inferior to STS and/or Euroscore (87, 88). Comparatively, they all perform 
reasonably well. The STS score is known to provide slightly higher discrimination in 
relation to long term outcomes for patients undergoing conventional but isolated 
surgery, but this needs to be weighed against practicality since additional variables 
make it more time consuming. Furthermore, application of these scores in the 
prediction of mortality for patients undergoing transcatheter valve procedures has not 
been well established. Indeed, multiple studies focussed on drawing a comparison 
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between risk scores (STS score, logistic Euroscore, Euroscore II) found that none of 
the scores were predictive of 30 day mortality across populations of patients who had 
undergone transcatheter aortic valve implantation (TAVI) (89, 90). Similarly, these 
tools were found to be insufficient in predicting mortality in patients undergoing TMVR, 
with recommendations suggesting the need for validated surgical risk tools for 
transcatheter intervention (91). Although most studies have suggested that these tools 
overestimate the risk of mortality due to the less invasive nature of transcatheter 
interventions, the combination of potential for real complications and failure to consider 
frailty, porcelain aorta and previous radiation makes absolute risk interpretation 
challenging. Regardless of these findings, the value of surgical risk tools in defining 
patients who are high risk and thus ineligible for conventional surgical intervention still 
holds strong.  Moreover, these tools are useful in determining patients candidacy for 
transcatheter interventions, assisting the decision making process and also 
determining when even transcatheter interventions may be futile and unlikely to 
improve quality of life and longevity. The challenge here lies in determining where the 
precise cut points rest, an issue still under debate and perhaps best made within a 
collaborative Heart Team incorporating interventional and surgical representation. 
Defined cut points would be very helpful but are only one piece in the puzzle 
determining suitability for transcatheter intervention. 
 
In our study there were 13 patients who met COAPT exclusion criteria due to left 
ventricular end systolic dimensions >70mm, pulmonary artery systolic pressure 
>70mmHg, moderate or worse right ventricular dysfunction, or a combination of two 
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or more of these parameters. Seven patients were excluded based on moderate or 
worse right ventricular dysfunction. The COAPT criteria excluded patients with 
‘physical evidence of right-sided congestive heart failure with echocardiographic 
evidence of moderate or severe right ventricular dysfunction as assessed by site‘. 
Firstly, physical evidence does not always align with echocardiographic findings, and 
it was not possible to combine the two in our retrospective study. Additionally, 
designation of RV dysfunction as mild, moderate or severe is somewhat subjective 
given national and international recommendations that RV function should be 
assessed using an integrative approach (including visual estimation of longitudinal and 
radial contractility, TAPSE, RV S’ and FAC). Of note, patients were not excluded 
based on RV function in the EVEREST HHR study (which focussed on high risk 
patients) or RESHAPE-HF trial. In theory, if patients with moderate or severe RV 
dysfunction based on echo criteria but without physical evidence of right heart 
congestion were eligible, the potential for treatment in our cohort may have been 
underestimated. With that said, in our study, given the established utility of 
transcatheter aortic valve interventions, we did not exclude patients with significant 
aortic valve disease. Additionally, in light of recent advances in transcatheter tricuspid 
valve procedures, we did not excluded patients with significant tricuspid valve 
regurgitation. Patients with both primary and mixed primary/secondary mitral valve 
disease were excluded.  
 
In a conceived variation with the COAPT trial, my study included patients with 
moderate MR. However ‘reported’ moderate MR using 2013-2017 national guidelines 
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aligned with the classification of moderate-severe or severe MR using EROA and 
regurgitant volume ranges in current guidelines (mainly due to the addition of a 
subcategory for secondary MR) (71, 92). Fortunately for intermediate and high risk 
patients, review of echocardiographic images meant that additional measurements 
were performed where possible to ensure alignment with current guidelines and 
classification of moderate-severe and severe MR categories. 
 
In total, there were 20 patients deemed potentially suitable for TMVR based on risk 
and echocardiographic criteria. When assessing these patients there was very high 
inter-operator reproducibility which should allow for a robust multidisciplinary team 
(MDT) approach to the assessment of these patients. 
 
Projecting these data to population level (using national HF audit data numbers) 
suggested a total of approximately 400 patients per year across England. It is 
important to note that these figures are based on patients with HF and secondary MR 
only – those with primary MR and mix primary/secondary MR potentially requiring 
TMVR were not taken into consideration, making our estimate particularly 
conservative. This clearly highlights a gap between existing provision and demand. 
Presently there are only three institutions in England commissioned to perform TMVR 
using the MitraClip edge to edge system. It is possible that initial hesitation in 
commissioning was due to uncertainty as to whether reduction in the severity of MR 
resulted in a survival benefit. In 2018, the final conclusions of a ‘Commissioning 
Through Evaluation Report’ supported a causal link between TMVR using MitraClip 
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and clinically important reductions in MR and improved quality of life (93). The 
availability of MitraClip is currently being reviewed at national level with plans to 
establish TMVR treatment centres outside the present designation. However, in light 
of a very uncertain health climate, it remains unclear whether decisions to extend the 






There were a number of limitations in this study. Firstly, surgical risk was determined 
based on Euroscore II alone and comparison with STS score was not possible.  
 
Secondly, as mentioned above there are inherent limitations in the use of the 
Euroscore II risk score, both in relation to the absence of additional co-morbidities 
(such as frailty and previous radiation) and its applicability in the sphere of 
transcatheter interventions.  
 
Thirdly, we based the selection of suitable patients upon echocardiographic criteria 
and Euroscore II alone. To be completely in line with COAPT recommendations, 
patients considered for TMVR should undergo both TTE and TOE. Our study was 
based on the assessment of MV aetiology and MR severity using TTE alone. Use of 
TOE may have resulted in different outcomes in relation to mechanism and/or 
suitability. Moreover, based on COAPT criteria a number of additional parameters 
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would have required consideration before a patient was deemed suitable. These 
include (but are not limited to) NT-pro BNP, creatine kinase-MB, coronary artery 
status, aortic valve disease, carotid stenosis, haemodynamic instability, and a life 
expectancy less than 12 months. 
 
Finally, this study was based on a real patient population with hypothetical 
assumptions. Patients were not formally turned down for conventional surgery and 
there is no way of knowing whether patients were prepared to consider conventional 





A substantial proportion of acute HF patients remain symptomatic with significant MR 
despite OMT. Based on echocardiographic and risk criteria, many are potential 
candidates for TMVR according to current international guidelines. However, there is 
a need to ensure that the appropriate funding and resource are in place to cater for 
this aging population.   
 
Although calculated risk score can assist in determining eligibility for intervention, 
additional clinical, imaging and haemodynamic variables need to be considered. The 
role of biomarkers and functional testing in the risk stratification of patients being 
considered for TMVR is poorly understood, demonstrating the need for further 
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characterisation of these markers in this cohort. These parameters, especially those 
relating to proportionate and disproportionate MR, may prove useful in selecting 














FUNCTIONAL TESTING IN TRANSCATHETER 
MITRAL VALVE REPAIR: A SYSTEMATIC REVIEW 





International experience of transcatheter mitral valve repair (TMVR) in patients with 
secondary mitral regurgitation (MR) continues to grow and its application has become 
more widespread as a result of numerous large multicentre trials vindicating the 
potential advantage of TMVR for patients with secondary MR who remain symptomatic 
despite optimal medical therapy (OMT) and/or cardiac resynchronisation therapy 
(CRT) (44, 60). Positive outcomes such as reduced rates of hospital admission and 
improvements in quality of life have been reported (60). However, there remains some 
degree of unpredictability in terms of symptomatic relief across the breadth of the 
population treated, with some patients gaining very little or no improvement in 
symptoms whilst others experience a new lease of life. It is therefore vital that clinical 
teams correctly determine which patients are likely to gain the greatest improvement, 
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in turn offering our patients more clarity and certainty in relation to the balance of risk 
and benefit. Patient selection therefore needs to focus on an individual yet integrative 
approach, including combined assessment of clinical signs, symptoms and 
echocardiographic findings, with further investigation needed into the value of 
functional testing within the TMVR population. 
 
 
5.2 Functional testing: background 
 
Aside from risk scores, echocardiographic criteria and clinical thresholds, the 
presence of symptoms is fundamental in identifying patients who require intervention. 
However, reported symptoms can be subjective, or minimal in those patients who 
progressively, incidentally or inadvertently reduce their activity. Functional testing 
therefore provides a more objective approach to the estimation of exercise tolerance 
and offers an opportunity for the assessment and unmasking of symptoms. It can also 
assist clinicians in assessing prognosis and evaluating potential response to 
treatment. Commonly used methods to determine functional capacity in patients with 
MR include exercise stress testing, exercise stress echocardiography, cardio-
pulmonary exercise testing and six minute walk tests.  
  
Exercise stress echocardiography (ESE) is invaluable in the assessment of structural 
heart disease, especially lesions affecting the mitral valve (MV). For patients with MR, 
ESE is of particular benefit in the assessment of symptoms, functional capacity and 
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when there is a mismatch between the degree of MR and perceived level of symptoms 
(94). The dynamic nature of MR means that ESE can provide pertinent information in 
relation to loading and cardiac haemodynamics (95). In the past, an inadequate 
increase in ejection fraction (EF) and a larger end systolic volume on exercise was 
shown to indicate limited contractile reserve, with potential for pre-operative EF to 
serve as a predictive marker following surgical MV repair (96). Today, we view EF as 
just the tip of the predictive iceberg, with concomitant markers such as exercise 
induced change in MR, cardiac output, right ventricular functional reserve and systolic 
pulmonary artery pressure all being viewed as important predictors of symptoms or 
early indicators for intervention.   
 
Moreover, a combination of both primary and secondary aetiologies means that 
assessing MR can be complex. As such, the reliability of exercise stress 
echocardiography in the assessment of dynamic MR offers incremental value. In a 
study investigating patients with primary MR, an increase in MR as a consequence of 
exercise was associated with lower symptom free survival. This was evaluated on 
exercise stress echocardiography using quantitative changes in effective orifice area 
and/or regurgitation volume, with conclusions suggesting a more aggressive treatment 
strategy within this patient cohort (97).  
 
Cardiopulmonary exercise testing (CPET) plays a critical role in prognostic 
assessment of heart failure (HF) patients (98). Said to be the ‘gold standard’, it is an 
established tool in the management of those HF patients with reduced ejection fraction 
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(EF), highlighting warning signs in symptomatic patients and discriminating exercise 
limitation in those who are functionally asymptomatic. A recent review paper which 
focussed on the application of CPET in HF emphasised differences in CPET results 
across specific groups (98). These included comparisons within genders, the aging 
population, those with increasing body mass index (BMI) and those with arrhythmias 
and comorbidities. CPET was useful in determining prognosis in these populations 
and the review questioned whether this learning could be useful in risk stratification 
for patients undergoing TMVR. Unfortunately, the limited availability of CPET in some 
centres means that pre-procedural testing may not be widely accessible. 
 
Perhaps a better reflection of routine daily activity, the six minute walk test (6MWT) is 
a commonly used tool in the assessment of functional capacity. It is simple to perform, 
reproducible and inexpensive, and requires limited or no equipment. The design 
allows participants to stop or pause as required, which means the test can be used for 
a wider (and potentially more symptomatic) patient population. An important marker of 
prognosis, studies have shown good correlation between 6MWT and peak VO2, with 
one study demonstrating equivalent predictive value (99, 100). Previous studies have 
suggested that patients with congestive HF and reduced EF with a 6MWT distance of 
less than 340m have a 3.5 times higher risk of death (101). Similarly, a recent large 
European multicentre registry demonstrated that HF patients with reduced 6MWT 
distance (<360m) experienced more frequent hospital admissions and a 14% increase 
in the risk of death (102). Findings within this study correlated with those outlined 
above - patients who were female, of older age, and with an increased heart rate and 
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comorbidities performed worst. The study reported that addition of the 6MWT did not 
improve predictive modelling in relation to prognosis in this cohort (c-index: 0.71 for 
primary outcomes, 0.73 for death) (102). It did, however, suggest that a 6MWT 
distance of 240m or less carried a much higher risk of death and/or hospitalisation 
(adjusted HR 2.41 [1.76–3.29] and 1.73 [1.38–2.18], respectively) (102).  
 
Drawing parallels with evidence in the HF population, there is optimism that functional 
testing in patients requiring TMVR may (A) assist in patient selection, (B) discriminate 
patients most likely to demonstrate improved left ventricular (LV) parameters, 
reduction in symptoms, and improved quality of life following intervention, (C) facilitate 
more careful risk stratification and interventional planning, and (D) help to avoid high 
risk procedures which may prove futile. However, the current role of functional testing 
in patients undergoing TMVR is poorly understood.  
 
Current European Society of Cardiology (ESC) guidelines state that functional 
capacity and symptoms assessed by CPET may be useful in asymptomatic patients 
(29). ESE is useful to quantify exercise-induced changes in MR, systolic pulmonary 
artery pressure and LV function. The guidelines suggest that ESE may be particularly 
helpful where the patient is symptomatic and there is uncertainty regarding the severity 
of MR at rest. For asymptomatic patients, rises in systolic pulmonary artery pressure 
with exercise (> 60mmHg) are thought to be of prognostic value (29). These 
recommendations are supported by the American College of Cardiology / American 
Heart Association 2020 guideline (31). Additionally the ACA / AHA recommend 
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exercise stress testing with a focus on symptoms, exercise capacity and blood 
pressure response which are of prognostic value in asymptomatic patients (31).  
 
 
5.3 Aims and Objective  
 
The primary aim of this systematic review and meta-analysis was to provide a 
qualitative and quantitative presentation of current evidence from original studies 
focussed on the role of functional testing in predicting outcomes of TMVR. I 
hypothesised that the literature would support the use of functional testing for risk 
stratification and prognostication in patients undergoing TMVR. The research question 
was to determine if functional testing was appropriate for risk stratification and 
determination of prognosis in patients undergoing TMVR.  
 
My objectives were to determine: (1) the number of articles in existence focussed on 
functional testing in relation to TMVR; (2) the number of articles involving TMVR and 
functional testing as a predictor of outcome; (3) the breakdown of different modes of 
functional testing; (4) the reported value of functional testing in risk stratification for 













5.4.1  Search Strategy 
 
A systemic review of the literature was performed according to Preferred Reporting 
Items for Systematic reviews and Meta-Analysis (PRISMA) methodology and 
registered with PROSPERO (ID192319, approval number CRD42020192319) (103). 
Three databases were used - Medline, Scopus and Google Scholar (US). In addition, 
clinical trials were identified through searches of the Cochrane Library and 
clinicaltrials.org (five databases in total). The search was focussed on all articles in 
existence involving humans up to May 25th 2020. Searches were performed in keeping 
with established search methods and MeSH strategy where possible. Key words and 















Table 5.1. Search terms used across five databases to determine articles relevant to our research 
question focussing on the use of functional testing for risk stratification and determination of prognosis 
in patients undergoing transcatheter mitral valve repair. 
Concept Search terms 
Medical diagnosis Mitral insufficiency, mitral regurgitation, mitral 
Procedural approach Percutaneous, transcatheter 
Exercise capacity Six minute walk test, 6 minute walk test, exercise test, stress test, 
stress echocardiography, stress echocardiogram, exercise 
echocardiography, exercise echocardiogram, cardiopulmonary test, 
VO2 max, CPET, CPEX. 
Other limits Adult, human, published in English 
   
 
Table 5.2. Search terms and strategy across five databases (Medline, Scopus, Google Scholar, 
Clinicaltrials.org and Cochrane library) and the number of results returned prior to filtering and exclusion 
of duplication. 
Database Search terms and strategy Results 
Medline (MeSH ‘mitral valve insufficiency’ OR (mitral or mitral regurgitation 
or mitral valve or mitral insufficiency).ti,ab,kw.) 
AND ((transcatheter or percutaneous).ti,ab,kw.) AND 
(exercise test* or stress test* or stress echo* or exercise echo* or 
minute walk test* or 6MWT or six minute walk test or 
cardiopulmonary test* or cardiopulmonary exercise test* or CPET 








exercise test/ or walk test/.) Limited to English and humans. 
Duplicates removed. 
Scopus MeSH ‘mitral regurgitation’ 
( TITLE-ABS-KEY ( "exercise test*"  OR  "stress 
echo*"  OR  "minute walk test*"  OR  "cardiopulmonary 
test*"  OR  "stress test*"  OR  "exercise 
echo*"  OR  "cardiopulmonary exercise 
test*"  OR  "6MWT"  OR  "CPEX"  OR  "CPET"  OR  "VO2 
max"  OR  "6 minute walk test*"  OR  "six minute walk 
test*" ) )  AND  ( TITLE-ABS-KEY ( "Mitral 
regurgitation"  OR  "mitral insufficiency" ) )  AND  ( TITLE-ABS-
KEY ( percutaneous  OR  transcatheter ) )  AND  ( LIMIT-
TO ( LANGUAGE ,  "English" ) )  AND  ( LIMIT-
TO ( EXACTKEYWORD ,  "Human" ) )  
264 
Google Scholar ("Transcatheter mitral valve" OR "percutaneous mitral valve") AND 
("exercise testing" OR "minute walk test" OR "exercise stress 
echo" OR "stress testing") 
Limited to English language 
647 
Clinicaltrials.org MeSH ‘mitral insufficiency’ AND (‘percutaneous’ OR 
transcatheter’) 
Limited to ‘with results’ 
8 





Once duplications had been excluded, two independent reviewers (KV, MHH) 
screened the retrieved citations, firstly using the title and secondly by reviewing the 
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abstract. Any pertinent articles were then reviewed in full according to pre-determined 
selection criteria (Table 5.3). Any trials without results were excluded. Discrepancies 
were resolved by consensus following input from a third reviewer (CC). We employed 
backward snowballing by examining the list of references in those articles that met 
selection criteria and subsequently including relevant and eligible articles. For articles 
involving pooled data and clear overlapping populations, we included only those that 
were most recent, had the longest follow up period or largest number of recruits. There 
was no direct patient involvement in this study. Microsoft Excel was used to collect 
data and Endnote for referencing. 
 
Table 5.3. Inclusion and exclusion criteria for selected articles related to functional testing in patients 
undergoing transcatheter mitral valve repair. 
Inclusion criteria Exclusion criteria 
1. Observational and randomised clinical 
trials in patients treated with 
transcatheter mitral valve intervention 
2. Evaluation of functional capacity by 
exercise testing (including six minute 
walk test, exercise test, stress 
echocardiography or cardiopulmonary 
exercise test) 
3. Outcomes showing that functional testing 
was predictive of outcome 
4. Studies including adult human 
participants 
5. Peer reviewed studies 
1. Duplicate reports 
2. Duplication of the sample size 
3. Case series with sample size <10 subjects 
or case reports 
4. Articles not written in English 
5. Abstracts, posters or presentations 
6. No original data or trial in progress 
7. Opinion papers, letters or editorials 
8. Review papers 
9. Guidelines or protocols 
 
____________________________________________________________________________________________ 




5.4.2  Data Extraction 
 
Two unblinded reviewers (KV, MHH) extracted data comprising publication-related 
characteristics, patient-related characteristics and data related to functional testing, 
hospitalisation and mortality. More specifically this included: authors, year of 
publication, country of origin, methodology and design, sample size, patient 
demographics (age, sex), medical history and comorbidities (diabetes mellitus, 
coronary artery disease, COPD, previous myocardial infarction, atrial fibrillation, 
surgical risk score), cardiac imaging data (MR aetiology and severity, LV function, LV 
dimensions, left atrium (LA) volumes). Additionally, the end-points, outcomes and 
limitations of each study were recorded alongside data related to functional testing, 
device type, mortality, and rates of hospitalisation. 
 
5.4.3  Quality 
 
The quality of selected articles was evaluated using Methodological Items for NOn-
Randomised Studies (MINORS) methodology (104) - an established tool in the 
assessment of non-randomised trials that has demonstrated validity across 











5.4.4  Statistical analysis 
 
Meta-regression analysis was performed to evaluate the value of 6MWTs in predicting 
outcomes only. The primary safety end point was a composite of all cause death, 
cardiac death, length of stay, re-hospitalisation for HF, and re-interventions during 
follow up. The primary efficacy end point was mean 6MWT distance. Where the 6MWT 
data were reported using categorical variables, the authors were contacted, and a 
request was made for continuous variable data. Hazard and/or odds ratios and sample 
sizes were used to calculate effect size. The studies were analysed using a forest plot, 
with a random effects model to assess differences in the means. Heterogeneity was 
expressed as an I2 statistic which describes the percentage variation across studies 
that is due to heterogeneity rather than chance. Analysis was performing using STATA 
13 (Statacorp, College Station, Texas 77845 USA). 
 
5.4.5  Individual contribution to the research team 
 
The entirety of this project was my responsibility. Prof Bernard Prendergast is the lead 
of valve services at the primary research site (Guy’s and St Thomas’ NHS Foundation 
Trust) and was the principal supervisor. Prof Mark Monaghan and Dr Jane Hancock 
assisted in conceptualisation of this chapter. Dr Garry McDowell and Dr Fiona 
Wilkinson were joint academic supervisors on behalf of Manchester Metropolitan 
University. Dr Matthew Hammond-Haley, Dr Chiara Cirillo and Dr Georgios 
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Georgiopoulos assisted with article screening, data extraction, interpretation of 





5.5.1 Systematic Review 
 
Our systematic review identified 43 studies involving TMVR and functional testing. The 
primary purpose of the majority of these studies was to assess the safety and efficacy 
of TMVR. There were only 6 studies that used functional testing as a means of 
predicting outcome. Samples varied from 46 to 326, with 3 of the 5 studies reporting 
a sample size greater than 100 participants. Figure 5.1 provides an overview of the 








   
Figure 5.1. Flowchart outlining selection process for the systematic review of patients undergoing 
functional testing and transcatheter mitral valve repair. 
 
All six of the studies of interest focussed on use of the MitraClip edge to edge device 
system, and five concentrated on application of the 6MWT. The remaining study 
examined the role of stress echocardiography using isometric handgrips and 
compared patients with severe MR against those with moderate MR that increased to 
severe on static exercise (105). Patients with moderate MR that increased to severe 
MR on exercise had smaller LV and LA cavity sizes, and lower all cause mortality, less 
frequent HF hospitalisation and less residual MR following TMVR compared to those 
with severe MR at rest. Although limited details were provided regarding the isometric 














based on duplication 
(n=81)





Records excluded based on abstract (n=91) including:
Review or meta-analysis (n=31)
No original data or clinical trial in progress (n=21)
Guideline or protocol (n=14)
Abstract, poster, presentation, thesis, not peer reviewed (n=14)
Not target population (n=12)
Opinion paper, editorial, letter (n=7)
Book chapter (n=7)
Case report (n=5)
Not in English (n=1)
Records screened 
(n=64)
Records excluded based on full text (n=23) including:
Abstract (n=1)
Not target population (n=2)
No original data (n=7)
Pooled data, cross over cohort (n=12)
Insufficient sample size (n=1)
Records screened 
(n=43)

























Records excluded based on full text:








that exercise stress echocardiography may have a role in discriminating patients likely 
to gain the greatest improvement from TMVR.  
 
The remaining five studies were based on the role of the 6MWT in the prediction of 
outcomes following TMVR. Table 5.4 provides an overview of the publication-related, 
patient-related and study-related outcomes, following which each study is then 
summarised. There was variation across the studies in relation to study design, 
sample size, defined end points, statistical approach and outcomes. 
 
 
Table 5.4. Overview of publication-related, patient-related and study-related outcomes for articles 
focussed on the role of the six minute walk test (6MWT) in predicting outcomes following transcatheter 
mitral valve repair (TMVR). Abbreviations: TRAMI: TRAnscatheter Mitral valve Intervention; P: primary; 
S: secondary; MR: mitral regurgitation; HF: heart failure; Pts: patients; f/u: follow up; CPET: 
cardiopulmonary exercise test; LVEDD: left ventricular end-diastolic dimension; LVESD: left ventricular 
end-systolic dimension; LAD: left atrial dimension; LVEF: left ventricular ejection fraction; LVEDVi: left 
ventricular end diastolic volume indexed; LVESVi: left ventricular end systolic volume indexed; LAVi: 
left atrial volume indexed; DM: diabetes mellitus; CAD: coronary artery disease; AF: atrial fibrillation: 
ESII: euroscore II; NHYA: New York Heart Association; MI: myocardial infarction; NT-pro BNP: N-
terminal pro B-type natriuretic peptide; COPD: chronic obstructive pulmonary disease; PASP: 
pulmonary artery systolic pressure; QoL: quality of life; +MINORS: Items were scored 0 (not reported), 
1 (reported but inadequate) or 2 (reported and adequate) - global ideal score 16 for non-comparative 









ID 1 2 3 4 5 
Reference 
(Year) 
Triantafyllis et al 
(2015) (106) 
Ledwoch et al 
(2018) (107) 
Saji et al     
(2018) (108) 
Lee et al 
(2019) (109) 
Baldi et al        
(2019) (110) 
Country The Netherlands Germany United States Taiwan Italy 
Methodology  / 
design 
Retrospective, 
consecutive high risk 
patients. 
Examined long term 
predictors of 
outcomes. 
Subset of TRAMI trial 
registry. Large 
multicentre real world 
population (21 sites). 
Pt assigned to either 
arm: <200m or > 
200m based on 
6MWT distance pre-
procedure. 
3 groups:  
6MWT >219m 
6MWT <219m or 










Compared pts aged 
<80 years and 





No details regarding 
how 6MWT was 
performed. 
 
No comparison group 
Investigators blinded 
to clinical details for 
CPET 
Sample size 136 326 162 46 74 







Mixed P and S MR 
(75% P MR). 
Moderate-severe and 
severe MR 
Mixed P and S MR 
(severe MR) 
P MR (moderate-
severe and severe) 
Mean age and 
sex (%) 
Mean age:  
75 ± 9 years 
Sex (male): 68%  
Mean age:  
76 years; 
Age:  
<200m: 78 years 
>200m: 74 years 
 
Sex (male):  
Arm 1: 61% 
Arm 2: 69% 
 
Overall mean age:  
79 ± 11 years.  
 
Unable to walk: mean 
age: 79 years, sex 
(male): 48%. 
Walk <219m: mean 
age: 80 years, sex 
(male): 32% 
Walk >219m: mean 
age: 76years, sex 
(male): 57%. 
Arm 1:  
mean age: 84 years 
Sex (male): 63% 
 
Arm 2:  
mean age 73 years 
Sex (male): 81% 
Mean age: 72 ± 8 
years 
Sex (male): 78%  
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Triantafyllis et al 
(2015)(106) 
Ledwoch et al 
(2018) (107) 
Saji et al 
(2018) (108) 
Lee et al 
(2019) (109) 
Baldi et al        
(2019) (110) 
Comorbidities Hypertension 52%; 
DM 23%, CAD 63%; 
AF 53%, ESII 9.6±7; 
NYHA III/IV: 89% 
Hypertension 79%; 
DM 35%; CAD 40%; 
prev MI Arm 1 32%,  
Arm 2 20%; AF 40%; 
Log ES Arm 1 22%, 
Arm 2 17%. NYHA 
class  III/IV Arm 1 
94%, Arm 2 74%. 
Hypertension 74%, DM 
23%, CAD 56%, prev 
MI 25%, AF 65%,  
 
NYHA III/IV differed 
between groups: 
unable to walk 79%, 






DM 27%, CAD 
53%, AF 61%, 
mean ESII 10.1%, 
NYHA III/IV 94%. 
Hypertension (39%), 
DM 36%, CAD 37%, 
prev MI 35%, AF 
42%, COPD 29%, 
ESII 6.1(mean), 
NYHA class III/IV 
92%. 
Echo Data Baseline only:  
P MR 17%, S MR 
78%, mixed 5%. 
Average LVEF 36% 
Baseline only: no 
difference in MR 
between groups 
EF<30%: Arm 1 
28%, Arm 2 37% 
 
EF30-50%: Arm 1  
EF35%, Arm 2 32% 
 
EF>50%: Arm 1 
37%, Arm 2 31% 




Mean LVEDD 52mm, 
mean LVESD 38mm, 
mean LAD 48mm, 
mean LVEF 48%. 
Baseline only: 
>80 years: P MR 
68%, S MR 32% 
<80 years: P MR 
37%, S MR 63%.  
 
LVEF: >80 years 
mean 55%; <80 
years mean 44% 
Baseline only (mean 
data): 










End point End points not clearly 
defined 
P MR: 1 year all-
cause mortality;  
 




symptom status at 1 
year 
Prolonged hospital 
admission defined as 
total length of stay >4 
days  (including death 
in hospital and 
discharge to 
rehabilitation centre).  












P MR: Cardiac death 
 
S MR: All-cause 
death, composite of 
cardiac death or re-
hospitalisation for HF 
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Triantafyllis et al 
(2015) (106) 
Ledwoch et al 
(2018) (107) 
Saji et al    
 (2018) (108) 
Lee et al 
(2019) (109) 




Evaluate long term 
survival and identify 
pre-procedural 
predictors of long 
term mortality 
Assess potential of 
6MWT to predict 1 
year mortality in pts 
undergoing TMVR  




in pts undergoing 
TMVR: >80 years 
vs. <80 year 
Identify baseline 
predictors of long 
term outcomes in S 
MR pts undergoing 
TMVR 
Outcomes TMVR has good 
survival rates in high 
risk pts. 
Functional tests, NT 
pro-BNP and 
advanced age predict 
long term cardiac 
mortality 
1 year outcome: pts 
with walking distance 
<200m had higher 
all-case mortality 
After adjustment for 
baseline risk factors: 
strong trend towards 
increased risk of all-
cause mortality 
Cardiac mortality 
higher in those with 









95% vs. 93% 
success rate across 
groups 
Improved NYHA 
class and severity 
of MR in both 
groups  
6MWT is a predictor 
of all-cause mortality 
LAVi and low peak 
O2 uptake increase 
the risk of death at f/u 
AF associated with 
all-cause mortality  
Low VO2 
independent 





did not include 
6MWT (only NYHA 
class). 
Multivariate analysis 
adjusted for age, 
gender, NYHA class, 
LVEF<30%, COPD, 
DM, smoker, renal 
failure, previous MI. 
Multivariate analysis 






for age, sex, LVEF, 





Limitations Observational, single 
centre trial.  
Selection bias as a 
result of ‘Heart Team’ 
Problems with f/u 
data (no QoL) 
Pts in the <200m 
group were more 
symptomatic, with 









up limited to 1 year.  
No control group. 
Small sample; did not 
distinguish between 
AF types (persistent 
vs paroxysmal). 
Only hard outcomes 
used. Uncertain 



























In 2015, a group from the Netherlands retrospectively recruited 136 consecutive high 
risk patients with a mix of primary and secondary MR who underwent TMVR (106). 
Their mean age was 75 years with a mixture of comorbidities (predominantly 
hypertension, atrial fibrillation and coronary artery disease). The study found that 
TMVR was associated with good survival rates in high risk patients at one and two 
years, and demonstrated that the 6MWT predicted long term cardiac mortality in 
univariate analysis (p=0.05).  Unfortunately 6MWT was not included in the multivariate 
analysis. The study therefore concluded that New York Heart Association (NYHA) 
class, N-terminal pro B-type natriuretic peptide (NT-pro BNP) and advancing age were 
predictors of outcome in this cohort with little focus on the contribution of the 6MWT. 
Of note, the study had limited data in relation to quality of life, inherent limitations due 
to its observational and single centre design, and lack of clarity regarding end points. 
 
Ledwoch et al and Saji et al subsequently used a slightly different approach. Both of 
these retrospective studies categorised patients into groups based on 6MWT distance 
(107, 108). Ledwoch et al separated patients into one of two groups (<200 metres (m) 
6MWT distance vs >200m 6MWT distance), based upon retrospective collection of 
data from the TRAnscatheter Mitral valve Interventions (TRAMI) registry (49). This 
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study suggested that patients with a 6MWT distance <200m were at increased risk of 
mortality at 1 year compared to those able to walk >200m (p=0.07). Cardiac death and 
hospitalisation were also higher in this group. Interestingly, a 6MWT distance <200m 
did not impact on symptom improvement 1 year following TMVR. This study excluded 
patients who did not undergo a 6MWT but failed to clarify whether this was because 
patients did not have the test performed or because patients were unable to perform 
the test due to poor health (which would have introduced positive bias into the 
analysis).   
 
Saji et al took this into consideration by separating patients into three groups: 1) 6MWT 
distance >219m; 2) 6MWT distance <219m; and 3) those unable to walk (102). This 
study focussed on assessing whether 6MWT distance was predictive of prolonged 
hospital admission. The study found that 6MWT distance was independently 
associated with prolonged hospital admission (defined as >4 days or discharge to a 
rehabilitation facility within 3 days, or death) and an effective discriminator (p<0.001). 
Only 162 patients were included and recommendations were made to investigate this 
further within a larger patient population. 
 
Although again limited by small sample size, a subsequent study from Taiwan showed 
that baseline 6MWT was a predictor for all cause mortality after TMVR (p=0.026) 
(109). This study compared patients by age, with those >80 years showing no 
difference in survival at 1 year following TMVR compared to their younger 
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counterparts. This study combined patients with both primary and secondary MR, and 
was limited by its retrospective single centre design. 
 
The final study to focus on 6MWT as a predictor of outcome was that of Baldi et al 
(110) that enrolled patients with secondary MR only and showed that 6MWT was a 
predictor of all cause mortality (p=0.023). Moreover, this study also demonstrated the 
utility of peak VO2 (obtained via cardiopulmonary functional testing) in the prediction 
of cardiac and all-cause mortality (p=0.018 and p<0.001, respectively).  Furthermore, 
left atrial volume indexed for body surface area >65mL/m2 and atrial fibrillation were 
also predictors of worse prognosis following TMVR. Unfortunately, this study excluded 
patients with >moderate residual MR following TMVR and failed to report quality of life 





Overall, five studies documented that 6MWT was predictive of outcome. Two of these 
reported a hazard or risk ratio based on categorical variables.  Ledwoch et al reported 
a trend for patients who walked <200m on a 6MWT to have higher mortality risk than 
those who walked 200m or more (p=0.71).  Saji et al showed that patients who were 
unable to walk or those who walked <219m were more likely to have a prolonged 
length of stay (p<0.001). Fortunately, on contacting the authors, Saji et al were able 
to provide additional supplementary data to allow us to interrogate these parameters 
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as continuous variables. The authors quoted an odds ratio of 0.992 (95% CI 0.988-
0.996) for 6MWT as a continuous variable.   
 
My meta-analysis was therefore based on four studies. Three of these examined the 
ability of the 6MWT to predict all cause mortality, while the remaining study focussed 
on an end point of prolonged hospital admission. After synthesising the four studies, I 
found that a reduced 6MWT distance was significantly predictive of the combined end 
point of increased mortality or prolonged hospital admission (pooled HR 0.935 per 
10m increase in walking distance, 95% CI 0.891-0.980, p=0.005) (Figure 5.2). 
However, severe heterogeneity was observed in the pooled analysis (I2 67.7%, 
p=0.023) and none of the studies included a control group.   
     
 
 
Figure 5.2. Forest plot using a weighted for random-effects model demonstrating that the six minute 
walk test (6MWT) is predictive of a combined end point of all cause mortality and prolonged hospital 
admission). The blue diamond on the left side of the vertical axis suggests that increased 6MWT 
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This systematic review concluded that although many studies incorporate functional 
testing in their research design, very few examine their discriminatory power to predict 
outcomes in patients undergoing TMVR. The finding of my meta-analysis supports the 
value of the 6MWT in predicting outcomes for patients undergoing TMVR. 
 
Findings from the study performed by Curio et al highlighted valid and pertinent 
questions relating to the role of exercise stress echocardiography (105), suggesting 
that patients with moderate MR that worsened on static exercise had lower rates of all 
cause mortality. It also suggested that these patients had smaller LV and LA cavity 
sizes. It may be that improved outcomes in patients with moderate MR at rest and 
severe MR on exercise who have smaller LV and LA volumes are related to 
intervention at an earlier stage of the disease process. Based on current guidelines, 
TMVR would not be routinely indicated in this cohort of patients. On the other hand, 
this is perhaps the exact population to whom we should be offering TMVR. 
Additionally, Curio et al suggested that lower residual MR is commonly associated with 
better long term outcomes in those with exercise induced severe MR. Interestingly, 
recent evidence in patients undergoing surgical mitral valve intervention suggests that 
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favourable outcomes are seen when MR is treated at an earlier stage (111, 112). 
Perhaps this early disease stage learning needs to be adopted for patients undergoing 
the transcatheter alternative, guided by the use of exercise stress echocardiography 
to assist in determining those patients with worsening MR on exertion.   
 
There is a growing body of evidence suggesting that 6MWT distance predicts 
outcomes for patients undergoing TMVR. Arbitrary cut points of 200m and 219m have 
been used to determine outcome based on mean walking distance within this high risk 
population. Previously, a threshold of 300m has proved effective in providing 
additional prognostic information for pre-operative patients undergoing aortic valve 
replacement (113). Other studies in patients with HF suggest that thresholds of 300m 
(but also up to 490m) were predictive of capacity (114).  In patients with COPD, a 
threshold <350m has been associated with increased mortality (115). Regardless of 
numerical variation, this suggests that 6MWT distance is valuable in the prediction of 
end points. In this context, it is noteworthy that the ongoing RESHAPE-HF trial 
examining the use of MitraClip in a high risk functional MR population is applying 
6MWT distance as one of the exclusion criteria. Nevertheless, no test is without 
limitations and 6MWT distance can be influenced by HF status, LV function and 
participant motivation. Despite these limitations, it offers an objective, reliable and 
reproducible parameter that is easy to incorporate into daily practice.  
 
As suggested by Baldi et al, there may also be value in performing sub-maximal 
functional testing using CPET. However, CPET requires specialised equipment and 
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appropriately trained personnel in order to perform the test, making it less likely to be 
adopted in the setting of randomised controlled trials or daily practice (102). Usefully, 
6MWT distance has demonstrated moderate correlation with peak VO2 in multiple 
studies and systematic reviews (114).  
 
Predicting risk within this TMVR population is complicated. Using parameters such as 
6MWT distance and exercise induced MR alongside surgical risk score may assist in 
discriminating those who are most likely to improve. Future studies should focus on 
implementing these tools routinely with the hope that more defined thresholds can be 
determined. More holistically, these tools will facilitate better understanding of the 
prognosis for TMVR patients and provide a more solid foundation for optimal medical 





There were a number of limitations within this systematic review and meta-analysis. 
In some cases, internationally pooled data were difficult to decipher from other 
international studies. Although attempts were made to ensure that duplicated data 









My meta-analysis was based on only five studies. Therefore inference and 
generalisability within our discussion may be skewed. Although attempts were made 
to contact authors who had reported categorical data in a request for continuous data, 





Many studies perform functional tests in order to evaluate symptoms and exercise 
capacity. Less commonly, however, do these studies use functional testing as a 
means of determining outcome. There is a growing body of evidence suggesting that 
6MWT distance may assist in discriminating between patients who see an 
improvement with TMVR and those who do not. Exercise stress echocardiography has 
also proven effective in the assessment of patients with early stage exercise induced 
severe MR. These observations suggest that such tests may be useful in providing 
enhanced diagnostics in the TMVR population.   
 
Unfortunately, the evidence in relation to this is scarce and further studies into the use 
of 6MWT and exercise stress echocardiography are required before their value can 
be determined. The hope is that these functional parameters alongside imaging, 
laboratory and clinical data will prove useful in further defining the characteristics of 
patients who gain the greatest improvement following TMVR, whilst simultaneously 
ensuring careful patient selection to prevent high risk futile procedures.  
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TRANSCATHETER MITRAL VALVE 
REPAIR: PREDICTING IMPROVEMENT IN 





Based on retrospective data, my thesis has been able to demonstrate mitral 
regurgitation (MR) is a common problem within the heart failure (HF) population, and 
many patients remain symptomatic despite optimal medical therapy (OMT). 
Additionally, for those patients in intermediate and high risk groups, trials have 
demonstrated that transcatheter mitral valve repair (TMVR) is safe and feasible, with 
potential to improve quality of life (QoL) and reduce subsequent hospital admissions. 
However, outcome data are varied with some patients experiencing vast improvement 
and others feeling no different. A review of the literature suggests that functional 
testing may be a useful tool to predict those that may benefit, but this is based on 
limited evidence.  
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In this Chapter, I describe a prospective pilot study aimed at assessing the role of 
cardiac imaging, functional testing, and clinical and laboratory data in predicting 
changes in left ventricular (LV) performance, symptoms and QoL following TMVR in 
order to facilitate more careful risk stratification, interventional planning and avoidance 
of high risk futile procedures. I hypothesised that the combination of echocardiography 
with clinical, functional and laboratory data would help to identify those patients who 
experience the greatest relief from symptoms. 
 
 
6.2 Aims and Objective 
   
The primary aim of this study was to determine the usefulness of clinical, imaging, 
functional and laboratory markers (in isolation and combined) in predicting patients 
who demonstrate improvement following TMVR. 
 
The principal objective of this prospective study was to determine whether 
transthoracic echocardiography (TTE) could predict changes in left ventricular (LV) 
size and function following TMVR.  
 
The secondary objectives were to: (1) evaluate the feasibility and usefulness of 
functional testing and its role in discriminating MR patients who demonstrate improved 
LV parameters and QoL following TMVR; (2) assess the relationship between 
improvements in LV performance and the degree of residual MR; (3) explore and 
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characterise the relationship between changes in LV parameters and clinical 
outcomes; (4) assess the usefulness of TTE parameters combined with functional, 
clinical and biochemical parameters in providing better prediction of post-procedural 





6.3.1 Study design 
 
This prospective longitudinal cohort pilot study was performed across two tertiary care 
centres, involving collaboration between the Department of Cardiology at Guy’s and 
St Thomas’ NHS Foundation (GSTT), Department of Cardiology at King’s College 
NHS Foundation Trust (KCH), and the Department of Life Sciences and Centre for 
Bioscience, Manchester Metropolitan University (MMU). The study involved 
prospective recruitment of patients who had been accepted for TMVR on clinical 
grounds and following review by the Heart Team. Routine clinical data collected during 
work up, peri-procedural care and follow up were collected. In addition, the patients 
underwent a pre- and post-procedural blood test, six minute walk test (6MWT), QoL 
questionnaire, and a pre-procedural exercise stress echocardiogram (ESE). Figure 
6.1 provides an outline of the investigations performed and their timing. Pre-procedural 
tests were performed approximately 3 months (maximum 6 months) prior to 
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Figure 6.1. Flow diagram of the patient journey during the prospective transcatheter mitral valve 
research study. Activities beyond routine clinical care are highlighted in bold.   
 
 
 A comprehensive list of parameters recorded and relevant data sources is provided 




Assessment at follow up































Table 6.1. Parameters recorded for the prospective transcatheter mitral valve research study including sub-category, relevant data sources and time points. 
MR: mitral regurgitation; EROA: effective regurgitant office area; RVol: regurgitant volume; VC: vena contracta; MV: mitral valve; 2D: two dimensional; PISA: 
proximal isovelocity surface area; LVOT: left ventricular outflow tract; MVA: mitral valve area; TTE: transthoracic echocardiogram; TOE: transoesophageal 
echocardiogram; LV: left ventricle; EF: ejection fraction; LVEDD: left ventricular end diastolic dimension; LVESD: left ventricular end systolic dimension; GLS: 
global longitudinal strain; TDI: tissue Doppler imaging; VTI: velocity time integral; AV: aortic valve; SV: stroke volume; CO: cardiac output; PW: pulsed wave; 
LA: left atrium; RA: right atrium; RWMAs: regional wall motion abnormalities; RV: right ventricle; PASP: pulmonary artery systolic pressure; NYHA: New York 
heart association, EPR: electronic patient record; HR: heart rate; LVH: left ventricular hypertrophy; MI: myocardial infarction; BP: blood pressure; O2: oxygen; 
BMI: body mass index; BSA: body surface area; NT-pro BNP: N-terminal pro B-type natriuretic peptide; CRP: C-reactive protein: eGFR: estimated glomerular 
filtration rate. 
Category Assessment Type Parameter Time points Data Source 
Demographics General Age, gender, height, weight, ethnicity, BSA, 
BMI 
<6months prior to intervention and 
3-6 months post-intervention 
EPR/EPR Sunrise/E-
noting 
Clinical General Evaluation of symptoms, medical history, 
comorbidities, medication, NHYA class, 
Euroscore II, heart rate, heart rhythm, BP, O2 
saturation, peripheral oedema, orthopnoea, 
<6months prior to intervention and 









date of initial review, date of follow up review, 
death 
Echocardiography Mitral assessment Visual impression of severity of MR, EROA, 
RVol, VC area, mechanism of MR, 
concomitant valve disease, MV leaflet 
thickening, annular diameter, tenting height, 
flail gap, flail width, coaptation length, 
coaptation depth, central jet area, pulmonary 
vein reversal, 2D PISA, 2D vena contracta, 
regurgitant volumes, LVOT angle, MVA, MV 
gradients, mobile length of posterior leaflet 
TTE: Pre-intervention (<6months 
before), immediately post-
intervention (1-2 days) and 
approximately 3 months later.  
TOE: Pre-intervention (<6months 




(reports and digital 
images). 
 LV assessment LV 3D EF, LV Simpson’s biplane EF, visual 
LV EF, first phase ejection fraction (EF1), 
LVEDD, LVESD, visual impression of LV 
systolic function, GLS, strain, speckle 
tracking, TDI, LVOT VTI, AV VTI, SV, CO, 
TTE: Pre-intervention (<6months 
before) and approximately 3 
months post. TOE: Pre-













PW MV, LA volume, RA volume, assessment 
of RWMAs. 
 Other Visual impression of RV function, TAPSE, RV 
S’, PASP 
TTE: Pre-intervention (<6months 
before) and approximately 3-6 
months post. TOE: Pre-





(reports and digital 
images). 
Functional testing Exercise stress 
echocardiogram 
Exercise duration, total Watts, symptoms on 
exertion, severity of MR (colour flow imaging 
and spectral Doppler), 2D LV volumes 
(Simpson’s biplane), 2D ejection fraction 
(Simpson’s biplane), cardiac output (LVOT 
VTI), PASP, heart rate (HR) at rest and peak, 
percentage of age-predicted maximal HR 
<6 months prior to intervention Exercise stress 
echocardiography 
(reports and digital 
images). 
 Six minute walk test Distance, symptoms, timing of symptom 
onset, distance of symptom onset, duration (if 
other than 6 mins), number of pauses 
<6 months prior to intervention 
and 3-6 months post-intervention 
Recorded in research 
site visit file. 
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required, scoring for breathless and fatigue 
pre- and post-test, percentage change 
between pre- and post-intervention 
Laboratory General NT-Pro BNP, ST2, galectin-3, CRP, 
haemoglobin, eGFR, creatinine 
<6 months prior to intervention 
and 3-6 months post intervention 
EPR/EPR Sunrise/E-
noting and Viapath 
reports, Cyberlab 
Electrocardiogram General HR, rhythm, QRS duration, evidence of LVH, 
myocardial infarction or atrial enlargement 
<6 months prior to intervention 
and 3-6 months post-intervention 
EPR/EPR Sunrise/E-
noting 
Quality of Life  SF-36 questionnaire Physical function, role limitations due to 
physical health or emotional problems, 
energy/fatigue, emotional well-being, social 
functioning, pain and general health, total 
score, comparison between pre- and post 
<6 months prior to intervention 
and 3-6 months post-intervention 
Recorded in research 
site visit file. 
Intervention Procedural details Device type and size, complications, 
approach, success 










6.3.2 Study population 
 
This study was performed across two sites - Guy’s and St Thomas’ (GSTT) and King' 
College Hospitals (KCH). Patients were recruited based on referral to GSTT or KCH, 
a diagnosis of mitral valve (MV) disease and clinical eligibility for TMVR. Study 
approval was granted by the Health Research Authority (HRA) on 17 June 2019. 
 
Based on power calculations using data from the Everest I and II trials, the expected 
change in left ventricular ejection fraction (LVEF) was approximately 5.5% (standard 
deviation 11%), providing an estimated sample size of 32 participants to achieve 
sufficient power (53).  Therefore, the proposed target sample size was 50 participants 
to allow for unexpected deaths or complications, and those patients lost to follow up. 
 
6.3.3 Inclusion and exclusion criteria 
 
Patients were included and excluded based on the selection criteria below (Table 6.2).  
 
Table 6.2. Inclusion and exclusion criteria for patients recruited to the prospective transcatheter mitral 
valve repair study. Abbreviation: MR: mitral regurgitation. 
Inclusion Criteria Exclusion Criteria 
1. 18 years or older 
2. At least moderate to severe symptomatic MR 
3. Life expectancy >1 year post-intervention 
4. Able to provide informed consent 








6.3.4  Patient recruitment 
 
Study participants were recruited via two arms: 
 
1) Participants already involved in another MV research study were also invited to 
take part in this study. The invitation was extended to the participant by a 
member of the direct care team with access to identifiable information as part 
of routine clinical care. The invitation was either in person or via the telephone. 
Interested patients were given or sent the research patient information sheet 
(PIS) and contacted via telephone to confirm interest. At this time, a date was 
organised for the lead investigator (KV) to receive consent and begin pre-
procedural research assessments. Data between studies were shared to 
reduce unnecessary repeat investigations.  
 
2) Participants not involved in an additional MV research study, were identified as 
eligible by a member of the direct care team at KCH or GSTT, either in the 
course of direct clinical care or following review at an MDT meeting. The 
participant was contacted by a member of the direct care team via telephone. 
If interested, they received a PIS and initial contact letter, and a follow up 
telephone call to confirm interest. If they were still interested, a date was 








Informed consent was obtained from patients by a clinical scientist, researcher, doctor 
or other medical professional with appropriate training (Valid Informed Consent, 
Human Tissue Act training and Consent training). Informed valid consent was received 
in person. There were no patients considered vulnerable or unable to provide consent, 
and no children involved in this study. There was no direct payment for participation 
in the research project. All consented patients spoke English so there was no need for 
an interpreter.  
 
6.3.5  Clinical review and patient interview 
 
All participants were assessed clinically within six months prior to the procedure date. 
This included an evaluation of symptoms and New York Heart Association (NYHA) 
class. The patient interview was performed by either a Cardiologist, specialist registrar 
or HF specialist nurse. Additional recorded clinical parameters included heart rate and 
rhythm, blood pressure, oxygen saturation, the presence and extent of peripheral 
oedema, and assessment of orthopnoea. Additional demographic data included 
gender, age, ethnicity, height, weight, body surface area (BSA) and body mass index 
(BMI). A repeat clinical assessment and review was performed 3-6 months following 










6.3.6 Transthoracic and transoesophageal 
echocardiography 
 
All patients underwent both transthoracic echocardiography (TTE) and 
transoesophageal echocardiography (TOE) as required in the diagnosis, peri-
operative and follow up phases of the study. These investigations included 
comprehensive two-dimensional (2D), colour flow (CFI), spectral and tissue Doppler 
(TDI), strain and three-dimensional (3D) imaging. MR was assessed using an 
integrative approach aligned with the algorithm outlined in the COAPT trial (Chapter 
4, Table 4.3, Figure 4.3). Measurements were performed in accordance with 
recommendations from the British Society of Echocardiography (BSE), American 
Society of Echocardiography and European Association of Cardiovascular Imaging 
(69, 71). Ultrasound systems used were from a variety of vendors, including Philips 
EPIQ and IE33, GE E9 and E95, and Siemens SC2000 scanners. Images were 
obtained using a 3MHz or 5MHz fixed array ultrasound probe, stored using digital 
loops and transferred to an archiving database to enable further offline analysis. 
Imaging and measurements were performed by BSE TTE and TOE accredited 
operators. 
 
TTE was performed at three time periods:  
 








2. Immediately following intervention (approximately day 1-4; prior to discharge).  
3. Assessment at follow up: approximately 3-6 months after intervention.  
 
TOE was performed as per routine practice (pre-procedure and intra-operative 
assessment).  
 
6.3.7 Functional testing  
 
Functional testing was performed using both exercise stress echocardiography and 
6MWT. 
 
 6.3.7.1    Exercise stress echocardiography 
 
Stress echocardiography was performed approximately 3 months (maximum 6 
months) prior to MV intervention on a bicycle using a standard protocol recommended 
and endorsed by the American Society of Echocardiography and European 
Association of Cardiovascular Imaging (95, 116). Study parameters included an 
assessment of exercise duration, total workload, symptoms on exertion, blood 
pressure response, percentage of age-predicted maximum heart rate and cardiac 
function (including the degree of MR using CFI and spectral Doppler, cardiac output 
using the left ventricular outflow tract velocity time integral, left ventricular volumes 
and EF, strain, and estimated pulmonary artery systolic pressure [PASP]). The reason 
for termination of the test was documented. 
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6.3.7.2     Six minute walk test (6MWT)  
 
This assessment of functional capacity was performed in accordance with 
recommendations from the American Thoracic Society (117). Data collected included 
distance, symptoms (at baseline and end of test), scoring of symptoms and 
timing/distance of onset, and duration (if other than 6 mins) and compared (as a 
percentage) against age-predicted standards. The test was performed at 
approximately 3 months (maximum 6 months) prior to the procedure date with follow 
up evaluation approximately 3-6 months following MV intervention. In this instance, an 
additional calculation of percentage change between tests was performed. 
  
6.3.8 Laboratory biochemical sampling 
 
Blood sampling was performed as per routine clinical practice less than 6 months prior 
to cardiac intervention. Additionally, a post procedure follow up blood sample was 
acquired (approximately 3-6 months). These tests were used to measure N-terminal 
pro B-type natriuretic peptide (NT-pro BNP), C-reactive protein (CRP), haemoglobin, 
estimated glomerular filtration rate (eGRF), and creatinine.  
 
Aside from routine blood tests, a small volume of additional blood was obtained and 
analysed for troponin T, ST2 and galectin-3 before (<6 months before) and after (3-6 
months) intervention. Details regarding blood sample collection and storage are 
further detailed in Section 6.3.13. 
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6.3.9  Electrocardiogram  
 
Participants underwent an electrocardiogram within 6 months prior to the procedure. 
This was repeated in the follow up phase, approximately 3-6 months following MV 
intervention. Details of the rate, rhythm, QRS duration, and evidence of myocardial 
infarction, left ventricular hypertrophy or LA enlargement were noted.  
 
6.3.10      Quality of life questionnaire  
 
All patients completed the RAND Health 36-item short form survey (SF-36) pre- and 
post-TMVR. Total scores and percentage change before and after intervention were 
determined across all categories (physical functioning, role limitations due to physical 
health or emotional problems, energy/fatigue, emotional well-being, social functioning, 
pain and general health).  
 
6.3.11       Intervention 
 
All participants underwent TMVR. Data concerning device type and approach as well 
as the relative success of the procedure and any complications were collected. 
Patients who subsequently required conventional MV surgery for complications were 









6.3.12  End points 
 
Given the descriptive nature of this study, a number of variables were used as end 
points and collected 3-6 months following MV intervention. Global longitudinal strain 
(GLS), tissue Doppler, first phase ejection fraction (EF) (EF1), 3D and 2D EF were 
used to assess improvement in LV systolic function. Residual MR was assessed using 
quantitative and qualitative parameters. Overall outcomes were assessed by death, 
improvement in QoL, 6MWT, NHYA class, reduction in symptom severity and 
biochemical markers. Our aim was to demonstrate that TTE combined with clinical, 
demographic, biochemical and functional parameters could be used to predict 
outcomes for patients undergoing TMVR. End points were determined based on 
consensus from an expert panel of specialists, including Consultant Cardiologists with 
expertise in imaging and intervention, researchers, clinical scientists and specialist 
nurses.   
 
Table 6.3. Imaging and clinical endpoints for the transcatheter mitral valve study. Abbreviations: LV: 
left ventricle; LVEDD: left ventricular end diastolic dimension; LVEDV: left ventricular end diastolic 
volume; 2D: two dimensional; 3D: three dimensional; GLS: global longitudinal strain; EF: ejection 












No End points Parameters 
 
1. Improvement in LV size and systolic function 
(evidence of reverse remodelling) 
LVEDD, LVEDV (2D and 3D), 2D and 3D 
GLS, EF (3D and 2D), EF1 
2. 
 
Improvement in clinical outcomes  
 
Death, NYHA classification, quality of life 
assessment, 6MWT, symptoms, biomarkers  
 
 
6.3.13  Blood sample collection and storage  
 
Blood tests were performed as per routine clinical practice less than 6 months prior to 
cardiac intervention. A post-procedure follow up blood test was performed at 
approximately 3-6 months. Additional blood was taken for troponin T, ST2 and 
galectin-3 assays. Samples were collected by medical professionals trained in 
phlebotomy using BD vacutainer tubes at room temperature. As soon as possible after 
phlebotomy, the sample was transported at room temperature and hand delivered to 
Viapath for analysis. Viapath falls under the host Trust licence. Samples were 
accompanied in transit by a study-specific sample request form with instructions and 
labelled with a unique pseudoanonymised coding, meaning that the sample was not 
traceable to the patient except by the investigators. Samples taken at GSTT were 
transferred to KCH via internal transport. Storage was at -20 degrees Celsius in a 
temperature-controlled suite monitored with Comark Probes in a contract research 
and development (R&D) suite with restricted access (2nd floor, Cheyne Wing, KCH). 
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For ST2 and galectin-3, samples were batched prior to analysis. For troponin T, 
samples were stored for analysis using Roche analysers. 
 
6.3.14      Data Management 
 
All information collected during the course of this study was kept strictly confidential 
according to the Data Protection Act 2018. Data were transferred electronically via e-
mail from an NHS.net to the same NHS.net account so that the results could be placed 
into a single encrypted spreadsheet. The patient’s hospital number, name and other 
identifiable data were removed prior to transfer. A master spreadsheet was kept at 
GSTT. Access required password entry and the individual document was password 
protected. The recording of these data from a collection, recording and quality 
perspective was maintained by the primary researcher but remained the responsibility 
of the chief investigator. E-mail access required password entry. There are two 
investigator binders containing details of GSTT and KCH patients that were kept 
separately at the host institutions. All blood samples and reports were 
pseudoanonymised using a study number (i.e. KCH_001) and all patient identifiable 
information was removed at this point. Results were made available electronically 
using a secure results online service (Cyberlab). Access to Cyberlab was only granted 
to authorised users and all information encryted and stored within a secure password 
protected spreadsheet on secure Trust servers. The researchers adhered to rules 








All patient data were handled according to NHS information governance procedures. 
All personal identifiable data were anonymised before analysis and publication to 
ensure confidentiality. No other individuals other than the research team had access 
to the data outside the direct care team. Professor Prendergast was custodian of the 
data. 
 
6.3.15    Statistical analysis 
 
In this study I aimed to identify significant change between two time points, and 
relationship between the primary outcome (change in TTE pre- and post-intervention), 
functional testing and clinical assessment variables. Continuous variables were 
summarised using means and standard deviations and categorical variables as 
frequencies and percentages. TTE change was examined using a one sample T-Test 
with the null hypothesis being no difference pre- and post-intervention (change = 0). 
A univariate linear regression model was used to compare predictive variables with 
changes in TTE. Paired T-Test was used to compare QoL pre- and post-intervention. 
Similarly, paired T-Test and simple linear regression was used to assess QoL change 
in relation to predictive variables. Variables that showed an association with the 
outcome (either TTE or QoL) were entered into a multivariate linear regression 
analysis. Outcomes which showed a non-normal distribution were dichotomized and 
logistic regression analyses performed. An alpha of <0.05 was used for all analyses. 
Based on power calculations using data from the Everest I and II Trials the expected 
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change in LVEF was approximately 5.5% (standard deviation 11%) (53), providing an 
estimated sample volume of 32 participants.  
 
I performed statistical analysis using IBM SPSS Statistics Version 25.0 (72) Statistics 
on a personal computer or laptop following anonymisation. 
 
6.3.16     Research ethics statement 
 
This research project was granted formal approval by the Health Research Authority 
(HRA) and Health and Care Research Wales (HCRW) (IRAS 248271, REC reference 
19/LO/0619) (Appendix D). The project underwent proportional review with R&D at 
GSTT, and following ‘capacity and capability’ with the GSTT research team, GSTT 
provided sponsorship (Appendix E) that was agreed and supported by Manchester 
Metropolitan University (Appendix F). Additionally, the project was granted ‘capacity 
and capability’ status and registered as a study at King’s College NHS Foundation 
Trust (reference KCH19-100) (Appendix G). Finally, the project was verified by 
Manchester Metropolitan University (review reference 2020-20464-14239). 
 
6.3.17    Individual contribution to the research team 
 
This entire project was my responsibility. Prof Bernard Prendergast (valve service lead 
at the primary research site, GSTT) was the principal supervisor. Prof Mark Monaghan 
and Dr Jane Hancock assisted in the logistical planning and conceptualisation. Dr 
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Garry McDowell and Dr Fiona Wilkinson were joint academic supervisors on behalf of 
Manchester Metropolitan University. Dr Jon Bryne and Prof Simon Redwood were the 
lead structural interventionalists at KCH and GSTT, respectively. Karen Wilson and 





A total of eight patients were recruited to this research study. We calculated that we 
would need approximately 50 patients (minimum 32 patients) for adequate power to 
achieve statistical significance. Unfortunately, all research ceased in March 2020 due 
to the COVID-19 pandemic. As a result, no further recruitment was permitted and 
patients were barred from attending the hospital for research purposes alone. Where 
patients were scheduled for clinical follow up, this was undertaken virtually, thereby 
precluding the possibility of scheduled research activity aligned with clinical face to 
face appointments. However, I was able to obtain follow up QoL data via post. 
 
The findings of this pilot research study will therefore be presented descriptively. My 











6.4.1 Demographic and clinical data 
 
The recruited cohort was split evenly between men and women with an average age 
of 77 years (± 13.5 years) and all were of white ethnicity. Three quarters of the cohort 
(75%) had either coronary artery disease (CAD) or atrial fibrillation (AF), and half 
(50%) had hypertension. Two patients had previously undergone cardiac surgery, two 
patients had intra-cardiac devices (pacemaker or ICD) and one patient had undergone 
both cardiac surgery and device implantation. Table 6.4 outlines the demographic and 
clinical data. 
 
All patients presented to GSTT or KCH with shortness of breath. Two had a previous 
diagnosis of HF and four had pulmonary and/or peripheral oedema. All patients were 
in NYHA classification IV at presentation and five of the seven patients (1 death) 




















Table 6.4. Demographic and clinical characteristics of patients recruited to the transcatheter mitral valve 
study. *Analysis based on eight patients only. Abbreviations: BMI: body mass index; IHD: ischaemic 
heart disease; COPD: chronic obstructive pulmonary disease; ICD: implantable cardioverter 






Patients  n 8* 
Age (years)  Mean ± SD 77 ± 13.45 
Sex (male)  n (%) 4 (50%) 
Ethnicity (white)  n (%) 8 (100%) 
BMI (kg/m2)  Mean ± SD 24 ± 3.2 
Comorbidities Hypertension n (%) 4 (50%) 
 
IHD n (%) 6 (75%) 
 
Diabetes n (%) 2 (25%) 
 
COPD n (%) 2 (25%) 
 
Asthma n (%) 0 (0%) 
 Atrial fibrillation n (%) 6 (75%) 
 Prior cardiac surgery n (%) 2 (25%) 
Pacing or ICD  n (%) 3 (37.5%) 
NYHA class (III/IV)  n (%) 8 (100%) 
Device Edge to edge n (%) 8 (100%) 
 MitraClip n (%) 5 (62.5%) 
 No of devices >1 n (%) 5 (62.5%)  
Mortality at 30 days  n (%) 1 (12.5%) 
Readmission at 30 days  n (%) 2 (25%) 
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6.4.2    Intervention 
 
All eight patients underwent transcatheter edge to edge repair using at least one 
device without immediate complications. Four patients received two devices and one 
received three. Five patients had MitraClip devices deployed and three patients were 
treated with a Pascal device. Following the procedure one patient developed urinary 
retention and another had confusion and acidosis. A separate patient was re-
intubation and required transfer to the intensive care unit on day 2 of recovery due to 
a hospital acquired pneumonia. This patient was known to have underlying COPD.  
 
Unfortunately, one patient died approximately 4 weeks post TMVR. The cause of 
death was documented as: 1) multiple organ failure, 2) right heart failure, 3) mitral 
valve disease, 4) COPD. A further patient elected to undergo subsequent high risk 
mitral valve replacement at a different institution. Two patients were re-admitted to 
hospital with symptoms of breathlessness within one week - on both occasions the 
TMVR was deemed satisfactory based on echocardiographic examination, and 
discharge was possible within three days after optimisation of medical therapy. 
 
6.4.3  Quality of life 
 
Quality of life (QoL) was assessed using eight different categories integrating physical 
and emotional function. Eight patients completed the pre-procedural questionnaire but 
matching data were only available for six (1 death and 1 lost to follow up). Analysis 
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showed that three patients reported an improvement in quality of life, two patients 
experienced deterioration and one saw no real change (Table 6.5, Figure 6.1).  
 
Table 6.5. Absolute and total quality of life scores for each patient across sub-categories of the SF-36 
questionnaire. Abbreviations: Pt: patient; Pre: prior to intervention; F/U: follow up.  
 
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 
Categories Pre F/U Pre F/U Pre F/U Pre F/U Pre F/U Pre F/U 
Physical functioning 25 15 20 5 20 45 0 55 20 20 35 20 
Role limitations due to 
physical health 
0 0 0 0 0 25 0 50 25 25 0 0 
Role limitations due to 
emotional problems 
100 100 33 0 100 100 0 0 100 33.3 0 0 
Energy/ fatigue 15 0 15 10 20 45 0 45 45 50 0 40 
Emotional well-being 92 88 48 32 88 96 68 92 80 88 4 60 
Social functioning 50 25.5 50 12.5 12.5 50 0 87.5 62.5 50 0 0 
Pain 35 22.5 57.5 22.5 100 100 20 57.5 55 90 27.5 32.5 
General health 35 30 45 15 25 40 80 55 65 65 10 15 









Figure 6.2. Quality of life scores before and after transcatheter mitral valve repair (n=6).   
 
 
There was no clear relationship between improvement in QoL in primary or secondary 
MR. The degree of improvement or deterioration varied across the cohort and given 
the small sample size and risk of bias, further analysis was not performed. Similarly, 
there was no significant difference in individual QoL domains before and after 



































Table 6.6. SF-36 quality of life questionnaire scores (individual domains and overall total) before (left) 
and after (right) transcatheter mitral valve repair. Statistics: paired t-test. Abbreviations: TMVR: 











 Mean SD Mean SD  
Physical functioning 20.00 11.40 26.66 19.15 0.586 
Role limitations due to physical health 4.16 10.21 16.16 20.41 0.203 
Role limitations due to emotional problems 55.5 50.21 38.88 49.07 0.204 
Energy/ fatigue 15.83 16.56 31.67 21.13 0.175 
Emotional well-being 63.33 33.12 76.0 25.04 0.271 
Social functioning 29.17 28.17 37.58 31.58 0.676 
Pain 49.17 29.01 54.17 34.27 0.679 
General health 43.33 25.82 36.67 20.66 0.394 
















Table 6.7. Baseline echocardiographic parameters prior to transcatheter mitral valve repair. 
Abbreviations: MR: mitral regurgitation; RUPV: right upper pulmonary vein; MV: mitral valve; LVEDD: 
left ventricular end-diastolic dimension; LVESD: left ventricular end-systolic dimension; LVEDV: left 
ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; BSA: body surface area; 
EF: ejection fraction; RV: right ventricle; TAPSE: tricuspid annulus plane systolic excursion; PASP: 
pulmonary artery systolic pressure. 
Variables   
Patients  n 8 
Mitral Valve Mechanism (functional) n (%) 4 (50%) 
 MR severity (severe) n (%) 8 (100%) 
 RUPV flow reversal  n (%) 4 (50.0%) 
 MV E peak (>1.5m/s) n (%) 3 (37.5%) 
Left Atrium Biplane volume indexed (mL/m2) Mean ± SD 65.97 ± 17.6 
LV size and function LVEDD (cm) Mean ± SD 5.56 ± 1.1 
 LVESD (cm) Mean ± SD 3.86 ± 1.7 
 LVEDV (mL) Mean ± SD 137 ± 72.4 
 LVEDV indexed for BSA (mL/BSA) Mean ± SD 81.34 ± 40.1 
 LVESV (mL) Mean ± SD 75.0 ± 55.0 
 EF (%) Mean ± SD 46.7 ± 13.7 
 EF <50% n (%) 3 (37.5%) 
Right ventricle RV dilated (>4.3cm) n (%) 3 (37.5%) 
 RV function (TAPSE, cm) Mean ± SD 1.9 ± 0.47 
 PASP (mmHg) Mean ± SD 60 ± 16 
 
 
All patients had severe MR based upon integrative TTE and TOE assessment and half 
of the cohort had secondary MR. There were three patients with MV leaflet prolapse 
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(2 posterior, 1 anterior). The last patient had undergone previous MitraClip 
implantation and the residual MR jet was complex. Accurate quantitative 
measurements were not possible in all patients due to MR jet eccentricity.  
 
Three patients had a dilated left ventricle (LV) and three had impaired systolic function 
(EF <50%, range 31-65%). The mean indexed LV volume in diastole was 81.34mL/m2 
and biplane left atrial volume was increased in all patients with a mean indexed volume 
of 65.97mL/m2. Three patients had a dilated right ventricle but the majority (80%) had 
normal right ventricular systolic function. The mean pulmonary artery systolic pressure 
was 60mmHg.  
 
Post-procedural TTE (0-4 days) demonstrated moderate to severe residual MR in two 
patients. This had been noted on the peri-procedural TOE, but no further transcatheter 
intervention was possible.  
 
6.4.5 Functional testing 
 
At baseline, seven patients were able to perform a 6MWT. One was unable to perform 
the test due to severe fatigue and breathlessness at rest, and one walked 5:32 mins 
before terminating the test. The mean walking distance was 187m (range 120-245m). 
Patients were permitted pauses throughout (range 0-4) and asked to score their 
breathlessness and fatigue at rest and upon completion of the test. Scores are outlined 
in Table 6.8. 
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At follow up, only two patients performed a 6MWT. One was the patient who was 
unable to perform the test at baseline so no comparison could be drawn. The other 
reported a significant deterioration in walking distance (from 180m to 118m) 
accompanied by a decline in QoL scores and reduced LV systolic function (EF 30-
35% to 10-15%) despite reduction in the severity of MR (severe to moderate). 
Unfortunately, the remaining five patients were unable to attend for follow up 
assessment as a result of the COVID-19 pandemic. 
 
Table 6.8. Six minute walk test outcomes prior to transcatheter mitral valve repair. Abbreviations: m: 
metres. 














1 0 3 180 5 5 
2 2 0 244 10 3 
3 5 5 120 9 9 
4 3 6 189 8 8 
5 6 0 246 8 7 
6 2 2 173 5 5 
7 1 0 160 5 0 
 
 
Regrettably, no exercise stress echocardiograms were performed for a variety of 
reasons (artificial legs, extreme breathlessness and fear).  
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6.4.6 Laboratory results 
 
Baseline blood results were obtained for all patients (Table 6.9) but additional research 
assays (ST2, galectin-3) could not be processed due to batching and the reallocation 
of resources during the COVID-19 pandemic. Therefore, these results are not 
available. Post-intervention results were also limited due to reduced face to face follow 
up, batching and reallocation of resources.  
 
Table 6.9.  Laboratory results prior to transcatheter mitral valve repair. ̂ n=5, *n=4. Abbreviation: eGFR: 
estimated glomerular filtration rate; CRP: C-reactive protein.  
Variables   
Patients  n 8  
Pre-intervention biochemistry NT-pro BNP  Mean ± SD 6943 ± 5525 
 Troponin T Mean ± SD 34 ± 25.2 
 eGFR Mean ± SD 51.3 ± 20.7 
 Creatinine Mean ± SD 128.6 ± 72.4 
 CRP^ Mean ± SD 16.4 ± 22.62 
 Haemoglobin* Mean ± SD 128.8 ± 13.9 
 
 
Post intervention NT-pro BNP was available for three patients. In one patient with no 
significant improvement in MR severity, worse QoL, reduced EF and 6MWT distance, 
NT-pro BNP increased from 2978ng/L to 9276ng/L. In the other two patients with 
reduced MR severity, no change in EF and improved or equivocal QoL, NT-pro BNP 
fell by an average of 8414ng/L. 
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Despite limited data collection due to unforeseen circumstances, this Chapter 
highlights important concepts that need to be considered in relation to symptomatic 
improvement, and parameters useful in the selection of TMVR candidates.  
 
Current recommendations suggest that an integrative echocardiographic approach 
should be used in the assessment of MR severity incorporating a constellation of 
qualitative and quantitative measures alongside characteristics features commonly 
seen in severe MR (e.g. LV size and function, systolic reversal in the pulmonary vein) 
(85, 118). Aside from the renowned methodological errors associated with 
echocardiographic measurements, experiences and learning related to data extraction 
in this pilot study support the importance of using an integrative approach. Limitations 
associated with eccentric and multiple jets meant that certain measurements were not 
accurate or reliable and decisions regarding the assessment of MR need to 
incorporate a multifaceted approach. The presence of atrial fibrillation or frequent 
ectopy also meant that it was not always possible to perform every measurement 
precisely or with consistency. Furthermore, the effects of sedation and its bearing on 
blood pressure needed to be considered when TOE was used in combination with 
TTE to determine MR severity. Put simply, defining severe MR is complex and 
certainly not defined by one or two parameters in isolation. There is an argument that 
specific training should be provided to specialist echocardiographers undertaking 
evaluation of these patients to ensure rigid adherence to the COAPT algorithm 
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(Chapter 4, Table 4.3 and Figure 4.3), thereby correctly identifying high risk patients 
who are most likely to respond and thrive after TMVR. Going forward, it would be 
interesting to better understand the role of the LA, annular dilation and the proportional 
ratio between the LV and LA within this population, and whether these parameters 
also play a role in the integrative approach to defining MR severity.     
 
A novel and interesting component of this pilot study was the incorporation of 
functional testing. We requested that patients undergo a 6MWT in addition to a bicycle 
exercise stress echocardiogram. Seven of the eight patients were able to perform a 
6MWT and the results offered a useful, objective parameter of sub-maximal functional 
capacity. By comparison, no patients were willing to undergo a bicycle exercise stress 
echocardiogram, often because of extreme breathlessness, fear or anxiety. All but one 
patient had breathlessness at rest, questioning the feasibility of performing a more 
‘maximal’ exercise test in symptomatic HF patients. In a Belgian multi-centre trial, Van 
de Heyning et al recruited 31 patients to perform exercise pre and post TMVR. 
Although enrolling a slightly younger population (mean age 72 years), they were able 
to demonstrate haemodynamic improvement in secondary MR patients following 
TMVR (119). Similarly, as outlined in Chapter 5, Curio et al were able to achieve 
similar findings using a novel isometric handgrip exercise protocol (105). Other studies 
have examined the impact of exercise in HF, albeit in less symptomatic patients 
(NYHA I/II) with less severe MR (120, 121). Ongoing investigations in this population 
include a COAPT sub study assessing the feasibility of cardiopulmonary exercise 
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testing - however data from this component of the trial are limited and recruitment is 
ongoing (NCT01626079) (122).  
 
An empirical observation in my study relates to two patients with moderate to severe 
residual MR despite device deployment who reported deterioration in overall QoL. 
Theoretically, it is possible that this relates to increased left atrial pressure resulting 
from the combination of residual MR paired with mitral stenosis. One patient had a 
mean MV gradient of 6mmHg on TOE whilst under sedation following device 
deployment. The other had a mean gradient of 3 mmHg at follow up TTE in the context 
of a poor LV and significantly reduced stroke volume (28mL).  Moderate or more 
residual MR after TMVR is associated with lower survival, reduced symptom relief and 
an increased likelihood of further recurrent MR (123-125). However, the solution - an 
additional device - may lead to iatrogenic mitral stenosis and further symptomatic 
deterioration (126). A recent study compared TMVR patients with greater than 
moderate residual MR against those with less than moderate residual MR but with a 
mean MV gradient >5mmHg, demonstrating that those with less than moderate MR 
and an MV gradient >5mmHg were less likely to require subsequent hospitalisation 
(127). Operators need to be cautious when making decisions regarding the 
deployment of multiple devices, particularly when further improvement of MR is 
unlikely. Similarly, industry partners should bear this conundrum in mind when 











Unfortunately, the study outlined in this Chapter was significantly curtailed by the 
effects of the COVID-19 pandemic. Firstly, restrictions on research project activity 
meant that no further patients could be recruited. Although in-patient recruitment was 
technically feasible, this would have had no bearing on the study since all TMVR 
procedures were cancelled.  
 
Secondly, all patients scheduled for routine clinical follow up were advised to avoid 
hospital attendance, meaning that follow up tests including TTE, 6MWTs and blood 
tests could not be performed. This restricted my capacity to draw pre- and post-
intervention comparisons.  
 
Thirdly, no research blood samples were processed due to limited recruitment and 
follow up, and as a consequence of the reallocation of blood centre resources 
(personnel and equipment). 
 
Fourthly, patients were reluctant and/or unable to undergo exercise stress 
echocardiography evaluation. Furthermore, follow up QoL questionnaires were sent 
to recruited patients for completion during the national COVID-19 lock down when the 
prevailing circumstances would have had significant impact on responses relating to 








Finally, this was a small dual-centre observational prospective pilot study that did not 





This pilot study was unable to successfully meet the proposed objectives as a result 
of the COVID-19 pandemic and limited recruitment. As a consequence, no solid 
conclusions could be determined from this work.  
 
Reflecting on the small patient cohort recruited, I assessed a combination of patients 
with primary and secondary MR who underwent TMVR. There was variation across 
the cohort in terms of comorbidities and underlying LV function. As reported in the 
literature, there was variation in the extent of symptom relief and QoL following 
intervention. I hope that continuation of this project work will result in the identification 
of echocardiographic and functional parameters that enable better selection of 













FINAL DISCUSSION AND FUTURE APPLICATIONS 
 
Transcatheter mitral valve repair (TMVR) presents a novel option for patients with 
symptomatic heart failure (HF) and prohibitive surgical risk. For those with secondary 
mitral regurgitation (MR) who undergo TMVR there is variation in the degree of 
symptom improvement and inconsistent impact on quality of life. A consensus view 
and unequivocal evidence regarding its effect on survival is yet to be determined. What 
is clear is that there is a population of HF patients who remain plagued by limiting 
symptoms despite optimal medical and device therapy. Accordingly, the existing 
evidence base needs prompt attention and resolution.  
 
For those patients undergoing TMVR, appropriate selection and eligibility is vital.  The 
first step is ensuring that patients are considered following an appropriate period of 
maximal medical optimisation with additional device therapy where applicable. 
Ensuring adherence to medical therapy should be made a priority. The use of objective 
measures to evaluate symptoms, frailty and functional capacity will also assist in the 
determination of risk and prediction of outcomes. Research into the application and 
amalgamation of biomarkers into the patient selection algorithm is ongoing and 
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integrative echocardiographic approaches continue to evolve. Importantly, focussing 
on the appropriate timing of intervention and more collaborative working in the early 
stages of HF to facilitate better risk stratification and patient selection will be needed 
for these advances to be useful in the future.  
 
The outcomes of the COAPT and MITRA-FR trials and their subsequent interrogation 
has led to a rethink in terms of how we consider MR in the setting of HF. As briefly 
mentioned in Chapter 2, the concept of proportionate versus disproportionate MR has 
been generating momentum with the understanding that proportionality is part of the 
explanation behind the complementary findings of the COAPT and MITRA-FR trials 
(65, 128). The theory surrounds inadequacies in the traditional evaluation of effective 
regurgitant orifice area (EROA) and its knock-on effect in relation to an assumed 
association with clinical outcomes. The concept suggests that far too much emphasis 
is being placed at the level of the mitral valve (MV) with little attention given to the 
critical contribution of left ventricular (LV) volumes, pressure and function in 
determining the impact on haemodynamics and prognosis (65). Thus the proposal is 
that EROA is dependent on LV end diastolic volume, and that using the Gorlin 
hydraulic orifice equation, LV volume and the regurgitant fraction (RF), an EROA can 
be determined, independent of MV interrogation (65). This focus on an EROA:EDV 
ratio therefore overcomes challenges associated with the traditional direct MV EROA 
measurement. Proportionate MR is hence defined by characteristics including larger 
LV volumes (LV >97mL/m2), and smaller EROAs at approximately 0.3cm2, therefore 
suggesting no need for intervention with treatment focussed on medical therapy (65, 
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129). Disproportionate MR is defined by a greater than expected EROA (0.3-0.4cm2) 
exceeding any enlargement of LV volume (LV <97mL/m2), indicating a population of 
patients who following optimisation of medical therapy may benefit from additional MV 
directed intervention. Although this concept has been considered as a possible next 
step in understanding secondary MR, much of the attention was gained as a result of 
news media and Twitter rather than citations, and as such there are also those who 
oppose the concept (130). Hagendorff et al disputes that the concept of 
‘disproportionate MR’ is questionable as disproportionateness of flow in 
communicating vessels can by definition not exist (131). The authors argue that 
regurgitant volume (RV) must be proportional to EROA in a system of communicating 
vessels at a single beat to beat measurement to align with the physical laws of 
conservation of mass and energy,  with disproportionate MR written off as a 
consequence of measurement error (131). Rather, a quantitative approach with 
accurate measurement of LV stroke volume (SV) (total and effective), regurgitant 
volume (MV level) and individual RF by echocardiography is recommended (131). 
Hagendorff et al’s reasoning has been supported by other groups with a focus on 
promoting the use of RF (132, 133).  Of note, the algorithm used for proportionate and 
disproportionate MR does not take into consideration LV EF, LV/LA pressure and 
compliance, the presence of atrial fibrillation, pulmonary venous/arterial pressure, 
pulmonary vascular compliance, tricuspid regurgitation, and right ventricular size and 
function. Moreover, determining disproportionately and TMVR candidacy may be 
irrelevant depending on the exact anatomy and MR mechanism. 
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The model described above is not the only one that has recently come to light. 
Alternative models suggest the primary use of echocardiography to define secondary 
MR, and its underlying pathophysiology, into one of four sub-types according to 
disease staging. This approach assesses the relationship between LV and LA 
remodelling in the setting of hypertension, cardiomyopathy, ischaemia or atrial 
fibrillation (134). Assessment of SV and RF is also recommended in this model.  
 
Whether secondary MR is based on proportions, stages of disease or chronicity, 
thresholds defining severity and indications for intervention are clearly required. 
Further prospective validation should therefore be performed in order to achieve and 
outline recommendations for widespread clinical adoption.  
 
Beyond the paradigm shift of how we treat MR, comes a rethink in relation to when. 
Since its generation, TMVR has been considered an end stage treatment for HF 
patients looking to extend longevity or gain quality of life.  Some may argue that given 
TMVR may be less effective in the setting of proportionate MR, do we need to consider 
referral for TMVR at an earlier stage, before LV dilatation becomes prohibitive? Early 
referral of patients with severe MR despite optimal medical therapy (OMT) may 
prevent irreversible LV remodelling. Maybe TMVR should no longer be viewed as a 
last resort option, but as a complementary prevention device that prevents (or delays) 
ventricular decline, worsening symptoms and deteriorating quality of life? Of course, 
to determine if this approach would be beneficial for patients, further research with 
carefully planned studies primarily focussed on the concept of ‘outcomes with early 
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MV referral and/or MV intervention’ are required. In addition to this it is highly 
recommended that further studies also focus on the benefits of TMVR across different 
clinical settings such as acute vs chronic HF; ischaemic vs non-ischaemic HF; the 
range of MR aetiologies including AF induced MR; and demographics including age, 
gender and ethnicity. It goes without saying that synergistic collaboration between 
interventional and valve teams, HF and care of the elderly specialists will be just as 
necessary in the research phase as in the clinical phase. With clear outcomes, these 
partnerships would allow for research findings to beget prompt clinical diagnosis, 
consideration of all treatment options and optimal timing of intervention for the benefit 
of patient. 
 
This pilot study has established the framework for the generation of future 
investigation, demonstrating that the protocol is feasible with capacity to perform such 
a project. My hope is that a return to ‘normal’ NHS services will facilitate the re-initiation 
of recruitment once more elective work is underway. Pandemic or not, we will still have 
patients with HF and significant MR so the demand will continue to grow. Timeframes 
for ethical approval have been extended and this project will be continued by the valve 
and intervention teams at Guy’s and St Thomas’ and King’s College Hospitals.  
 
Should the analysis of functional testing, novel biomarkers, echocardiographic 
parameters (or the combination thereof) yield promising results in terms of patient 
outcomes our plan would be to further extend the project. This would involve a national 
registry for patients undergoing TMVR allowing assessment of the utility of the patient 
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selection algorithm on a wider level. If effective, our vision would be to undertake a 
European-wide randomised controlled trial, enrolling patients randomised into groups 
based upon inclusion and exclusion criteria developed on the basis of the patient 
selection algorithm.    
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CONCLUSION AND FUTHER WORK 
 
 
Mitral regurgitation (MR) in the heart failure (HF) population is a common and growing 
concern but further research is needed in order to fully understand the breadth of the 
problem, effectiveness of treatment and strategies for the selection of best treatment 
option for individual patients. These concepts underlie the framework used to develop 
my research question and this thesis.  
 
The thesis opened with a retrospective investigation of patients with HF. By combining 
HF admission data with echocardiographic findings, I concluded that one fifth of all 
patients presenting with HF have moderate or more MR and that this sub-group have 
a greater risk of mortality. Patients receiving optimal medical therapy (OMT) reported 
relief from symptoms and a proportion also experienced reduction in the severity of 
MR. However, one half of patients with left ventricular (LV) dysfunction and MR 








Concentrating on a sub-group within the HF population, I then interrogated HF patients 
with moderate or more MR and reduced ejection fraction (EF) who remained 
symptomatic despite OMT. I demonstrated that a large proportion of patients at high 
and intermediate surgical risk (defined by Euroscore II) were suitable candidates for 
TMVR but that lack of resources and funding presented obstacles to the availability 
and accessibility of this treatment option at national level.  
 
My systematic review and meta-analysis of TMVR and the role of functional testing 
demonstrated that functional testing in this setting was very much focussed on use of 
the six minute walk test (6MWT), and that although commonly used in study design, 
the 6MWT was not readily applied in the extrapolation of data relating to outcome. A 
meta-analysis including all five available studies showed that the 6MWT was not only 
objective, fast and reliable, but also predictive of outcome for patients undergoing 
TMVR. Aside from this, the assessment of severe exercise-induced MR using a novel 
isometric handgrip protocol presented a useful and interesting concept for further 
interrogation. 
 
Finally, I presented an observational prospective study in patients undergoing TMVR 
to determine whether echocardiographic imaging combined with functional testing, 
clinical status and serum markers could assist in identifying patients most likely to 
benefit from intervention, thereby facilitating more careful risk analysis and device 
selection. Unfortunately, limited conclusions were possible due to the onset of the 
COVID-19 pandemic, although preliminary observations demonstrated considerable 
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variations in outcomes related to LV performance, symptoms and end points, even 
within a small cohort of patients. 
 
More widely, these findings confirm that the burden of MR within the HF population is 
significant and although medical optimisation assists in reducing symptoms and the 
degree of MR, high risk patients with LV systolic dysfunction remain symptomatic and 
may be candidates for TMVR. Further research into the utility of functional assessment 
and serum biomarkers, and the application of different echocardiographic models to 
re-define the relationship between MR and the LV are required to enhance patient 
selection and optimise clinical outcomes. The benefits of TMVR across a range of 
clinical settings (acute vs chronic HF; ischaemic vs non-ischaemic HF; the range of 
MR aetiologies; and demographics including age, gender and ethnicity) should form 
the focus of these studies, thereby ensuring reduction (or abolition) of symptoms, 
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Subject:
Date: 23 October 2020 at 14:24
To: Kelly Victor1 kellyvictor@hotmail.com
From: ASSEFA-KEBEDE, Hosanna (KING'S COLLEGE HOSPITAL NHS
FOUNDATION TRUST) [mailto:hosanna.assefa-kebede@nhs.net] 
Sent: 20 August 2019 16:36
To: MONAGHAN, Mark (KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST)
<mark.monaghan@nhs.net>; Victor Kelly <Kelly.Victor@gstt.nhs.uk>
Cc: MARE, Tracey (VIAPATH LLP) <tracey.mare@nhs.net>; BROWNE-MORGAN,
Melrose (KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST) <m.browne-
morgan@nhs.net>; BREEZE, Jonathan (KING'S COLLEGE HOSPITAL NHS
FOUNDATION TRUST) <jonathan.breeze@nhs.net>; MCDONAGH, Theresa (KING'S
COLLEGE HOSPITAL NHS FOUNDATION TRUST) <t.mcdonagh@nhs.net>;
Prendergast Bernard <Bernard.Prendergast@gstt.nhs.uk>
Subject: IRAS 248271: Confirmation of Capacity and Capability at King’s College





Full Study Title: Percutaneous Mitral Valve Intervention: Predicting
improvements in left ventricular performance
KCH Ref No: KCH19-100
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Location: Denmark Hill [CPMS code: RJZ01]
Target Recruitment: 25
Protocol Version: V1.0 11/03/2019
 
This email confirms that KING’S COLLEGE HOSPITAL NHS FOUNDATION TRUST
has the capacity and capability to deliver the above referenced study. Please find
attached our signed Organisation Information Document as confirmation.
 
We agree to start this study when the sponsor gives the green light to begin.
 
NB: Principal Investigator and research team, please note that capacity and
capability has been issued; however, recruitment must not start until you




The study has been registered as KCH19-100. Please quote this reference in any
communications with the R&I Office regarding your project.
 
A condition of the approval is to upload your recruitment data in real time into the
study record in EDGE. Please contact your research facilitator or our data central
email address kch-tr.data@nhs.net if you need assistance with training or EDGE
account activation.
 
If you would like help from the R&I office, have any concerns regarding the study
and/or want advice, please contact us. I have enclosed the R&I structure with contact
details for you.
The R& I facilitator allocated to your study is: Hosanna Assefa-Kebede
The R&I Lead for your clinical area, who can also provide support is: Professor
 
____________________________________________________________________________________________ 







Wishing you all the best with your research; we thank you for leading research at KCH







King’s College Hospital NHS Foundation Trust
The R&I Office| 161 Denmark Hill | London SE5 8EF
!DL: +44 (0) 20 3299 2763 (internal 32763) | ": hosanna.assefa-kebede@nhs.net
R&I: kch-tr.research@nhs.net  Contracts:  kch-tr.researchcontracts@nhs.net
QA:  kch-tr.researchqualityassurance@nhs.net  Data: kch-tr.data@nhs.net 
 




The information contained in this message and or attachments is intended only for the person or entity to which it is addressed
and may contain confidential and/or privileged material.
 
Unless otherwise specified, the opinions expressed herein do not necessarily represent those of Guy's and St Thomas' NHS
Foundation Trust or any of its subsidiaries.
 
The information contained in this e-mail may be subject to public disclosure under the Freedom of Information Act 2000. Unless
the information is legally exempt from disclosure, the confidentiality of this e-mail and any replies cannot be guaranteed.
 
Any review, retransmission,dissemination or other use of, or taking of any action in reliance upon, this information by persons or
entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the
material from any system and destroy any copies.
 
We make every effort to keep our network free from viruses. However, it is your responsibility to ensure that this e-mail and any





















END OF THESIS 
 
 
